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ABSTRACT
Several animal models of focal cerebral ischaemia have been developed to gain
insight into the pathophysiology and possible therapeutic treatment of stroke. This
thesis aimed to optimise & characterise a model of focal cerebral ischaemia that
utilises perivascular microinjection of endothelin-1 (ET-1) to occlude the middle
cerebral artery (MCA) of the rat, and to develop a novel model of endothelin-induced
MCA occlusion with controlled reperfusion.
The MCA of the anaesthetised rat was occluded by the intracerebral
microinjection of ET-1 into the outer layers of cortex adjacent to the MCA.
Elistopathological analysis of ischaemic brain damage three days following injection,
determined that ET-1 produced a large volume of ischaemic brain damage confined
to the vascular territory of the MCA within the dose range 33-300 pmols, whilst a 10
pmol injection was ineffective. The optimal injection volume was found to be in the
range 1-3pi. The isopeptide ET-3 was found to be equipotent with ET-1 in the
ischaemic insult it produced, having the same minimal effective dose, and being
effective over the same dose range. This is the first demonstration that ET-3 is
capable of producing ischaemic damage by constricting a major cerebral artery
The equipotency of ET-1 and ET-3 in terms of histopathological outcome in this
experimental model of stroke, was supported by laser Doppler flowmetry (LDF)
recordings of perfusion velocity from the parietal cortex, in which the severity and
duration of ischaemia was found to be the same between isopeptides. These
isopeptides are only equipotent at the ET0 receptor, however, ETB receptor
involvement was excluded by the ineffectiveness of the selective ETB receptor
agonists BQ3020 and IRL1620 in producing MCA occlusion. Furthermore, whilst
intracerebral injection of the specific ETA receptor antagonist FR139317 (3 nmols in
3 pi) 10 minutes before ET-3, blocked MCA occlusion, this dose of FR13 9317 was
ineffective against ET-1 -induced MCA occlusion. This suggests the involvement of
an atypical receptor in the contractile response of the rat MCA to endothelin
isopeptdies.
Intracerebral probes determined that striatal temperature remained unchanged
following ET-1-induced MCA occlusion. By contrast, striatal oxygen tension,
measured by intracerebral oxygen electrodes, and cortical tissue perfusion velocity,
measured by laser Doppler flowmetry (LDF) fell rapidly following ET-1 injection.
Oxygen tension did not recover for 3 hours following ET-1 injection, whilst the LDF
signal showed some recovery but still remained below 50% of baseline levels after 2
hours. [l4C]iodoantipyrine autoradiography determined that local cerebral blood flow
(CBF) was profoundly reduced throughout much of the vascular territory of the
MCA three hours after injection of ET-1. This pathophysiological profile suggests
that ET-1-induced MCA occlusion represents a model of permanent focal cerebral
ischaemia in which reperfusion is limited.
A 17mer sequence of the secreted form of (3-amyloid precusor protein (PAPP),
which has previously been shown to possess trophic and neuroprotective properties,
was evaluated using this experimental model of stroke. The 17mer peptide was found
to confer neuroprotection to both cortex and striatum, when delivered
intracerebroventricularly for three days before inducing ET-1-induced MCA
occlusion. However, the 17mer peptide did not improve functional recovery
iii
following ET-1-induced MCA occlusion as assessed by a model of skilled motor
control.
Both endothelin isopeptides were investigated in the development of a model of
MCA occlusion with controlled reperfusion. Quantitative histopathology determined
that ET-3-induced MCA occlusion was effectively reversed by intracerebral injection
of FR139317 delivered 10 minutes after ET-3. By contrast, injection of 3 or 30nmols
of FR139317 10 minutes after ET-1 had no significant effect on the volume of
ischaemic brain damage. The histopathological findings were confirmed with LDF
recordings of cortical perfusion velocity, in which FR139317 reversed ET-3-induced
ischaemia within 5 minutes of injection, whilst FR139317 had little effect on ET-1-
induced MCA occlusion. The effectiveness of FR13 9317 as an agent with which to
interrupt ET-3-induced MCA occlusion was confirmed by local CBF measurement
using [14C]iodoantipyrine autoradiography. ET-3-induced MCA occlusion with
controlled reperfusion was used to investigate very delayed (apoptotic) cell death.
FR139317 was injected 30 minutes after ET-3, and histopathology was performed 3
or 14 days later. There was no significant difference in the volume of ischaemic brain
damage between groups, and the component of very delayed (apoptotic) cell death in
this model is unlikely to contribute significantly to the volume of the ischaemic
lesion.
The ET-1-induced MCA occlusion model has the pathophysiological
characteristics of permanent arterial occlusion, and is not readily amenable to
controlled reperfusion using the ETA receptor antagonist FR139317. By contrast, ET-
3-induced MCA occlusion can be abruptly reversed by the intracerebral injection of
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CHAPTER ONE
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CHAPTER 1. GENERAL INTRODUCTION
1.1. Cerebrovascular disease
1.1.1. Human Stroke: Definitions, causes & consequences
Cerebrovascular disease encompases a number of pathophysiological conditions and
includes intracerebral haemorhage, cerebral aneurysm, and in particular ischaemic
stroke. The term "ischaemic stroke" or "focal cerebral ischaemia", describes the
consequences of CBF reductions that arise from a number of different pathologies.
Causes include cardiac arrest, embolism, & thrombosis, reflecting transient global
CBF reductions, gradual or sudden narrowing of a major supply artery to the brain or
microembolism of smaller arteries (Hossmann, 1982). The underlying cause of most
ischaemic strokes is occlusion of an intracranial artery (Garcia et al. 1996b), of
which occlusion of the middle cerebral artery (MCA) is most common in humans
(Nedergaard, 1988). By convention, symptoms must last for more than 24 hours
(Kalimo et al. 1997). Focal neurological deficits that resolve within 24 hours are
termed transient ischaemic attacks (TIAs). Although not refered to as a stroke, such
ischaemic episodes may nevertheless result in some permanent damage despite
lacking symptoms (Dyken et al. 1984; Kalimo et al. 1997).
Worldwide, approximately 4.6 million people die from stroke each year (Bonita
& Beaglehole, 1995), making stroke the third leading cause of death among adults
(Gorelick, 1995), and the most common disabling and lethal neurological disease of
adult life (Dyken et al. 1984). In the USA, approximately 500,000 strokes occur a
year, with a cost to the nation of $30 billion. In the U.K figures are proportionally
similar, with 100,000 people experiencing first-ever strokes, accounting for fatality
rates of 2 in 1000 (12% of all U.K. deaths) (McAuley, 1995). Of the patients
affected, roughly one third will die, one third experience a subsequent stroke, and
many of the remaining live with some form of disability (Heros 1994). Indeed,
cerebrovascular lesions not only result in physical diability such as paralysis, but
many emotional and behavioural disorders occur following stroke including
depression and anxiety (Robinson, 1997). Despite high prevelance, burden of illnes,
economic cost and safe and extensive measures with which to prevent or minimise its
occurance (Gorelick 1995), an accepted treatment to limit brain damage following
stroke is not in clinical practice.
1.1.2. Human Stroke: Incidence & risk factors
The prevelance of the various forms of cerebrovascular disease vary according to
where the studies were performed and whether the data are from hospital records or
population surveys (Dyken et al. 1984). Population studies reveal that the large
majority of strokes are caused by ischaemia and infarction following small and
medium-artery disease, atherothrombotic brain infarction, whilst cerebral
embolisation accounts for -14-20% (Dyken et al. 1984).
There are a number of clearly identified risk factors for stroke, our knowledge of
which has advanced considerably during recent decades and indeed exceeds that of
other major neurological diseases (Gorelick 1995). Several of these factors are
considered non-modifiable such as advanced age, male gender, race and heredity, are
not amenable to preventative approaches (Dyken et al. 1984). The key predisposing
factors include hypertension, cardiac disease, diabetes mellitus, blood lipid levels,
asymptomatic carotid artery stenosis, transient ischaemic attacks (TIAs), cigarette
smoking, alcohol and exercise (Gorelick 1995). Hypertension & cardiac disease
constitute risk factors where treatment is both feasible and the value has been
established, and up to 70% of strokes may be avoidable by treatment of hypertension
(Dunbabin & Sandercock 1990). By contrast, factors such as obesity, cigarette
smoking and oral contraceptive use, represent risk factors which are treatable but
where the value of this has yet to be established (Dyken et al. 1984). While cardiac
disease and stroke are highly correlated, the effect of prevention and treatment of
cardiac disease on stroke requires further study (Gorelick 1995), although it is
believed that the treatment and prevention of cardiac disease might shift the balance
of stroke risk. For example, treatment of some cardiac disease with antithrombotic
agents reduces ischaemic stroke risk. However, the counterargument is that an
increase in the survival of cardiac disease patients could increase the pool of people
at risk from stoke (Whisnant 1992).
Diabetes is another key risk factor (Dyken et al. 1984), although whether control
of diabetes mellitus would reduce stroke risk is still uncertain. Similarly, whilst
asymptomatic carotid artery stenosis represents risk factors for stroke, myocardial
infarction & death, treatment has yet to confirm overwhelming effectiveness in
reducing stroke and death incidence, although the incidence of neurological events
such as TIAs may be reduced by carotid endarterectomy (Hobson et al. 1993).
Cessation or reduction of cigarette smoking and heavy alcohol consumption would
reverse the predisposition to stroke in these groups within a few years (Gorelick
1995). Since hypercholesterolaemia could account for a significant number of
strokes, treatment of blood lipid level abnormalities seems prudent although further
study is needed (Dunbabin & Sandercock 1990; Atkins et al. 1993; Gorelick 1995).
Prior stroke is also a key risk factor, with the risk of a recurrent stroke increasing
many times that of suffering a first-time stroke (Dyken et al. 1984).
1.1.3. Brain function & structure
The function of the cerebral circulation is to provide the necessary substrates for the
brain, & remove the products of metabolism, and the cause of brain injury following
stroke is invariably consequent on the decreased delivery of oxygen and metabolic
substrates to the brain (Sokoloff, 1986). The endogenous stores of brain substrates
for metabolism are almost neglible compared to the rates of utilisation, and highly
specialised and differentiated tissues such as those found in the brain require large
and continuous amounts of oxygen and glucose to support function since the brain
utilises oxygen and glucose at very rapid rates (Farber et al. 1981; Sokoloff, 1986).
Despite comprising only 2-3% body weight, the brain receives 15% of the cardiac
output, and consumes 20% of the oxygen and 25% of the glucose within circulating
blood (Graham, 1985). The oxygen extraction fraction of the brain is 40-50% whilst
that of glucose is -10% (Heiss & Podreka, 1993), and the oxygen content of the
blood decreases from 19.6 to 12.9 ml/dl when passing through the brain, whilst
carbon dioxide levels increase by 14% from 48.2 to 54.8 ml/dl. The combination of a
respiratory quotient close to unity, an almost stoichiometric relationship between
oxygen uptake and glucose consumption, and the absence of significant
arteriovenous differences for any other energy-rich substrate suggests glucose is the
sole source of oxidative (aerobic) respiration (Graham 1985; Sokoloff, 1986). Under
normal circumstances no other energy-yielding substrate other than glucose is
significantly extracted by the brain from the blood (Sokoloff, 1986). Very few
substrates can restore normal cerebral function during a hypoglycaemic state, and no
substance normally present in the blood can replace glucose as the substrate for
cerebral energy metabolism (Sokoloff, 1986). There are a limited number of
conditions such as starvation, under which the brain can substitute other substances
for glucose (Seisjo, 1984). These include ketone bodies and some monocarboxylic
acids. However, there is no evidence that these can completely replace glucose
(Seisjo 1984; Sokoloff, 1986).
Glucose (a hexose) enters the glycolytic pathway where it is metabolised into
two pyruvate molecules. Pyruvate enters the mitochondrion and is metabolised to
carbon dioxide (C02) and water via the mitochondrial respiratory chain of enzymes.
This process produces a total of 42 ATP molecules (the cell's short-term energy
storage molecule) from one glucose molecule (Auer & Benveniste, 1997). In the
absence of sufficient oxygen, pyruvate is converted into lactic acid, via the enzyme
lactate dehydrogenase, which yields a much smaller amount of energy (Stryer, 1991).
Production of lactate instead of ATP rapidly depletes cellular glucose levels and
causes intracellular acidification from ATP hydrolysis, and directly from lactic acid
production (Auer & Benveniste, 1997). Since the brain lacks substantial energy
stores (Auer & Benveniste, 1997), dependency of the brain on oxidative metabolism
of glucose makes the brain so susceptible to damage during ischaemic episodes
(Siesjo, 1992a).
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Brain tissue consists of two types of cells, glia and neurones. There are
approximately one order of magnitude greater numbers of glia (10") than neurones
(1010), and these are the supporting cells for the neurones. In addition to these cell
types, the brain receives its metabolic substrates via the cerebrovascular network,
which consists of endothelial and smooth muscle cells. The number of different
neurone types are vast and whilst neurones are defined both morphologically (e.g.
medium spiny neurones of the striatum) and neurochemically (e.g. dopaminergic).
Glia are divisible into three clasess; oligodendroglia (active in the formation and
maintenance of myelin), astrocytes (supporting cells which function in
neurotransmitter uptake and local metabolism) and microglia, which perform
multiple tasks including cellular proliferation and regulation of cytotoxic reactions
(Nakajima & Kohsaka, 1993; Auer & Benveniste, 1997). Originally perceived as
relatively inactive in metabolic terms compared to neurones, glia are now understood
to possess cell surface ion transport systems and neuroreceptors although lacking the
metabolic expenditure of axoplasmic transport, a function exclusive to neurones
(Auer & Benveniste, 1997).
A crucial component of the brain's structure and function is the blood brain
barrier (BBB). Homeostatic maintenance of the internal milieu of the CNS is
essential if the brain is to avoid being affected by sytemic fluctuations in blood levels
of hormones and ions induced by factors such as feeding, exercise and stress. It is the
BBB which provides the ability of the brain to control such fluctuations (Edvinsson
et al. 1993c). Ehrlich's classic experiments in 1885 showed that intravenous injection
of a dye failed to penetrate the brain, whilst staining the other tissues of the body.
This was supported by Goldmann's studies in 1913 that established the presence of a
barrier to the blood. Subsequently, studies have determined the presence of a
physico-chemical lining of the cerebral blood vesses (Dermietzel & Krause, 1991).
The physical basis for the BBB resides in continuous tight cell junctions between the
endothelial cells lining cerebral vessels (Dermietzel & Krause, 1991). This barrier
does not cover the entire brain area and a small number of "breaks" exist in the BBB
at sites including the pituitary and pineal glands, which allows the passage of blood-
borne molecules essential in regualtion of the neuroendocrine system (Dermeitzel &
Krause, 1991).
The BBB also constitutes a "chemical" barrier to substance passage. Tight cell
junctions physically prevent the passage of large proteins (>m.w.l000) and many
micromolecular substances (Dermietzel & Krause, 1991). Small molecules may pass
the barrier according to particular properties of that substance, of which lipid
soluability is the most decisive (Edvinsson et al. 1993c). Lipid soluble molecules
readily cross the BBB, since the membranes comprising the BBB are composed of
lipid molecules. By contrast, hydrophilic molecules (e.g. ions, proteins and
saccharides) possess poor BBB penetration (Dermietzel & Krause, 1991). Penetration
of energy substrates and amino acids that cannot be synthesised within brain cells is
achieved by enzyme transporters specific to the nutrient (Edvinsson et al. 1993c).
Regulation of molecule passage is also by cellular metabolism within the BBB,
whereby a substance entering an endothelial cell may be converted into a form
incapable of traversing the antiluminal membrane (Edvinsson et al. 1993c).
Disruption to the integrity of the BBB may contribute directly to neuronal injury
8
(Edvinsson et al. 1993c). Following stroke, the integrity of the BBB may become
disrupted, which may lead to exposure of brain tissue to unregulated levels of blood-
borne substrates as well as contributing to oedema formation within ischaemic brain
tissue (Betz et al. 1994).
1.2. Cerebral circulation
1.2.1. Anatomy of the cerebral circulation
The blood supply to the brain in humans is from two pairs of large arteries, the
internal carotid arteries and the vertebral arteries, which provide anterior and
posterior flow respectively (Kalimo et al. 1997). The internal carotid arteries give
rise to the anterior cerebral artery (ACA), MCA and the anterior choroidal artery. By
contrast, the vertebral arteries form the basilar artery, posterior inferior cerebellar and
anterior & posterior spinal arteries. The basilar then bifurcates to form the posterior
cerebral arteries (PCA) and four other vessels including the superior cerebellar
(Edvinsson et al. 1993a). The basilar & internal carotid arteries anastomose at the
base of the brain to form the circle of Willis. This structure ensures adequate blood
supply to the brain despite occlusion of any major artery supplying the circle of
Willis (Kalimo et al. 1997). From the circle of Willis, the major cerebral blood
vessels supply the brain. The anterior cerebral artery is responsible for supply to
midline cortical structures and deep structures such as the basal ganglia. The MCA
supplies most of the lateral cortex and deep structures such as the caudate nucleus via
the lenticulo-striate branches. The anterior choroid artery supplies structures such as
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the choroid plexus and hippocampus, whilst the PCA supplies caudal structures such
as the cerebrellum.
In the assessment of various animal species as to their relevance as models to
study human stroke, the anatomy of the cerebral circulation is of importance. Major
differences between a given species and man should be taken into account in the
design of models of focal cerebral ischaemia and in the interpretation of
pathophysiological outcome. A number of differences exist between the cerebral
circulation in man and that of the main animal species used in stroke research
(Scremin, 1995). Such differences prompt caution in the adoption of certain species
in cerebrovascular disease research. Prominent amongst these is the presence of the
carotid rete mirablis, absent in primates, it is an intricate system of branching
arteries, veins and sinuses that exists in cats, sheep, pigs and to a lesser extent, in
dogs (Scremin, 1995). By contrast the rat and rabbit do not posses this, and the rat,
which is currently the most extensively used species in in vivo stroke research, shares
major similarities to human cerebrovascular anatomy (Yamori et al. 1976). Thus the
rat brain receives blood from four arteries, the two common carotids and two
vertebrals, the former of which divide to form the external and internal carotid
arteries. The internal carotid gives rise to the posterior communicating artery, and
then is incorporated into the circle of Willis, whilst the vertebral arteries form the
basilar artery which later feeds posterior structures of the brain via the posterior
cerebral artery. Like the human circulation, a number of major cerebral arteries arise
from the circle of Willis and feed anterior and midline structures (ACA), the midway
cortical and striatal territories (MCA) and the posterior brain structures such as the
cerebellum (PCA) (Scremin, 1995). The MCA originates at ~2mm caudal to bregma,
and courses laterally and rostrally giving off the corticostriate artery, which feeds
parts of the piriform cortex, and the anterior & posterior striate arteries, which feed
the striatum and are the equivalent of the lenticulo-striate arteries in the human. The
MCA then curves over the lateral surface of the cerebral hemisphere giving rise to a
variable number of rostral, caudal and medial vessels (Scremin, 1995).
However, whilst there is a general resemblance to the human, a number of
differences exist between the human and rat cerebral circulation (Scremin, 1995).
These include a (relatively) larger posterior communicating artery and the general
absence of an anterior communicating artery, and relatively differential lengths of the
internal carotid and posterior communicating arteries (Scremin, 1995).
The appropriateness of the cerebral anatomy & whole animal physiology, the
detailed understanding of neurotransmitter systems in the rat as a consequence of this
species widespread use in biological research, and the economic & pratical advantage
of small animals in research when compared to primates or other larger mammals
such as the dog, has fuelled the extensive adoption of the rat within cerebrovascular
disease research (Macrae, 1992).
Even within a single species, there may be considerable variation in the outcome
following focal cerebral ischaemia. This may arise not only from experimental
conditions, such as physiological monitoring, but is inherent as a consequence of the
variability of the cerebral anatomy even within a single strain (Brown, 1966).
Extensive studies by Brint et al. (1988) and Duverger & Mackenzie, (1988)
addressed inter-strain differences in the outcome following MCA occlusion in the rat.
Their conclusions were that spontaneously hypertensive rats produced the largest
volume of ischaemic damage following MCA occlusion, whilst Wistar/Kyoto rats
exhibited the smallest infarcts. Concensus on the most appropriate rat strain is
lacking, although consultation of the literature suggest that the Sprague-Dawley rat is
the most commonly applied strain. However, whether this is the ideal strain is far
from clear and Duverger & Mackenzie, (1988) recommended the Fischer 344 strain
based on studies using the main strain variants.
In the development of the most appropriate animal models of stroke there is
undoubtedly a need for a degree of consensus between experimental practice to allow
closer comparison between studies, whilst maintaining a sufficiently broad range of
practical approaches so as not to exclude necessary variability to reflect clinical
heterogeneity. There has been an emerging convergence on the use of only a very
narrow range of species in models of MCA occlusion (the rat, mouse and cat), whilst
studies on forebrain and global models have been predominantly conducted in gerbil.
Particular strain use is currently unregulated and this may need to be reviewed if
inter-study variability is to be decreased and greater consensus achieved.
1.2.2. Cerebral blood flow autoregulation
The maintenance of cerebral blood flow is controlled within the cranium by a range
of autoregulatory, neurogenic and metabolic mechanisms. The relationship between
perfusion pressure and cerebral blood flow is primarily controlled by the
phenomenon of autoregulation (Graham, 1985). Autoregulation of blood flow refers
to an intrinsic ability of an organ or tissue to maintain constant tissue perfusion
despite blood pressure changes (Paulson et al. 1990). This may be described as the
physiological regulatory mechanism that maintains constant flow over wide ranges of
arterial blood or perfusion pressures (Lassen 1959; Paulson et al. 1990). The concept
of autoregulation was recognised about 100 years ago (Roy & Sherrington 1890;
Bayliss 1902). It was Lassen (1959) that firmly established the concept of blood flow
constancy during perfusion pressure changes (Strandgaard & Paulson, 1983),
establishing the significance of CBF autoregulation and its lower limit, and
introducing and applying the term "autoregulation" to the cerebral circulation field
(Paulson et al. 1990). However, there are limits outwith the organ cannot operate. In
the case of the cerebral circulation, autoregulation fails outwith the blood pressure
limits of 60-150mmHg (Paulson et al. 1990), and disease states may alter these
limits. Below ~65mmHg, vessels are maximally dilated and flow is dependent only
on perfusion pressures, decreasing with decreasing blood pressure (Graham, 1985).
However, studies have brought into question the actual lower limit of autoregulation,
and Tuor & Farrar (1984), suggested that whilst the pressure at which CBF begins to
decrease is 65mmHg, the true lower limit of autoregulation at which pressure-passive
reductions in CBF occurs, is at 35mmHg.
At the upper autoregulatory limit, there is forced dilation of cerebral vessels with
the inability of cerebral vasoconstriction to compensate, with subsequent cerebral
oedema and the production of hypertensive encephalopathy (Graham, 1985;
Edvinsson et al. 1993b). Whilst it is stated that mean cerebral blood flow to the brain
is approximately 50ml/100g/min, this does not reflect the constant re-adjustment of
local blood flow to meet the various metabolic demands of brain cells. This point is
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of fundamental importance not only to understanding the mechanisms controlling
cerebral blood flow, but to the appreciation of the consequences of blood flow
interruption to the brain. The mechanisms controlling blood supply are
fundamentally geared to the fact that the greater the metabolic demand of a brain
region, the greater the blood supply and vice versa (Villringer & Dirnagl, 1995).
The mechanism of autoregulation of cerebral blood flow remains unclear
(Strandgaard & Paulson, 1983). There are three main hypotheses that might account
for autoregulation: the metabolic, neurogenic and myogenic hypotheses (Paulson et
al. 1990; Edvinsson et al. 1993b). The metabolic hypothesis postulates that products
of cerebral respiration control blood pressure. The hypothesis postulates that a fall in
pressure would lead to a transient accumulation in metabolites that would cause
vasodilatation and consequently the restoration of flow. In general, increasing
metabolic demands due to neuronal activation leads to highly localised and restricted
changes in flow, which might reflect the effects of metabolic mediators. The
proposed mediators include C02, H+, 02, adenosine/adenine nucleotides, K+ and Ca2+
(Kuschinksy & Wahl 1978; Paulson et al. 1990; Edvinsson et al. 1993b). The role of
these metabolites in autoregulation has yet to be established. For example, adenosine
is a product of energy metabolism and a potent dilator of vessels within the brain
(Winn et al. 1980), but adenosine antagonists do not affect the pressure-flow
relationship with autoregulatory limits (Phillis 1989a). The evidence for H+/pH
involvement is also a matter of debate. Cerebral arterioles dilate in response to a
decrease in pH and constrict in response to alkalosis. That extracellular pH exerts a
dominating or overiding influence is tenous (Siesjo, 1984), while pH has no effect
during hypotension (Edvinsson et al. 1993b), and extracellular K+ does not change
during hypotension (Kuschinsky 1978; Paulson et al. 1990).
The neurogenic hypotheis of cerebral autoregulation proposes that vasodilation
and vasoconstriction occurs in response to pressure changes under perivascular
nervous control. All vascular segments of cerebral vessels are innervated (both extra-
and intraparenchymal) by nerves from both the peripheral and central nervous
systems, and a number of neurotransmitters and receptors reside within such
innervations (McCulloch & Edvinsson 1984; Lou & Edvinsson 1987; ETddman &
Edvinsson 1989; Paulson et al. 1990; Branston, 1995). While a review of this area of
research is outwith the scope of this section, both parasympathetic and sympathetic
nerves innervate vessels, whilst transmitters such as DA, substance P and NO are
implicated (Paulson et al. 1990; Branston, 1995). The extent to which such
neurogenic mediators control autoregulation is yet to be determined. Activity of the
autonomic nervous system and extrinsic nerves may shift the limits of autoregulation
both up and down, and may attenuate the hypercapnic response (Paulson et al. 1990;
Edvinsson et al. 1993b). However, autoregulation is generally preserved following
surgical or pharmacological blockade of cervical autonomic nerves (Paulson et al.
1990; Edvinsson et al. 1993b; Branston, 1995), suggesting limits in the contribution
to autoregulatatory functions.
The myogenic hypothesis proposes that an intrinsic property within the smooth
muscle wall of cerebral vessels makes them responsive to changes in flow pressures,
whereby vessels contract in response to a rise in transmural pressure (Paulson et al.
1990; Edvinsson et al. 1993b). The rapid autoregulatory response to changes in
transmural pressure of resistance vessles does seem to favour this hypothesis, and
would account for the vasoconstriction associated with hypertension (Edvinsson et
al. 1993b). Such changes rest not on local changes in the milieu but the ability of
actin & myosin elements to sense intravascular pressure changes, a principle known
as the Bayliss effect (Bayliss 1902; Paulson et al. 1990). However, the mechanism
behind this property is not well understood. There is some evidence that stretching
muscle fibres may alter membrane permeabilities to ions such as Ca2+, whilst studies
of vessels from spontaneously hypertensive animals suggest they have altered ionic
permeabilities (Harder 1984; Harder & Lombard 1985; Paulson et al. 1990). There
may be no unifying explanation for the autoregulatory responses to changes in blood
pressure or fluctuations in metabolic demand by brain cells, but that rather a
collection of factors such as inherent myogenic properties coupled with the effects of
metabolic products and nervous innervation act to control and exercise
autoregulation. Paulson et al. (1990) comment that the mechanism controlling
autoregulation may differ from the processes involved in chemical (C02 reactivity)
and metabolic responses of the cerebral circulation.
1.2.3. Cerebral blood flow regulation (1): Physiological control
Whilst autoregulation maintains constant blood flow within certain perfusion
pressures as a result of as yet poorly defined mechanisms, there are myriad of
neurotransmitters, neuropeptides and endothelium-derived factors that elicit effects
on cerebral blood vessels and consequently modify cerebrovascular tone and CBF.
The main agents affecting cerebral vessels are shown in Table 1.



















































Table1.Majorneuralndlocalm diatorsw thffectonr bralblfl w(S r min,1995).
Whilst detailed discussion of the ralative contributions of these agents is outwith
the scope of this thesis, the above table lists those of significance. Regulation of CBF
is mainly subserved by the precapillary resistance vessels (Siesjo, 1984). However,
activation of neural networks (e.g. serotonergic projections) may modify CBF,
although the functional significance of such changes in CBF are a matter of debate
since with the notable exception of the endothelins, these mediators are incapable of
overwhelming homeostatic mechanisms and reducing CBF to ischaemic levels.
However, activation of certain pathways may be of importance in disease states such
as stroke and migraine, when autoregulatory capacity is lost. However, as yet no
clear functional framework has been established for the roles of neurochemical
manipulation by neurotransmitters.
1.2.4. Cerebral blood flow regulation (2): Pathophysiological aspects
Pathophysiological aspects of CBF regulation can be broadly divided into the loss of
autoregulatory capacity and blood flow & metabolic abnormalities. CBF
autoregulation can be modified or disturbed in several disease states, such as
hypertension, diabetes and particularly following cerebral ischaemia (Paulson et al.
1990). The extent to which this occurs depends on the disease state, and whilst
chronic hypertension induces a re-setting of limits towards higher pressure,
ischaemia profoundly affects autoregulatory capacity (Symon et al. 1973; Harris &
Symon, 1984; Paulson et al. 1990). In uni- or bilateral carotid disease regional
vasodilatation may maintain CBF within the supply territory of the occluded vessel.
However, occlusion of arteries such as the MCA precludes such compensatory
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mechanisms (Heiss & Podreka, 1993). Loss of autoregulation within such fields has
two major implications for ischaemic tissue. First, the inability of CBF to match
metabolic demand, and second, the potential for damage aggravation on
recannilisation. The latter predicament arises from the sustained loss of
autoregulatory capacity during the initial phase of reperfusion, whereby any blood
pressure increase will aggravate tissue oedema and BBB damage (Floedt-Rasmussen
et al. 1967; Paulson, 1990).
Pathophysiological abnormalities in blood flow and metabolism have been
investigated using modem neuroimaging techniques, although the limited number of
studies have left inconsistencies (Heiss & Podreka, 1993). Changes in the local
haemodynamics and energy state offer an insight into the interrelationships of
perfusion and brain acticvity (Baron et al. 1989). Positron emmision tomography
(PET) and single photon emission computed tomography (SPECT) studies performed
on patients suffering ischaemic stroke have elucidated uncoupling of regional CBF
(rCBF), regional cerebral blood volume (rCBV), cerebral metabolic rate for oxygen
(CMR02) and the cerebral meatbolic rate for glucose (CMRglu). Whilst these
variables are coupled under homeostatic conditions when parametrs such as pC02 are
accounted for, occlusive disease states uncouple these (Heiss & Podreka, 1993).
These variables are individually affected and uncoupled during ischaemia, and
measurement of haemodynamic and metabolic parameters allows distinction of
ischaemia from oligaemia or reperfusion which also affect these physiologic
parameters (Baron et al. 1989; Heiss & Podreka, 1993). Multiple parameter
assessment is necessary because, except under conditions of tissue infarction in
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which CBF is <12ml/100g/min, CBF measurement alone is insufficient to assess
tissue viablility (Heiss & Podreka, 1993).
In chronic states of arterial (e.g. MCA) occlusion, three or more metabolic and
perfusion abnormalities are distinguishable consequent on the severity of occlusion
(Baron et al. 1989). In the first stage, CBV increases in the presence of normal CBF,
consequent on the vasodilatory compensatory mechanisms of autoregulation.
However, as obstruction becomes more severe, oxygen extraction fraction (OEF)
increases consequent on a fall in CBF, and as this reserve becomes exhausted with
further perfusional deficits, oxygen consumption falls (Baron et al. 1989). In acute
stroke, CMRglu is generally reduced within the affected area, although non-oxidative
respiration may cause an increased rate, and measurement of CMRglu and pH shifts
are a sensitive measure of metabolic disturbance and tissue infarction (Heiss &
Podreka, 1993). PET studies have demonstrated with few exceptions that regions
demonstrating increased CMRgkl and decreased CMROz undergo necrosis although
such tissue represents that salvageable by therapeutic intervention (Heiss & Podreka,
1993).
Neuroimaging techniques have also provided insight into the more remote effects of
ischaemia whereby metabolic and haemodynamic disturbances exceed the
morphologically damaged tissue (Heiss & Podreka, 1993). Studies of CBF following
stroke have suggested that neuronal connectivity between brain regions may be
responsible (Tamura et al. 1981). Regions affected include the substantia nigra,
which receives GABAergic inhibitory input from the striatum (damaged following
occlusion of the MCA), and the cerebellum (Perani et al. 1987). In conclusion,
pathophysiological aspects of CBF regulation are manifest as differential alterations
in perfusional and metabolic parameters such as CBF and CMR02, as
cerebrovascular compensatory mechanisms compensate within certain limits to acute
and chronic ischaemic conditions. Neuroimaging techniques have significantly
contributed to our understanding of pathophysiological aspects of cerebral perfusion
and metabolic disturbances during ischaemia, and application of such techniques
have led to definable alterations in blood flow and metabolic parameters that allow
identification of differential vascular occlusion states and morphological outcome
following stroke.
1.3. Ischaemic cell death
1.3.1. Histopathology of ischaemic tissue
Correct identification of pathologically damaged tissue following an ischaemic insult
is vital since it allows quantification of ischaemic brain damage in experimental
models of stroke and facilitates the model's employment as a screen for putative
neuroprotectants. A large number of studies and reviews have addressed the
histological identification of pathologically damaged cells in ischaemia (Graham,
1985). As a consequence, some generalisations may be made concerning the nature
of such cells at the microscopic level. However, as will be addressed subsequently,
ischaemic insults do not cause the same form of cell death throughout brain tissue.
1.3.2. Necrosis & apoptosis
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There are two basic pathways by which cells may die: necrosis and apoptosis.
Apoptosis may also be the mechanism by which cells die which currently come
under the term delayed neuronal death (DND) (Du et al. 1996). Necrosis may reflect
a "passive" cellular response as a consequence of trauma causing acute loss of
regulation and function (Kerr & Harmon 1991; Cotman & Anderson 1995). By
contrast the term apoptosis refers to a different pathology, where the cell may
actively participate in its death by gene-directed suicide, and such a program may be
initiated in response to a signal in the form of a toxin, insult or via a physiological
pathway (Bursch et al. 1992).
Brain lesions of ischaemic origin may be defined according to whether neurones
only (selective) or all cell types (pan-necrosis or infarction) are affected. The former
represents changes to selected neurones, whilst in pan-necrosis all cells die (Auer &
Benveniste, 1997). Definitions of cells irreversible damaged by ischaemia have been
documented previously (Farber et al. 1981; Farber, 1982; Trump, 1984). Necrotic
neurones can be identified as exhibiting pyknosis, karyolysis and cytoplasmic
eosinophilia. Cells may exhibit cellular alterations such as scalloping, swelling and
breaks in plasma & nuclear membranes, marginal clumping of chromatin
(karyorrhexis), dilatation of the endoplasmic reticulum, & ribosome dispersal (Garcia
et al. 1995). Subsequently, cells undergo rupture of nuclear, organelle and plasma
membranes, dissolution of ribosomes & lysosomes, the nucleus swells and the
membrane ruptures. Finally, basophilia (staining) is lost, and a "ghost" remains with
cell boundaries becoming indistinct. Further to this is the involvement of surrounding
cells and exudative inflammation develops in adjoining tissue with damage to other
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cells and an inflammatory response, although debris is eventually phagocytosed by
specialised cells (Kerr et al. 1972; Wyllie et al. 1980).
The second morphological and pathophysiological category of cell death is
apoptosis. Kerr et al. (1972) first coined the term apoptosis to describe a previously
recognised process by which cells died in a controlled manner. There are striking
differences between necrotic cell death and apoptosis. Work by Kerr et al. (1972) and
Wyllie et al. (1980) established most of the fundamental and significant aspects of
apoptosis, identifying its particular morphology, that it is an active, inherently
programmed phenomenon, and that certain environmental stimuli can initiate or
inhibit it. Furthermore they recognised it as an important basic phenomenon in the
turnover of cells in normal and neoplastic tissues. Furthermore, apoptosis commonly
affects single cells rather than populations. In the earliest stages of apoptosis,
chromatin is seen to aggregate in masses that touch the nuclear membrane, which
becomes convoluted and later grossly indented. Following the early changes in the
nucleus, cytoplasmic condensation begins, and cell attachments disappear.
Organelles become crowded, vacuoles may appear and nucleus fragmentation occurs.
Finally, apoptotic bodies form, with the production of membrane-bound spherical
shapes containing the cellular contents such as organelles and chromatin still intact.
Apoptotic bodies, which may vary widely in size and number are subsequently
dispersed into the intercellular space, and then are commonly phagocytosed.
Phagocytosis is a rapid process and no inflammation is detectable (Kerr et al. 1972).
Once ingested autolysis of phagocytosed material occurs and the phagocytosed
apoptotic bodies are eventually reduced to residual lysosome bodies prior to
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disappearance. The process is of sudden onset and early stages are quickly effected,
with the process of cellular shrinkage and membrane "blebbing" being completed
often within minutes (Wyllie et al. 1980). Wyllie et al. (1980) suggested that there
was no answer to how quickly apoptosis might be initiated after a stimulus, with
times varying according to stimuli and cell.
In addition to the morphological characteristics that identify cells as apoptotic is
the presence of a DNA ladder resolved by gel electrophoresis. This ladder pattern is
representative of the actions of endonucleases cleaving cell DNA into multiples of
-180 base-pairs (bp) (Wyllie et al. 1980). This pattern of endonucleolytic damage is
often used as an indicator that cells having undergone apoptosis (Li et al. 1995a).
Considerable research has now addressed the molecular mechanism of apoptosis.
Evidence is accumulating that the path by which a cell undergoes apoptosis may be
linked with the cell cycle (Steller, 1995). Furthermore, it has been suggested that
apoptosis is a premature, abortive mitosis, although distinct biochemistry
distinguishes apoptotic and mitotic processes (Meikrantz & Schlegel, 1995).
Suggestions have also been made that apoptosis occurs as a consequence of
incompatible signals for proliferation and cell cycle arrest (Yonish-Rouach et al.
1993). A connection of the two processes was the observation that apoptosis occurs
in vivo during proliferation of tissue (Oppenheim, 1991). Similarly, cells undergoing
mitosis, mitotic catastrophe (when the cell cycle is disrupted by overexpression of
cell cycle components or sustains mutations; Russel & Nurse, 1987) or apoptosis
have been seen to share morphological and biochemical similarities (King &
Cidlowski, 1995).
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There are a number of genetic changes that have been identified in cells
undergoing apoptosis. A number of important findings relating to genetic
transcription were shown in the studies by Pandey & Wang (1995). They used
density arrested Swiss 3T3 cells which die by apoptosis when deprived of serum.
Apoptosis was determined based on identification of DNA laddering and
morphology, such as plasma membrane blebbing, formation of apoptotic cell bodies
and chromatin condensation. Using incorporation of [3H] thymidine and
bromodeoxyuridine (BrdU) following serum deprivation, they found cells synthesise
a small amount of DNA. Furthermore, using a cell cycle marker, proliferating cell
nuclear antigen, they showed that this occurred during the G1 phase of the cell cycle.
They also found evidence that synthesis and fragmentation of DNA could occur in
the same cell as seen by BrdU incorporation and 37-end labelling of DNA by
biotinylated uridine. Thus it seems apoptosis in this model is intimately linked with
the cell cycle and cells can undergo DNA synthesis and degradation simultaneously.
The results of Pandey & Wang (1995) are suggestive of cells being released from the
quiescent state to enter the cell cycle en route to apoptotic death as indicated by
induction of cell cycle proteins. Furthermore these molecular events characterise a
G1 phase nucleus, although the re-entry is brief, incomplete and essentially abortive.
Pandey & Wang (1995) also suggest c-fos and c-jun, immediate early genes (IEGs),
combine to form the AP-1 complex, a transcription factor essential to the apoptosis
machinery. Thus the nucleus of a cell must synthesise its own suicide machinery.
Studies in the nematode worm Caenorhabditis elegans (C. elegans) provide the
most direct evidence that apoptosis occurs via a gene directed suicide programme
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(Raff et al. 1992). In C. elegans, 1090 cells are generated during the development of
the worm. Of these, 131 die by an intrinsic mechanism (Kumar, 1995). Studies have
revealed that 14 genes function in this programmed cell death. Of these genes, ced-3,
ced-4 and ced-9 play the most important roles in the control of cell death. The other
genes function in the engulfment and disposal of dead cells (Hengartner & Horvitz,
1994). The genes ced-3 and ced-4 are essential for the death of the cells, while ced-9
functions to protect cells from the death programme in cells not destined to die.
Elegant studies have been performed manipulating the expression of these genes in
order to determine their role in apoptosis. Mutations removing either ced-3 or ced-4
result in the worm having extra cells, although these extra cells do not cause the early
death of the worm (Ellis et al. 1991). By contrast mutants lacking ced-9, which
seems to act as a brake on the suicide program, undergo extra cell death and die early
in development (Hengartner et al. 1992). Further mutation experiments reveal that
the ced-3 expression is not dependent on ced-4 function since mutation of ced-4 has
no effect on ced-3 mRNA (Yuan et al. 1993). While ced-3 deletion results in extra
cells in C. elegans, overexpression of ced-3 has been shown to enhance apoptosis
(Miura et al. 1993).
Cloning of ced-3 reveals a protein of 503 amino acids of a novel cytoplasmic
cysteine protease family. The protein has many phosphorylation sites and expression
is greatest during PCD execution (Yuan et al. 1993). By contrast, ced-4 encodes a
novel protein with two potential Ca2+ binding domains (Ellis et al. 1991).The cloned
ced-3 revealed homology to the mammalian enzyme interleukin 1 P-converting
enzyme (ICE) (Yuan et al. 1993), suggesting evolutionary conservation of PCD,
although a mammalian homologue of ced-4 has not been discovered (Kumar, 1995).
Consequently a number of researchers have studied ICE with a view to
understanding whether it mediates apoptosis in human cells. ICE cleaves a 31 KDa
interleukin-ip precursor (pro-IL-ip) to generate the mature 17.5 KDa IL-ip
(Kostura et al. 1989), a cytokine and mediator of cell death itself (Yamasaki et al.
1995). ICE itself is activated by proteolytic cleavage from a 404 amino acid
precursor (p45) to form a dimer of p20 and plO, both of which are required for
function (Thornberry et al. 1992) as a tetramer of (p20-pl0)2. A number of lines of
evidence now suggest ICE and its homologs like prICE regulate apoptosis in
mammalian cell lines (Kumar, 1995).
Bcl-2 is structurally and functionally homologous to the C. elegans gene ced-9
(Vaux et al. 1992). As mentioned ced-9 acts as a brake on the actions of ced-3 and
ced-4 in C. elegans apoptosis. Abnormal activation of ced-9 abolishes the normal
developmental cell death, whilst if ced-9 is inactivated, many cells which normally
survive now die. Hengartner et al. (1992) showed that if ced-3 and ced-9 are both
inactivated neither the normal nor extra cell deaths occur, and the animal survives.
Bcl-2 encodes a membrane-associated protein (Martinou et al. 1994) from its proto-
oncogene sequence first identified in human follicular cell lymphomas. It is thought
to be associated with the cytoplasmic surface of the nuclear envelope, mitochondria
and endoplasmic reticulum. Bcl-2 protein is expressed in most neurones (Martinou et
al. 1994), but with age, expression declines in most neurones of the CNS but is
retained in peripheral nervous system neurones (Merry et al. 1994). The exact
function of Bcl-2 is unknown (Hockenberry et al. 1990; Raff et al. 1993). Bcl-2 is
now recognised as one member of a family of related gene-products including bcl-xl
and bax (Raff 1993; Martinou et al. 1994). It has since been identified as an
apoptosis suppresser in a number of models. Bcl-2 oncoprotein has been shown to
support cultured cells such as sympathetic neurones (Garcia et al. 1992; Allsopp et
al. 1993), cerebellar & nigral cells (Zhong et al. 1993) and PC 12 cells (Mah et al.
1993).
It appears that apoptosis is a gene directed program which, while distinct from
the cell cycle, may utilise proteins of the mitotic cycle. Specific enzymes and other
proteins essential to the cell cycle may be essential to a cells ability to undergo
apoptosis, although unique proteins may also be required. Of these genetic products,
a number of key regulators are beginning to emerge as well as some enzymes such as
ICE which may prove central to apoptosis. A cell may leave the cell cycle to undergo
a program of apoptosis, and studies have shown that most cells will in fact undergo
apoptosis if presented with the right environment and stimulus.
1.3.3. The ischaemic core
Studies suggest that a number of factors determine the ischaemic damage that results
from focal cerebral ischaemia. These include the severity of the blood flow reduction,
the duration of occlusion, the regional location of the insult, and the metabolic state
of the tissue prior to the ischaemic episode (Traystman et al. 1991). Consequently,
multiple mechanisms may contribute to cell death, and a given ischaemic insult
produces a gradient of challenges to cerebral tissue as a consequence of the vascular
blood supply. This translates into a broadly definable separation of the ischaemic
environment. The core or focus of an ischaemic area represents tissue heavily
dependent on perfusion from the occluded vessel, and cell death here is likely to be
due to loss of perfusional pressures causing severe tissue oedema within a localised
area. Cells within this area may well undergo lysis due to subsequent osmotic-
mechanical stresses (Siesjo 1992a). The interuption or cessation of blood flow to this
region is intense, and the complete collapse of cell membrane ionic gradients means
that cells undergo rapid and profound osmotic pressures whereby water enters cells
down a osmotic gradient. It is predicted that cell death within the core of an
ischaemic insult may result from such chemo-mechanic stresses.
Cerebrovascular morphology allows some generalisation as to the anatomical
distribution of core regions of ischaemia. Identification of major anastomoses as well
as end-territory vessels means that occlusion of a specific artery produces regions
reliably encompases by the term "core" and "penumbra". Rat MCA occlusion models
have documented the anatomical regions that fall within these terms in greatest
detail. The core region of ischaemia following MCA occlusion lies within the
striatum, which recieves its blood supply by the striate (lenticulostriates in humans)
branches of the MCA. Brain regions within the supply of this vessel do not receive
collateral perfusion, and occlusion of even short duration leads to infarction, as a
consequence of rapid energy depletion and osmolytic pressure. Neuroprotection
strategies show poor success in reducing striatal damage following MCA occlusion
in most cases (Butcher et al. 1990). By contrast much of the cortex within the
vascular supply of the MCA may receive some collateral circulation and areas distal
to the core may be amenable to neuroprotective intervention. However, certain
cortical structures close to the proximal segment of the MCA also represent core
regions, such as piriform cortex.
1.3.4. The ischaemic penumbra
Whilst the tissue closest to the site of occlusion (eg. piriform & insular cortex and
lateral striatum) is the core of the ischaemic area wherein energy failure due to
substrate depletion is rapid and often complete, the tissue lying further away from the
focus suffers less severe reductions in substrate depletion. Such an area may receive
some collateral perfusion, although still subject to oxygen and glucose deprivation,
and has been termed the "penumbra". This region displays characteristics specific to
its ischaemic predicament and represents the region of ischaemic tissue which may
be recoverable with pharmacological agents. The importance of intervening in the
penumbral events is illustrated by PET scan findings in human subjects that show
that penumbral (or peri-infarct) tissue is recruited to infarct over time (Heiss et al.
1992).
Astrup et al. (1981) defined the penumbra of an ischaemic region as brain tissue
perfused at a level between the thresholds of functional impairment and of
morphological integrity, which has the capacity to recover if perfusion is improved.
They made the point that the term ischaemic penumbra is descriptive only,
constituting tissue experiencing a compromised energy state and existing within the
boundaries of upper and lower thresholds but where residual perfusion prevents
deterioration towards necrosis. However with subsequent studies it is becoming clear
that despite "penumbra" being a term to describe a particular tissue state, within this
delineation some physiochemical factors are constants, some vary and some are still
a matter of debate.
Subsequent definitions of the penumbra of ischaemic tissue recognise the
complexity of the phenomena and the penumbra must be envisaged as an ischaemic
area where perfusional disturbance is tolerated according to the severity and duration
of the insult. This relationship and secondary mechanisms that extend this
disturbance make the penumbra a dynamic region in which damage progresses with
time from the core to the periphery of the ischaemic brain region (Heiss, 1992).
In researching what is a dynamic process of changes in ischaemic tissue (Strong
et al. 1983; Heiss et al. 1994), problems are inherent since the application of
techniques often requires established tempero-spatial details of the penumbra itself,
which is accepted as poorly definable in absolutes and more reflects a concept than a
physically definable entity, (i.e. one needs to know where the penumbra is in order to
study it but such a requirement is difficult to address due to the nature of the
phenomenon). Hence caution must be exercised in interpreting findings from "the
penumbra". Certain events have been used as constants in its definition such as the
loss of EEG activity in tissue not in the core of an occluded vessel's vascular territory
(Takagi et al. 1993), and monitoring the region of increased local glucose use
(lCMRglc) in combination with moderate acidosis (Peek et al. 1989). More erroneous
methods of definition have also been employed such as assigning a particular region
of neocortex (Folbergrova et al. 1992), an assumption which may not be altogether
valid. The penumbral region of an infarct may also be delineated pharmacologically
as that part of the infarct salvageable by drugs (Siesjo, 1992b).
The main metabolic characteristics of the penumbra are increased oxygen
extraction, acidosis, high glucose utilisation and residual ATP (Obrenovitch, 1995).
This is consequent to anaerobic respiration within the penumbra and increased
metabolic demands on the cells due to changes in extracellular EAA levels causing
depolarisation. There is not yet a precise consensus as to what level of CBF
constitutes "penumbra". Whilst the order of physiological and biochemical variables
is consistent between brain regions and tissues, the absolute values for a given region
are dependent on the metabolic and functional state of the tissue at the time of the
insult (Obrenovitch, 1995).
Many studies have however correlated blood flow reductions to metabolic
changes such as increases in lactate, and extracellular potassium. If penumbral tissue
represents that which is quiescent but within which the cells retain their structural
integrity, quite accurate levels of blood flow can be ascribed to the penumbra. This
level must therefore be below the threshold at which protein synthesis is inhibited
(~50ml/100g/min), but above that where ion and water homeostasis is lost (6-
15ml/100g/min) (Hossmann, 1994), which would represent irreversibly damage
tissue.
The penumbra constitutes a relatively narrow rim surrounding the core area of
ischaemia (Obrenovitch, 1995). Hossmann (1994) suggests the physical location of
the penumbra following MCA occlusion can be visualised by subtracting the region
where ATP is reduced from an image of decreased pH, and an emerging consensus
on where the penumbra typically exists has been achieved to some extent in models
of MCA occlusion. Many studies (Folbergrova et al. 1992; Takagi et al. 1993;
1994a; Tomlinson et al. 1993) identify the area of penumbra following MCA
occlusion as a region in the parietal cortex which overlies the core. The basis for this
varies between studies but usually derives from CBF reductions in regions not
commonly infarcted after MCA occlusion. Neuronal loss does occur within
previously penumbral tissue, but not as extensively as in the core, and penumbral
tissue will either infarct (if flow is not reestablished), recover (if flow is
reestablished) or remain functionally inactive (Tomlinson et al. 1993; Heiss et al.
1994; Hossmann, 1994). This latter point is poorly understood in a quantitative and
temporal context (Siesjo 1992a).
How recruitment occurs and how it can be prevented is much debated (Siesjo,
1992a). Either infarction will proceed, absorbing penumbral tissue until well-
perfused tissue is reached, or islands of necrosis develop in penumbral tissue that
may coalesce within the penumbra to extend the infarct. The excitotoxicity and
anoxic depolarisation theories may well account for the latter process, causing
already "at risk" cells to be subjected to conditions they are unable to withstand
(Heiss & Graf, 1994). This is supported by the finding that the magnitude of
glutamate release during ischaemia is correlated to infarct volume and hence, final
outcome (Takagi et al. 1993; Taguchi et al. 1993; Butcher et al. 1990). Evidence
exists that spreading depression contributes to recruitment (Obrenovitch, 1995).
Nedergaard & Astrup (1986) first described depression-like depolarisations which
might account for the expansion of tissue injury. However, SD is rarely observed in
humans or cats casting doubt as to its widespread significance in this context
(Obrenovitch, 1995).
That tissue within the penumbra can fully recover was demonstrated in the study
by Tomlinson et al (1993) in rabbits, using umbelliferone fluorescence to identify
changes in pH and CBF. Recordings showed the region comprising much of the
penumbra remained acidotic for 45 minutes post occlusion but returned to normal
after 3 hours. The pattern of return showed regions closest to collateral vessels
recovered first. Acidic foci within this region of mild (pH 6.61) acidosis were seen to
coalesce as time proceeded presumably as recruitment to infarct occurred, while
other areas recovered, supporting a number of outcomes for the ischaemic penumbra.
Specific protein and nuclear events may occur in the ischaemic penumbra (Heiss
& Graf, 1994). Of these, the expression of IEGs and heat shock proteins (HSPs) after
focal cerebral ischaemia has stimulated considerable interest (Welsh et al. 1992;
Kinouchi et al. 1993). Welsh et al. (1992) and Uemura et al. (1991) showed that
MCA occlusion in rats induces temporal and spatial patterns of c-fos protein
expression although c-fos is not expressed in the core. Furthermore c-fos expression
is modulated by MK801, a drug effective in salvaging penumbral tissue. Thus,
ischaemia may induce protein synthesis and nuclear transcription not normally
occurring in brain tissue. However, complications arise again since the distribution of
ischaemia and expression of c-fos, jun-B (another IEG) and HSP may occur in
territory not directly affected by MCA occlusion-induced ischaemia (Welsh et al.
1992). It is unclear at present as to the implications of IEG and HSP expression,
although there is the suggestion that it reflects progression of ischaemic injury as
well as the vulnerability of certain cell populations (Heiss & Graf, 1994).
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1.3.5. Mechanisms of cell death in stroke (1): Ionic changes
Three factors are of central importance in explaining the response of brain tissue to
ischaemia. The first of these is that the energy demands of the intact mammalian
brain are met almost exclusively by the oxidation of glucose (Siesjo, 1984;
Hossmann, 1994). Second is the high energy demands of the brain, which utilises
20% of circulating oxygen (Graham, 1984), and third is the inability of the brain to
store glucose in any significant quantity, making brain cells dependent on the
continuous delivery of substrates.
Since oxidative catabolism of glucose is required for adequate ATP production
via the mitochondrial respiratory chain, ischaemia rapidly devastates ATP production
and inadequate oxygen is available for any remaining glucose to be metabolised
efficiently. Neurones are capable of anaerobic respiration although this is an
inefficient and inadequate source of cellular ATP. ATP is the cells major source of
energy for enzymatic actions. In the resting neurone, an unequal distribution of
physiological ions and a membrane potential exist as a consequence of passive and
energy driven ion flux across the membrane. This uphill transport depends directly or
indirectly on ATP hydrolysis. The membrane potential is maintained by the Na/K-
ATPase, with the distribution of the K+ ion determining to a large extent the
membrane potential (Kuffler et al. 1984).
The Na+ gradient, which is distributed across the membrane with a roughly ten¬
fold difference between extracellular (high) and intracellular (low) concentrations, is
also of crucial importance as it is the ion that not only the propagates action
potentials but is a source of energy for the movement of other ions and substrates
into and out of the cell and for the reuptake of neurotransmitters (e.g. glutamate).
Loss of the Na+ gradient and hence Na+ homeostasis will prevent the extrusion of
certain ions, prevent cessation of certain neurotransmitter effects, and promote
cellular oedema as water is an obligatory molecule in Na+ movement. The initial
event following CBF interuption is thought to be the loss of sufficient ATP
production to maintain the crucial energy-dependent homeostatic functions such as
the Na/K-ATPase. Pump failure, as well as enhancement of membrane leaks are
believed to cause loss of ion homeostasis. Ion fluxes occur in two main phases in
cerebral ischaemia. First there is intracellular K+ loss and H+ accumulation. The latter
is a consequence not only of the switch to anaerobic metabolism which has the
consequence of producing H+, but also accumulation of intra- and extracellular
carbon dioxide (C02), which is no longer being removed and causes acidification of
the milieu as it forms the bicarbonate anion releasing H+ in water (Siesjo, 1992a;
Seisjo, 1984).
During the second phase, K+ still leaves the cell, and Na+, Ca2+ and CI" enter the cell
through voltage dependent sodium (VDSCs) and calcium (VDCCs) channels. The CI"
ion is obligate to Na+ movement. This causes cellular depolarisation, which is
preceded by extensive energy failure (Siesjo, 1992a; Seisjo, 1984).
The deranged pump-leak relationship, and the critically low ATP state of the cell
has the consequence that Na+, Ca2+, K+ and H+ ion levels cannot be re-established,
and they initiate a series of biochemical events which in the case of Ca2+ and Ff have
direct pathophysiological consequences for the cell, while the loss of the Na+ gradient
further promotes Ca2+ accumulation. Another pathologically important consequence
of the Na+ and CI" movement into the cell as the Na/K-ATPase fails is that
osmotically obligated water enters the cell, causing cell swelling and osmolytic
damage (Siesjo, 1992a; Seisjo, 1984).
1.3.6. Mechanisms of cell death (2): Excitatory amino acids and Ca2+
One of the key consequences of ionic homeostasis failure is extracellular
accumulation of neurotransmitters and evidence from a range of studies implicate
glutamate and other neurotransmitters as key factors mediating ischaemic cell death
(Choi, 1990). Indeed, of the neuroactive amino acids, accumulation of glutamate is
the most profound (Butcher et al. 1990). A number of processess lead to high
extracellular levels of glutamate during ischaemia including neuronal vesicle
exocytosis, compromised glial and neuronal reuptake (due to the compromised ATP
levels which are required for this process) and from the metabolic pool as a
consequence of cell lysis.
Glutamate release, and subsequent activation of its receptors during ischaemia,
has direct pathophysiological consequences for neurones. Glutamate is the most
abundant neurotransmitter in the brain, accounting for neurotransmission at -95% of
all central synapses, and acts at both ionotropic (NMDA and AMPA/KA) and
metabotropic (or quisquilate) receptors (Choi, 1990). In the case of the ionotropic
receptors, Na+ entry is gated directly by activation of either of the receptor "groups",
leading to cell depolarisation. The NMDA receptor additionally gates Ca2+ entry,
while the AMPA/KA receptors, although not directly gating Ca2+ entry, facilitate
Ca2+ entry via the opening of voltage dependent calcium channels (VDCCs) of which
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the L- (dihydropyridine) N-, P- and T- are best studied. The metabotropic glutamate
receptors are G-protein coupled receptors (GPCR) linked to phospholipase C (PLC)
and adenylyl cyclase. The former is a membrane bound enzyme which hydrolyses
membrane lipid to form diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).
IP3 is an hydrophilic molecule that triggers release of sequestered Ca2+ via the
opening of IP3 sensitive stores in the neuronal sarcoplasmic reticulum. Thus the
consequence of glutamate release is the depolarisation of postsynaptic cells, the
further propagation of action potential in the postsynaptic cell and a considerable rise
in intracellular calcium.
The involvement of glutamate in neurotoxicity can be traced back as far as the
demonstration by Lucas & Newhouse (1957) that L-glutamate could destroy
neurones in the retina. Excitotoxicity was the term used to describe the effects of
glutamate and related compounds, and this led to the postulation that such
compounds might contribute to the pathogenesis of CNS cell death in disease states
(Olney, 1969; Olney, 1986).
The neurotoxicity of glutamate can be divided into a three stage process (Choi et
al. 1990) - induction, amplification and expression. This is expressed as the initial
ionic intracellular derangements caused by glutamate receptor activation, with
resultant accumulations of Na+, IP3 and DAG. The derangements are then amplified,
most importantly by Ca2+ build up, and the pathogenic significance of Na+ and the
products of PIP2 hydrolysis elevating may be largely due to an enhancing effect on
Ca2+ accumulation. The final stage of glutamate neurotoxicity as outlined by Choi et
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al. (1990) is expression via the cascade of events which may include some or all of
the aforementioned consequences of raised Ca2+.
In vivo support for this hypothesis has been gained from studies examining
changes in excitatory amino acid (EAA) levels during stroke, and studies have
correlated increases in amino acids such as glutamate with histopathological
ischaemic damage following MCA occlusion in rats. Butcher et al. (1990) utilised
microdialysis to measure striatal and cortical changes in excitatory amino acids,
finding increases of >2000% for glutamate, and other potentially neurotoxic EAAs
following MCA occlusion in the rat, correlating these increases to the volume of
ischaemic damage. Wahl et al. (1994) provided evidence, not only of this raised
extracellular glutamate during stroke, but also evidence for the relative contributions
of different glutamate "pools" to extracellular accumulation. Using a rat model of
focal cerebral ischaemia and microdialysis, they found a biphasic increase in
extracellular glutamate after ischaemia was initiated. First phase (~10 min.) saw an
increase to ~36pM, the second phase (reaching a maximum after 55min.) reached
~82pM while at resting values levels were ~6pM. The overall changes in
extracellular glutamate were similar in zero Ca2+ ACSF, although the first phase
plateau was absent and extracellular glutamate increased at a slower rate in early
ischaemia. They concluded that most glutamate released into the extracellular space
in severe ischaemia is not from transmitter pools but metabolic in origin - a
consequence of ischaemia-induced neuronal damage, an idea first suggested by
Jorgensen & Diemer, (1982). However, this does not rule out the contribution of
neurotransmitter glutamate following cell death or consequent on glutamate uptake
reversal. The evidence in this report might be considered cautiously given the
complex problems in producing zero calcium in the extracellular milieu and in light
of the findings of Obrenovitch et al. (1995) who showed that microdialysis can
influence pathological conditions during studies by buffering changes in extracellular
fluid composition. However, it seems that Ca2+-dependent ischaemia-induced
glutamate release (i.e. from neuronal pools) may be minor in comparison to total
overflow of extracellular glutamate. This is also supported by the finding that
exocytosis would not be sustainable for more than a few minutes as NMRS has
shown ATP depletion within 10 minutes of complete ischaemia (Shimizu et al.
1993).
Induction of massive glutamate release during ischaemia leads to an
unphysiological influx of Ca2+ to the cell (Choi, 1990). An increased intracellular
Ca2+ concentration is one of the mechanisms that contribute to ischaemic cell damage
(Heiss & Podreka, 1993), and perhaps the most important consequence of a perturbed
cellular energy state (Siesjo & Bengtsson, 1989). Extrusion of Ca2+ is decreased due
to reduced Ca2+-ATPase or the 3Na+/Ca2+ exchange activity and decreased binding or
sequestration of Ca2+ which is compromised by the failure of sarcoplasmic reticulum
pumps and displacement of Ca2+ from binding proteins due to intracellular acidosis.
Identification of specific downstream effectors of pathological Ca2+ levels is
incomplete, but activation of one or more Ca2+-dependent enzymes such as PLA2,
PKC or the calpains has been proposed to account for at least some damage that can
originate from Ca2+overload and maybe kill neurones.
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1.3.7. Free radicals and nitric oxide
There is growing evidence that the formation of free radicals also contributes to
ischaemic brain damage (Kiyota et al. 1993; Choi el al. 1993). The sequential,
univalent reduction of molecular oxygen results in the formation of a number of free
radicals (molecules with an unpaired electron). These include the superoxide anion
(02") and the hydroxyl radical (OH ), while another free radical species, nitric oxide
(NO), may also be of significance (Werns & Lucchesi, 1990).
Although NO mediates some neurotransmission, it may be neurotoxic under
certain conditions (Dawson & Snyder, 1994), and NO has been postulated as having
a role in the pathogenesis of brain damage during ischaemia (Dawson et al. 1992).
Dawson et al. (1991) proposed that NO formation by neuronal cNOS (constitutive
nitric oxide synthase) mediates NMDA receptor-mediated neurotoxicity. NO has
subsequently been implicated in glutamate neurotoxicity from studies in a variety of
tissues including striatal slices (Kollegger et al. 1993), hippocampal slices (Izumi et
al. 1992; Moncada et al. 1992; Wallis et al. 1992) and cell culture experiments
(Corasaniti et al. 1992, Tamura et al. 1992; Dawson & Snyder, 1994). Contradictory
evidence of a role for NO inhibition in glutamate neurotoxicity has also been
reported (Demerle-Pallardy et al. 1991; Pauwels & Leysen 1992; Regan et al. 1993).
A role for NO in mediating neurotoxicity are derived from the efficacy of
procedures that decrease NO production and effects. These include inhibitors of nitric
oxide synthase (NOS), calmodulin antagonists (essential NOS cofactor), flavoprotein
inhibitors and reduced haemoglobin (which scavenges NO), which reduced
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neurotoxicity in primary cultures of cerebral cortical neurones (Dawson & Snyder,
1994).
Glutamate activates NO production by gating Ca2+ entry via NMDA receptor
activation and NOS is activated by increases in intracellular Ca2+. It is suggested the
neurotoxic effects of NO over-production in cells probably evolves from its
interaction with the superoxide anion to form peroxynitrite (Beckman et al. 1990;
Beckman, 1991). Such species (or NO itself which can exist in free radical form)
may then damage intracellular components leading to cell death or lysis. NO may
damage cellular DNA (Zhang et al. 1994), which may have a secondary neurotoxic
effect. Damage to cellular DNA stimulates the nuclear enzyme poly (ADP ribose)
synthetase (PARS) to catalyse attachment of 50-100 ADP-ribose units to proteins
such as histones as well as PARS itself (de Murcia et al. 1991). For each molecule of
ADP-ribose added, 1 NAD is used, and 4 ATP is used to regenerate NAD. NO is also
known to poison the mitochondrial chain (Dawson & Snyder, 1994), attenuating
cellular function on restoration of metabolite levels.
Evidence exists for changes in NO levels during focal cerebral ischaemia.
Malinski et al. (1993) found increases from <10nM to 2.2pM subsequent to transient
MCA occlusion, while Sato et al. (1993) reported increases in NO commensurate to
the degree of global ischaemia, and Kader et al. (1993) reported NO metabolite,
cGMP and NOS activity increases following onset of focal cerebral ischaemia.
However, it is currently unclear as to the contribution of each potential source of NO
(neuronal, glial and/or endothelial.
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1.3.8. Intracellular enzymes
Activation of Ca2+-dependent enzymes such as the calpains has been proposed to
account for some ischaemic cell damage. Calpain is a Ca2+-activated neutral protease,
of which there are two major isoforms. Calpain also appears to be a selective enzyme
for a subset of intracellular proteins (Lee et al. 1991). Amongst its targets are
cytoskeletal proteins (e.g. spectrin), G-proteins, enzymes involved in signal
transduction and transcription factors. Cytoskeletal breakdown may therefore be
triggered by activated calpain, leading to decreased membrane continuity and as a
consequence of compromised energy, loss of the ability of the cell to resynthesize
necessary membrane components. This may lead to cell lysis. In vitro and in vivo
evidence for a role for calpain include:
1. The calpain inhibitor MDL 28170 and calpain inhibitor 1 were shown to improve
functional recovery of hippocampal and gerbil neocortical slices from hypoxia
(Arlinghaus et al. 1991; Hiramatsu et al. 1993).
2. In vivo, MDL 28170 significantly decreased infarct in a rat model of focal
cerebral ischaemia (Hong et al. 1994), while Rami & Kriegstein (1993) found
calpain inhibitor 1 to be protective in the CA1 subfield of the hippocampus in a rat
model of global ischaemia.
3. The novel calpain inhibitor AK295 has been shown to be protective in a focal
cerebral ischaemia model (Bartus et al. 1994).
There is growing evidence for a role for the protein phosphatase calcineurin in
mediating cell death. Calcineurin is a Ca2+-activated protein phosphatase of the
serine-threonine type that has been identified in a number of tissues including the
brain. Recently the immunosuppresant FK506 has been demonstrated to exhibit
potent neuroprotectant actions following focal cerebral ischaemia. Sharkey &
Butcher, (1994) demonstrated that FK506 is as efficacious as MK801 in reducing the
volume of infarct following MCA occlusion. FK506 (Tacrolimus) is a 23-membered
ring macrolide, which has strong immunosuppressive effects (Kino et al. 1987;
Tamura et al. 1994). It has been widely employed for suppressing organ transplant
rejection as well as some other applications including treatment of autoimmune
diseases (Tamura et al. 1994). Its intracellular effects show some mechanistic
analogy to other immunosuppressants like cyclosporin A and rapamycin. FK506
binds to an intracellular receptor (immunophilin) now designated FKBP 12 (a 12 kDa
molecule). (Harding et al. 1989; Siekierka et al. 1989a; 1989b). Immunophilins are
small soluble receptor proteins that mediate the drugs actions of FK506, rapamycin
and cyclosporin (Sabatini et al. 1994). Cyclophilin and FKBP differ markedly in
amino acid sequence, but both have peptidyl-propyl cis-trans isomerase activity
(rotamase activity). This activity is inhibited by cyclosporin and FK506 respectively
(Heitman et al. 1992). This action alone has been shown not to account for the
immunosuppressive effects (Bierer et al. 1990; Tropschung et al. 1989). In fact the
mechanism by which FK506 exerts this effect is by binding of the FK506-FKBP
complex to calcineurin (Liu et al. 1991). Calcineurin is a Ca2+-activated protein
phosphatase of the serine-threonine type, whose activity is required for the Ca2+-
dependent step in T-cell activation via the T-cell receptor. Calcineurin inhibition
decreases IL-2 mRNA transcription by blocking dephosphorylation of the IL-2
specific nuclear promoter factors (Flanagan et al. 1991; Lea et al. 1994), and
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preventing consequently formation of active nuclear factor of activated T-cells.
(Schreiber & Crabtree, 1992).
Rapamycin, is another immunosuppresant which binds the same immunophilin
as FK506 and each will compete for this site in vivo (Bierer et al. 1990; Sharkey &
Butcher, 1994). However the intracellular target of the rapamycin-FKBP complex
has not yet been identified, but Sabatini et al. (1994) identified rapamycin and FKBP
targets 1 & 2 (RAFT 1& 2).
An immunosuppressive action could account for FK506's neuroprotection
abilities, however there are a number of reasons to suggest this is not its mechanism.
The extent to which FK506 can reduce damage is far greater than effects found with
whole body irradiation (Kane et al. 1992), and rapamycin, which is
immunosuppressive and binds FKBP 12, is not neuroprotective (Sharkey et al.
1994). Evidence for the presence of components necessary to a neuronal site of
action was reported by Dawson et al. (1994). They found that FKBP, cyclophilin and
calcineurin are heterogeneously distributed, and mainly neuronally located. A very
close co-localisation of FKBP & calcineurin, and cyclophilin & calcineurin was
reported by Jayaraman et al. (1992). Timerman et al. (1993) showed that FKBP 12
interacts with the ryanodine receptor which can mediate intracellular Ca2+ release and
an interaction with the IP3 receptor has also been found (Sabatini et al. 1994). An
interaction in this process might modify the neurotoxicity of increases in intracellular
Ca2+ during ischaemia. Furthermore Ca2+ has been shown to damage mitochondria,
especially under oxidative stress (Connern & Halestrap, 1994), opening pores in
mitochondrial membranes which allows potentially irreversible swelling damage. An
immunophilin is believed to mediate the pore formation and cyclosporin A, by
binding a specific immunophilin, inhibits this. The process of Ca2+-activated IP3-
mediated Ca2+ release, which is one of the processes by which the IP3 Ca2+ signal is
increased, appears to be Ca/CaM kinase II mediated, and FK506 is found to affect
this (Zhang et al. 1993). FK506 is also neuroprotective against glutamate-induced
toxicity in cortical cultures via the prevention of calcineurin mediated
dephosphorylation of NOS (Dawson et al. 1994).
1.3.9. Thresholds in cerebral ischaemia
Critical threshold CBF values required for maintenance of functional and structural
integrity of the brain have been determined through a number of species and models
(Kalimo et al. 1997). These thresholds for events during ischaemia lie within certain
ranges (Hossmann 1994), although differences exist between species. In the rat, these
flow thresholds include inhibition of protein synthesis at 55-80ml/100g/min, acidosis
at 40-47 ml/lOOg/min & ATP loss at 13-19 ml/lOOg/min (Jacewicz et al. 1986; Mies
et al. 1991; Hossmann, 1994; Kohno et al. 1995). However, it must be recognised
that such thresholds are not definitive, and are dependent on the duration of
ischaemia (Heiss & Rosner, 1983). Consequently, whilst CBF may need to fall below
15ml/100g/min for infarction, if a level of ischaemia has been maintained for a
particular duration, the threshold level will increase such that higher levels of CBF
may still lead to infarction despite being above levels that at acute CBF levels are
insufficient to cause inraction. Consequently caution must therefore be exercised in
interpreting the implications of flow thresholds.
1.4. Modelling stroke
1.4.1. Methods of imaging stroke
Techniques which allow the imaging of the brain, both in terms of structure and
function can provide experimental research and clinical practice with potentially
valuable tools in cerebrovascular disease research. Indeed, there is considerable
cross-over between imaging techniques used in the clinic such as magnetic resonance
imaging (MRI) and computed tomography (CT), and the experimental situation,
although the laboratory research setting enables more invasive procedures to be
employed. Neuroimaging techniques are broadly divisible into invasive and non¬
invasive techniques. Invasive techniques, that include laser Doppler flowmetry
(LDF) and [,4C] iodoantipyrine autoradiography, will not be addressed in this section
since both approaches are described in greater detail in specific sections in which
these techniques have been applied. These techniques may be further separated
according to whether they measure changes in physical parameters such as water and
ions, or are functional, whereby the imaging technique may measure metabolic rates
which may (or may not) allow interpretation of cerebral events.
Early imaging of cerebral blood flow was based on l33Xe clearance rates, but
modern nuclear medicine techniques allow three dimensional mapping of cerebral
imaging and quantification of physiological variables. CT utilises multiple X-ray
absorption measurements to construct an anatomical image, whereby X-rays are
differentially absorbed according to tissue density (Auer & Benveniste, 1997).
Hounsfield & Cormack received the Nobel prize for medicine in 1979 for the
development of the first CT system (Auer & Benveniste, 1997). CT has subsequently
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been used extensively in clinical practice as it represents a technique with relatively
low running cost with good anatomical resolution, although lacks the ability to image
CBF or metabolism. Furthermore, whilst CT enables resolution of haemorrhagic
stroke better than other imaging techniques, non-haemorrhagic stroke is difficult to
resolve early following stroke (Auer & Benveniste, 1997). Its use is still prominant in
the U.K. but is declining in the U.S.A. as a consequence of the more widespread
introduction of MRI (Bruggen et al. 1994).
The technique of transcranial Doppler sonography (TCD) can accurately
evaluate cerebral blood flow velocities in intracranial vessels such as the MCA (Kerr
et al. 1993). The technique has been claimed to be as useful as a predictor of clinical
improvement in acute stroke as cerebral angiography, the technique of x-raying
cerebral blood vessels following introduction of a tracer, when performed early
(Hasley et al. 1988; Kushner et al. 1991). TCD provides a simple & cheap (by
comparison to techniques such as PET) non invasive method to assess vessel patency
and flow levels. As such it provides a method for the rapid assessment of stroke
patients when admitted to hospital.
Nuclear magnetic resonance imaging (NMR) or MRI was first applied to
medical research 40 years ago. Traditionally used as a non-invasive technique for
anatomical imaging with better resolution than CT (Budinger & Lauterbur, 1984),
MRI has become the imaging method of choice for CNS diagnostic investigation
(Bruggen et al. 1994). However, developments have enabled MRI imaging of certain
brain metabolites (Auer & Benveniste, 1997), employing MRI-detectable nuclei such
as 31P to detect metabolites such as ATP. MRI imaging can be broadly separated into
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perfusion and diffusion imaging, which represent blood movement and water
diffusion respectively. Blood perfusion may be studied by MR angiography,
clearance studies and bolus track imaging with MRI (Hossman & Hoehn-Berlage,
1995). Whilst, MR angiograpy, by which blood perfused vessels can be imaged in a
manner similar to conventional angiography, and clearance studies, which determines
blood flow according to conventional isotope clearance methods, are somewhat
limited in spatial resolution, bolus track imaging provides greater spatial resolution
and is the most attractive perfusion technique (Hossman & Hoehn-Berlage, 1995),
when combined with fast imaging techniques allowing subsecond temporal
resolution (van Bruggen et al. 1994). The technique is based on the introduction of a
magnetic susceptibitlity contrast agent to the circulating blood, the passage of which
is then tracked through the brain. Such agents include metal ions with high magnetic
moment which cause perturbations in the normal magnetic field during their passage
which can be imaged as a loss of signal intensity (van Bruggen et al. 1994; Hossman
& Hoehn-Berlage, 1995).
MRI diffusion-wieghted imaging is based on brain water diffusion modulation
of signal intensity (Hossmann & Hoehn-Berlage, 1995), and in practice MRI is
applied most effectively to the detection of the proton signal from 'H20, as the high
water content of the brain (80% by weight) means the proton concentration is greater
than 80M resulting in high spatial and temporal resolution (van Bruggen et al. 1994).
Since ischaemia rapidly induces changes in ion and water homeostasis due to
membrane potential collapse, diffusion-weighted images (DWI) allow rapid
assessment of ischaemia-induced parameters, and diffusion-weighted MRI has been
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applied to a large number of focal cerebral ischaemia studies, providing detailed
spatio-temporal information both in the clinic and in experimental research (Back et
al. 1994a; Mintorovitch et al. 1991; Zhang et al. 1997). The technique has also been
correlated and validated against histological end points. Studies suggest diffusion
images correlate well with histopathology, although DWI may encompase a larger
area than becomes recruited. DWI and brain water changes may not necessarily
represent irreversibly damaged tissue (Hossmann & Hoehn-Berlage, 1995).
Experimental therapeutic interventions have also been assessed using MRI, to assess
the tissue response, and evolving infarct (Seega et al. 1993; Zhang et al. 1997).
Whilst, MRI may be applied to resolve water/oedema and metabolite changes in
the brain, PET and SPECT allow direct determination of CBF, CBV, CMR02 and
permit assessment of tissue functionality. PET represents the most costly and
complex neuroimaging technique, requiring an on-site cyclotron, for the generation
of positron-emitting tracers such as H2150, and a team of radiation physicists,
chemists, radiologists and specialists in nuclear medicine (Meyer et al. 1993).
However, since it can use carbon, oxygen and nitrogen tracers, it provides high
spatio-temporal resolution of all the main neurological parameters simultaneously,
including CBF, CBV, CMR02, tissue pH and CMRglu (Heiss & Podreka, 1993;
Wyper, 1993). By contrast with PET, SPECT utilises commercially available single
photon emiting racers such as "mTc and employs y cameras which are available to
many nuclear medicine deparatments (Wyper, 1993), but is limited in the parameters
that can be studied, and metabolites cannot be measured (Heiss & Podreka, 1993).
However, 123I labelled compounds mean that neurotransmitter systems can be
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investigated using SPECT for neuroreceptor binding determination (Wyper, 1993).
Thus, currently SPECT has found its most widespread application in localising
epileptic foci, and in vivo neuroreceptor binding (for example in schizophrenia
research) (Wyper, 1993), and it is likely to become the functional imaging technique
of choice due to its advantages over PET. In conclusion, neuroimaging techniques
such as MRI, PET and SPECT offer unprecedented insight into understanding the
pathophysiology of stroke, therapeutic intervention and may provide the basis for
clinical diagnosis in the future.
1.4.2. Modelling stroke: Medical importance
Understanding of the underlying pathophysiological mechanisms of cerebrovascular
disease is still incomplete (Akopov et al. 1997). However, most of our understanding
of the pathophysiology of cerebral ischaemia has arisen as a consequence of
experimental research in animal models of stroke (Overgaard, 1994). Whilst
neurological assessment and modern imaging techniques provide the clinician with
insight into human stroke, there are many reasons why experimental research in
animals is essential. Taking some of the most important examples in turn, animal
models provide the researcher with the capacity to control the duration of an
ischaemic insult, and include a secondary phase of reperfusion. In human stroke,
vascular occlusion may often spontaneously resolve (Overgaard, 1994), and at a time
point that cannot readily be controlled without specific intervention. This prevents
interpretation of the influence of time over the pathophysiological processes
following stroke. Another advantage of experimental modelling of stroke in animals
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is the avoidance of co-existent disease states and inter-patient variation which
introduce confounding influences in the maturation of a lesion and data
interpretation. These include differential vascular anatomy, hypertension and
cardiovascular disease which have profound influence on the pathophysiological
outcome following stroke (Macrae, 1992; Gorelick, 1995).
Animal models enable the researcher control of physiological parameters such as
blood pressure, plasma glucose, temperature and blood gases which may have
profound influences on ischaemic events (de Courten Myers et al. 1994; Xue et al.
1992; Macrae, 1992). For example, high pC02 causes a direct increase in CBF (Tuor
& Farrar, 1984), whilst temperature may reduce or exacerbate ischaemic damage
(Morikawa et al. 1992). Such parameters may vary widely between patients admitted
suffering cerebrovascular disease. Further considerations are the relative cost of
animal research to that in human subjects, the ability to use invasive methods and
ethical considerations.
Animal research also allows the genetic manipulation of certain parameters. This
is expressed in two major ways. First is the use of spontaneously hypertensive or
stroke prone rats (Coyle et al. 1984), which has benefited our understanding of the
influence of factors such as hypertension on stroke outcome, as well as providing
insight into the genetic basis for these conditions. Second is the breeding of animals
lacking (knock-out) or over-expressing particular genes, which has enabled the
contributions to ischaemia of very specific variables such as isoforms of nitric oxide
(Huang et al. 1994; Hara et al. 1996) and superoxide dismutase (Yang et al. 1994;
Kamii et al. 1995).
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1.4.3. Rodent models of stroke
No one species fulfills the ideal criteria for a practical, convenient, economic and
appropriate animal model of stroke. Satisfying criteria such as cost and practicality
by the use of rodents such as the rat sacrifices potentially important features of
comparativity; for example, unlike the primate and some larger species of laboratory
animal like the cat, the rat is not gyrencephalic. However, larger species such as the
cat have a different cerebrovascular anatomy to the primate whilst suffering short¬
falls in terms of practicalities and economic cost. Consequently, a range of species
are regularly used to model stroke, each having advantages and drawbacks. However,
it is the rat that has been most extensively adopted. An experimental model of stroke
in the rat was first described by Robinson et al. (1975), whereby the surgically
exposed MCA was ligated, which produced a somewhat variable cortical lesion.
Prior to this, O'Brien & Waltz (1973) had described MCA in the cat via a transorbital
approach.
1.4.4. Models of stroke (1): Focal vs global
Cerebral ischaemic insults to the brain are of two main types: Focal cerebral
ischaemia, describes the occlusion or narrowing of the lumen of a cerebral artery that
reduces CBF to a level that leads to functional impairment of neuronal function and a
"stroke". Global/forebrain cerebral ischaemia describes the situation in which
systemic circulation fails and CBF to the whole brain becomes insufficient. The time
interval between the onset of ischaemia and the appearance of neuronal damage is
dependent on a number of factors such as the severity and duration of ischaemia, but
also on the model type (Overgaard, 1994). Focal cerebral ischaemia usually leads to
tissue damage consisting of a central core of densely ischaemic tissue (infarct)
surrounded by a rim of selective neuronal loss, as a consequence of differential CBF
gradients. Furthermore, studies on a number of species have demonstrated that
infarction is uncommon within 3 days when occlusion times are 30 minutes or less
(Overgaard, 1995; Du et al. 1996). By contrast such gradients are absent following
global cerebral ischaemia, irreversible damage usually develops rapidly, and a
generalised pattern of tissue damage is found throughout the brain, although some
regions are selectively vulnerable (Auer & Benveniste, 1997; Kalimo et al. 1997;
Overgaard, 1995).
Since the majority of human strokes are caused by the occlusion of an
intracranial artery (McAuley, 1995), models of focal cerebral ischaemia have been
more extensivley applied to understanding stroke (Kalimo et al. 1997). Flowever,
application of both have yielded important information regarding the
pathophysiology of stroke, and the efficacy of a range of putative neuroprotectants.
Studies utilising models of global cerebral ischaemia have also showed that there is a
morphological hierachy of cell death following ischaemia, whereby neurones are the
most sensitive, and a selective vulnerability when ischaemia is brief (Auer &
Benveniste, 1997; Kalimo et al. 1997).
1.4.5. Models of stroke (2): Permanent vs reversible
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Models of both focal and global cerebral ischaemia may be either permanent or
reversible, describing either the permanent interuption of CBF or the re-introduction
of CBF respectively (Auer & Benveniste, 1997). The duration of ischaemia seems to
be a critical determinant in whether blood flow returns to the intracranial contents
(global) or vascular territory of the occluded vessel (focal). Indeed, permanent or
non-perfused brain is a clinical phenomoena associated with extended delay before
flow return and is believed to be caused by intrinsic resistance of the cerebrovascular
bed (Auer & Benveniste, 1997). This no-reflow phenomenon is also seen following
focal cerebral ischaemia with reperfusion (del Zoppo, 1994). Thus,
pathophysiological outcome in both permanent and reversible focal and global
cerebral ischaemia may be dependent on both recirculation as well as events during
the ischaemic insyult (Hossmann, 1982).
Models of permanent focal cerebral ischaemia have been of importance in our
understanding of the pathophysiology of stroke such as flow thresholds, the
ischaemic penumbra, the excitotoxic hypotheis of cell death and the evaluation of
putative neuroprotectants (Obrenovitch, 1995; Macrae, 1992; Hossmann, 1994).
However, with the understanding that human stroke is predominantly associated with
a degree of recannilisation (Overgaard, 1995), incorporation of occlusion with
reperfusion is becoming accepted as a prerequiste in models of focal cerebral
ischaemia. The addition of reperfusion to models adds a dimension to stroke research
that allows the identification of differential contributions of factors such as free
radicals and the inflammatory response which have subsequently been found to be of
pathophysiological significance following reperfusion. Furthermore, with the advent
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of licensing for "clot-buster" such as t-PA (NINDS, 1995), a more complete
understanding of the implications of reperfusion, its pathophysiology and temporal
importance, will be required.
1.4.6. Subtemporal MCA occlusion
Models of MCA occlusion based on surgical exposure and subsequent occlusion of
the MCA artery were developed in the 1930s through work on primates (Peterson &
Evans, 1937). More recently the approach has been adapted and applied to small
mammals, particularly the rat (Albanese et al. 1980; Robinson et al. 1975). MCA
occlusion following subtemporal craniotomy and proximal occlusion described in the
seminal papers by Tamura et al (1981a; 1981b) became the "gold standard" MCA
occlusion technique during the 1980s, and is still extensively used. The study
described both quantitative histopathology as well as quantitative autoradiographic
determination of local CBF by the [14C]iodantipyrine method of Sakurada et al.
(1978). The model was of permanent occlusion utilising diathermy to occlude the
MCA. The approach fulfilled many of the criteria desirable in modelling human
stroke, whereby the infarct was extensive, incorporating the cortical & striatal
structures within the vascular field of the MCA, reliable, and employed physiological
monitoring. Subsequently, the model has been implicit in our understanding of the
pathophysiology of stroke establishing flow thresholds for ischaemic injury, the
concepts of penumbral and core regions of ischaemic insults and neurological deficits
associated with experimental stroke (McAuley, 1995). Subsequent alterations have
led to models of cortical-dominant infarction by distal occlusion and early models of
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occlusion with reperfusion, that employed clips or ligatures in place of
electrocoagulation (Shigeno et al. 1985; Soriano et al. 1997). The model does have a
number of constraints. These include the need for craniotomy, which can lead to
tissue dessication and thermal injury, and the extensive damage to facial structures
incurred during the procedure which can limit application to behavioural analysis and
post operative recovery (McAuley, 1995; Sharkey et al. 1993).
1.4.7. Intraluminal filament models
Koizumi et al. (1986) introduced a new model of focal cerebral ischaemia which
utilised an intravascular thread, advanced to the origin of the MCA via the external
and internal carotid arteries to occlude the blood supply to the MCA territory. This
model, and subsequent variations (ZeaLonga et al. 1989), are established now as the
model of choice in experimental focal cerebral ischaemia studies on the rat. The
model has advantages over the transorbital approach by avoiding need for
craniotomy and the extensive surgical intervention incurred in exposing the MCA.
Furthermore the model is ideally suited to reperfusion, by simple withdrawal of the
suture, which can be performed in the absence of anaethesia. However, many
limitations exist with this approach which are not reflected in its extensive adoption.
In early studies infarct volume variability was a significant problem, although
subsequent modifications by coating the suture, for example in silicon, have
improved reliability. A second limitation of the model is damage to structures
outwith the vascular territory of the MCA. Damage to midline structures consequent
on occlusion of the ACA is common due to the limited spatial separation relative to
the MCA, whilst structures within the thalamus and the hypothalamus commonly
undergo ischaemic damage using this technique. This limits interpretation of
behavioural studies and may add additional problems such as hyperthermia
consequent to damage to such brain regions (Zhao et al. 1994). The third limitation
of the approach is due to the extensive damage to the endothelial lining of cerebral
blood vessels inherent in the occlusion procedure which may introduce an artifactual
inflammatory response (McAuley, 1995).
1.4.8. Photothrombotic models
An alternative approach to physical vascular occlusion are photothrombotic models
of focal cerebral ischaemia (Watson et al. 1985; Dietrich et al. 1987). The
experimental approach utilises irradiation of a photoreactive dye, systemically
introduced, to form a thrombus consequent on the reaction of free radicals that
damage the endothelial lining of cerebral vessels & blood elements by peroxidation
below the irradiation site. Vascular occlusion is achieved non-invasively, and vessel
damage is limited to a relatively small area by comparison to the intraluminal suture
approach. The model therefore possess inherent experimental simplicity and
versatility of target site. However, the model produces infarction only within cortical
structures and variability is high (McAuley, 1995), although the volume of infarction
may be as great as that seen in other models (Markgraf et al. 1993).
1.4.9. Thrombotic/embolic models
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The increasing need for investigation of thrombolytic therapy subsequent to t-PA
approval (NINDS, 1995) has driven an interest in the further development of models
of embolic and thrombotic stroke that more accurately replicate the clinical setting
(Overgaard, 1994). Early models employed the approach of injecting blood clots
directly into the carotid arteries (Hill et al. 1955), although the variability and
mortality rates have led to subsequent modification (McAuley, 1995). Microsphere
injection via the CCA allowed more reliable determination of ischaemic duration as
occlusion time was not subject to plasmin activation, although again variability in
lesion size and location have limited the application of this approach (McAuley,
1995; Overgaard, 1994).
Zhang et al. (1997) described a model of thrombotic focal cerebral ischaemia
that utilises the intraluminal suture approach to inject a thrombin-blood clot at the
origin of the MCA. This model proved reliable, with infarction within both cortex
and striatum, and was amenable to thrombolytic therapy (recombinant plasminogen
activator). Subsequent studies have demonstrated the efficacy of t-PA in this model
(Zhang et al. 1997).
1.4.10. Global/forebrain models
Global models of cerebral ischaemia, also termed forebrain ischaemia, have been
developed to model the conditions associated with cardiac arrest sensitive (Auer &
Benveniste, 1997; Kalimo et al. 1997). As with models of focal cerebral ischaemia, a
range of laboratory animals have been used including the cat, gerbil and most
commonly the rat. There are two basic surgical approaches, although different
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species require alterations. In the model described by Pulsinelli & Brierley, (1979),
four major arteries in the neck, the two carotids and two vertebrals, are occluded.
Bilateral carotid occlusion alone in the rat does not produce cerebral ischaemia due to
the vertebral artery supply, and injury is only achieved with 2-vessel occlusion when
combined with hypotension (Smith et al. 1984). However, in the gerbil, only the
carotid arteries need to be occluded to produce global ischaemia (Bode-Greuel et al.
1990), due to the absence of the vertebral arteries. Arterial occlusion times vary, but
are usually between 5 and 10 minutes, although this has been extended to 30 minutes
(Pulsinelli et al. 1979). The injury consequent on global ischaemia has been
addressed above, and is distinct from focal cerebral injury, with damage observed in
selectively vulnerable areas such as the hippocampal CA1 region, which is also seen
in humans following cardiac arrest and resusitation (Brierly & Graham, 1984; Petito
et al. 1987).
1.5. Neuroprotection in stroke
1.5.1. Introduction
Whilst clot-busting drugs such as t-PA, an anti-thrombotic agent, have recently been
approved for use in treating stroke victims (NINDS, 1995), this offers a method of
reintroducing blood flow to the brain but does not attempt to alter biochemical
pathways that may have been activated in cells still salvageable. Despite the
unavailability of a "stroke drug", a myriad of approaches have been tried. These
range from the early attempts to reestablish blood flow or reduce gross cellular
metabolism to current agents which may intervene in the cascade of biochemical
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messages which trigger cell death. Extensive research has helped elucidate the
mechanisms by which certain drugs or strategies may be neuroprotective which has
consequently provided information to facilitate not only our understanding of the
mechanisms of action of previously and currently employed research tools, but also a
detailed insight into the mechanisms by which cells die in ischaemia and an insight
into how we may approach therapy in the future. Historical aspects of both our
understanding of the events occurring in ischaemia as well as in drug development
means that different approaches have been employed at different times. Thus, initial
approaches were to physically reduce molecular events and reestablish blood flow on
a gross scale. This was superseded by attempts to interrupt the cascade of ionic
changes occurring, while more recently research has begun to centre on specific
disruption of the complex molecular cascades which may trigger cell death.
1.5.2. Physiological modulation
Influencing cellular metabolic activity, either to decrease oxygen/substrate demand
or improve mitochondrial efficiency, represents an early approach to treatment. Such
strategies or treatments include the application of hypothermia or the use of
barbiturates.
Interest in the application of hypothermia to reduce ischaemic damage dates back to
the 1950s (Lam et al. 1950; Rosomoff 1956; 1957). Xue et al. (1992) conducted
extensive animal studies into the effects of a variety of hypothermic conditions in a
rat model of permanent MCA occlusion, showing continual mild hypothermia
reduced neocortical damage volume, or at least retarded its development, while
transient mild intra-ischaemic hypothermia was seen to dramatically reduce the
volume of infarction with a transient MCA occlusion model. Morikawa et al. (1992)
also addressed the effects of hypothermia in models of both permanent and transient
focal cerebral ischaemia. They identified that hypothermia was beneficial in reducing
ischaemic damage, and found that hypothermia showed greatest efficacy in models
of transient MCA occlusion. Other studies have also demonstrated the efficacy of
hypothermia in focal cerebral ischaemi (Busto et al. 1987; Buchan & Pulsinelli,
1990; Onesti et al. 1991). Whilst hypothermia confers neuroprotection, hyperthermia
has been documented as detrimental to outcome following focal cerebral ischaemia
(Morikawa et al. 1992; Kim et al. 1996).
The mechanism of neuroprotection of hypothermia has been addressed.
Decreased temperature may inhibit the biosynthesis, release and uptake of various
neurotransmitters. Since enzymes perform the majority of cellular reactions, and all
these processes are energy dependent, a reduction in the kinetic energy of all cellular
molecules will mean all reactions slow down whilst energy containing molecules will
be sustained. A number of lines of experimental evidence supports a direct metabolic
action, and Hagerdal et al. (1975) demonstrated that cerebral metabolic rate (CMR)
declines linearly with temperature over the range 37-22°C.
Altering the glucose content of the blood during or after an ischaemic event has
been shown to have a number of effects on neuropathological outcome. In 1976,
Myers & Yamaguchi showed that hyperglycaemia could aggravate brain damage,
and a body of evidence has now accumulated to support a deleterious effect of
hyperglycaemia on neuropathological outcome (Myers & de Courten-Myers 1985,
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Siesjo, 1988b). Subsequently, effort has gone into determining if hypoglycaemia
might confer neuroprotection during ischaemia. The method usually used to produce
hypoglycaemia is by insulin infusion, and indeed a number of reports suggest such a
change can confer neuroprotection (Robertson & Grossman 1987; LeMay et al.
1988; Voll & Auer 1988; Voll et al. 1989; Strong et al. 1990). However, results from
studies where focal cerebral ischaemia models were employed, have not consolidated
the work in global models. De Courten-Myers et al. (1994) demonstrated that
hypoglycaemia, like hyperglycaemia, aggravates brain damage whilst outcome is
optimal in normoglycaemic conditions. This is also been supported by work by Yip
et al. (1991) and Jager et al. (1991) who also found that insulin-induced
hypoglycaemia aggravated brain injury. Possibilities for these discrepancies may lie
in the details of the ischaemic models, with beneficial effects being seen where
ischaemia was rapid and complete (<30min), while negative results were received in
studies where ischaemia was incomplete or prolonged. The mechanism itself by
which hypoglycaemia might work has not been extensively researched, but it is
thought that reduced glucose leads to a reduction in lactate production during
ischaemia might reduce the acidosis which occurs during ischaemia. However,
generation of protons from ATP hydrolysis may contribute to acidosis more than
from lactic acid production (Auer & Benveniste, 1997). Current evidence therefore
does not suggest therapeutic benefit from modulation of blood glucose.
Use of drugs to reduce energy demands or substrate requirement for a cell has
been investigated previously with the employment of drugs such as the barbiturates
and anaesthetics such as isoflurane. Such approaches follow the rationale that where
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oxygen supply is limited, depressing cerebral oxygen requirement may improve the
balance between supply and demand. However, the mechanism by which
hypothermia depresses metabolism (and hence enables the brain to tolerate prolonged
periods of circulatory arrest) probably differs from that of drugs such as the
baribiturates (Gisvold & Steen, 1985). Hypothermia causes a general depression of
cerebral metabolism, while barbiturates and perhaps anaesthetics, depress only that
part of metabolism related to active electrical function.
Barbiturate administration before or following vascular occlusion significantly
reduces the area of infarction in a number of species studied (Moseley et al. 1975;
Michenfelder et al. 1976; Tamura et al. 1979), although prolonged anaesthesia can
aggravate ischaemic damage following MCA occlusion (Selman et al. 1981; Sharkey
& Butcher, 1995). Barbiturates have been shown to have multiple synaptic and
nonsynaptic effects in the CNS, including decreasing presynaptic transmitter release
& decreasing Ca2+ conductances, and potentiating GABAergic responses (Rang &
Dale, 1991). Harvey et al. (1980) showed that barbiturates produce a dose-dependent
reversible depression of neurological function. Associated with this depression is a
parallel dose-dependent reduction in CMR and CBF, effects which plateau at the
point where the EEG becomes isoelectric (Shapiro, 1985). The suppression of
synaptic activity is associated with maximal depression of CMR02 and CBF of
-50% (Michenfelder, 1974). Furthermore, barbiturates cause non-uniform alterations
in local CBF and metabolism in different structures (Shapiro, 1975). Whilst the
mechanism by which barbiturates exert a protective effect is often accepted as via an
ability to depress brain metabolism during ischaemic periods, since barbiturates do
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not depress metabolism past an isoelectric EEG (Steen et al. 1983), and the
anticonvulsant action, that which decreases neuronal firing, may confer only minimal
metabolic depression in the energy-compromised ischaemic zone, the underlying
mechanism remains obscure..
1.5.3. Procedures to reintroduce blood flow
Blood flow can be improved by increasing blood pressure, reducing cerebrovascular
resistance or decreasing blood viscosity (Hossman, 1982). The reestablishment of
flow will theoretically reintroduce substrates to neurones to facilitate their survival.
The approach of directly influencing blood flow to an ischaemic region represents
one of the mechanisms by which early therapeutic strategies were targeted in stroke.
Such an approach may tackle the issue of cellular energy failure restoration, but not
the sequelae following energy failure and rather attempts to circumvent such
problems before they become irreversible.
Induction of hypertension which prevents or ameliorates the no-reflow
phenomenon, may be beneficial in later phases of post-ischaemic recirculation
(Hossman, 1982). The no re-flow phenomenon relates to regions of the brain that
cannot be reperfused after ischaemia (Gisvold & Steen, 1985). The cause of this
hypoperfusion may be due to erythrocyte sludging, platelet or neutrophil aggregation
and adhesion, pericapillary oedema or vasospasm (del Zoppo, 1995). Such
ischaemia-induced hypoperfusion may contribute further to damage avoidable with
adequate perfusion (Cantu et al. 1969). However, the benefits of induced
hypertension to overcome these events (e.g. with vasopressors) are controversial,
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with positive reports of induced hypertension to ameliorate no-reflow (Fischer &
Ames, 1972) being contrasted by contradictory results showing no effect
(Michenfelder & Milde, 1977) or deleterious effects (Fenske et al. 1978). Matsuoka
& Hossman (1981) report the lack of beneficial effect of induced hypertension as due
to the high resistance of collateral vessels greatly reducing the transmission of a
systemic pressure pulse to the ischaemic territory, while aggravation may be caused
by subsequent vasogenic brain oedema (Hossman, 1982).
Relief of vascular resistance using drugs such as nitroprusside (which releases
NO), Ca2+ antagonists, anti-adrenergic agents or by hypercapnia has been attempted
to improve reflow. However, with the exception of nimodipine, a Ca2+ antagonist
(Kazda et al. 1979), few of these therapies have been shown to reliably benefit
recovery (Hossman, 1982), with some exceptions (Zhang & Iadecola, 1994).
Reduction of blood viscosity has also been attempted, although there is also
controversy over its relative benefits for ameliorating ischaemic damage. The use of
viscosity reducing measures should improve oxygen delivery to the brain. Such
agents include albumin, saline, heparin (Stullken & Sokoll, 1976) and more recently
the antiplatelet agents like ticlopidine (Oster et al. 1994). Use of drugs affecting
prostaglandin synthesis (which includes aspirin) have also been implemented, but
results have not been successful (Boulu et al. 1981). However, haemodilution using
fluosol-DA, an oxygen carrier, has proved succesful in some focal cerebral ischaemia
studies (Peerless et al. 1981; Sutherland et al. 1984).
Despite research in the mid 1970s to early 1980s into ameliorating ischaemia-
induced damage by improving blood flow to ischaemic regions, there remains little
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compelling evidence that any dramatic effects are consistently seen with the
approach of the flow-improvement theory, although application of procedures in
combination may still be of therapeutic importance. For example Hallenbeck et al.
(1982) found the use of a drug combination of heparin with indomethacin and
prostacyclin improved neurological function in a canine model of ischaemia.
The most effective approach, and indeed the only therapy currently approved for
treatment of ischaemic stroke, is t-PA (NINDS, 1995). This protein activates the
plasminogen cascade that dissolves blood clots. This approach circumvents the need
to improve collateral perfusion, removing the vascular block directly. In mid-1996,
and following the NINDS t-PA Stroke Study, the Peripheral and Central Nervous
System Drug Advisory Committee to the US Food and Drug Administration voted
unanimously that t-PA was safe and effective therapy for acute ischaemic stroke
(Brott, 1996). However, there is a substantial risk of haemorrhage in patients treated
later than 3 hours post-stroke and for patients not suffering thrombotic/embolic
stroke.
1.5.4. 5-hydroxytryptamine
5-HT has been shown to increase during ischaemia in microdialysis studies (Richards
et al. 1993; Phebus & Clemens, 1989). However, a role for the serotonergic system
in the pathophysiology of ischaemia is still a matter of debate (Prehn et al. 1993). A
role in neurotoxicity was initially suggested by the findings of Berger et al. (1982),
who showed serotonergic denervation using 5,7 dihydroxytryptamine (5,7 DHT)
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partially protected the rat striatum from kainate neurotoxicity, whilst monoamines or
their metabolites may can become neurotoxic (Obrenovitch & Richards, 1995).
5-HT2/Ic antagonists have been shown to be neuroprotective in models of global
ischaemia (Bielenberg et al. 1989; Fujikara et al. 1989; Globus et al. 1992), and
protective effects of 5-HT1A agonists have been shown in a number of studies
(Bielenberg & Burkhardt, 1990; Bode-Greuel et al. 1990; Prehn et al. 1993). The site
of action of 5-HT during ischaemia has been addressed in a number of studies.
Effects on the cerebrovasculature are debatable since Nuglisch et al. (1990) showed
that the 5-HT1A agonist CM 57493 had no effects on intra- and postischaemic local
CBF in a rodent model of ischaemia (Prehn et al. 1993). Furthermore, Dietrich et al.
(1989) found that ketanserin, a 5-HT2 receptor antagonist increased local CBF in a rat
ischaemia model, but did not confer neuroprotection. However, a vascular site of
action was supported by the demonstration that 5HT antagonist Ketanserin increased
CBF within the area of focal ischaemia in a thrombotic model of stroke (Dietrich et
al. 1989). The involvement of the 5-HT2/lc system is confusing since, despite
neuroprotective findings of antagonists in models of forebrain and global ischaemia,
protective effects in focal cerebral ischaemia models have rarely been observed
(Prehn et al. 1993). Furthermore, the 5-HTlc antagonist emopamil also blocks the L-
type Ca2+ channel, complicating interpretation. 5-HT,c-receptors have been reported
to mediate excitatory effects (Beck, 1992), while 5-HT1A-receptor stimulation
activates a potassium conductance which would reduce neuronal activation by
hyperpolarisation (Andrade et al. 1986; Colino & Halliwell, 1987). The
hippocampus, where 5-HT1A ligands have been shown to be neuroprotective, is
enriched in these receptors (Chalmers et al. 1991) and, interestingly, the CA2
subfield, which is lowest in 5-HT1A-receptor numbers, has the greater susceptibility
to ischaemic damage.
5-HT1A agonists reduce glutamate release (Maura et al. 1988) which may offer
an explanation for how neuroprotective actions are mediated by certain 5-HT
receptors. By contrast, 5-HT2 receptor activation is detrimental, whilst antagonists of
this receptor confer neuroprotection (Zivin & Venditto, 1984), which might be
explained by evidence that 5-HT may enhance NMDA receptor responses (Reynolds,
1990). 5-HT, is also released from platelets, which may be involved in ischaemic
events by thrombotic occlusion.
1.5.5. Kappa opioids
The kappa opioid receptor (k receptor) has been clearly distinguished from other
opioid receptor subtypes such and selective ligands for the k receptor have been
developed. Tang (1985) and Hall & Pazara (1988) showed that agonists at the k
receptor, U50488 and U62066, reduced hippocampal CA1 cell loss resulting from
cerebral ischaemia in the gerbil. Furthermore, U50488 has been shown to reduce
mortality and oedema in the rat (Silvia & Tang 1986; Silvia et al. 1987) and the
cerebral oedema, cortical & striatal neuronal loss, and mortality occurring following
focal cerebral ischaemia in the cat (Silvia & Tang 1986; Tang & Silvia 1986). CI-977
(enadoline) has been shown to produce dose-dependent reductions in infarct volume
and brain swelling in a rat and cat models of focal cerebral ischaemia (Kusumoto et
al. 1992; Hayward et al. 1993; Mackay et al. 1993).
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The mechanism by which the effects might be mediated is still unclear, although
a number of suggestions have been made. These include a reduction in oedema and a
presynaptic mechanism to reduce release of EAAs, although the neuroprotective
mechanism is complicated by the number of effects of k receptor stimulation, k-
agonists may modulate the action of glutamate at presynaptic sites by inhibiting its
release, or a postsynaptic action by reducing EAA evoked Ca2+ entry, which is
supported by CI-977 inhibiting seizures in mice caused by NMDA (Singh et al.
1990), reducing glutamate release in vitro models of ischaemia (Lambert et al. 1991)
and the demonstration by McFadzean et al. (1987) that k-agonists acting
presynaptically inhibit transmitter release and EPSPs. Although k-agonists may
reduce the release of neuronal pools of glutamate, again the evidence that it is
glutamate of metabolic origin that comprises the majority of ischaemia-induced
glutamate release (Wahl et al. 1994), brings into question the significance of this
mechanism, although reduction of spreading depression may be a factor.
The other favoured mechanism by which k-agonists may mediate their effects is
by a reduction in cerebral oedema (Silvia et al. 1987; Silvia & Tang 1986). Kappa
agonists are diuretic and also modulate vasopressin release (Peters et al. 1987; Wells
& Forsling, 1991). Induction of a profound diuresis would increase plasma
osmolarity which may attenuate oedema formation and consequently secondary
ischaemic damage. A neuroprotective effect of diuresis has been reported for
mannitol, a hyperosmolar agent, which is neuroprotective in some models of
ischaemia (Little, 1978; Sutherland et al. 1988). Elowever, at the dose where CI-977
produces maximum diuresis, no significant effect was seen on ischaemic damage
(Hayward et al. 1993; Mackay et al. 1993). Furthermore, CI-977 confers
neuroprotection in the gerbil model of global ischaemia despite an absence of a
diuretic effect while the diuretic furosemide offers no neuroprotection at doses
producing diuresis in the gerbil (Hayward et al. 1992). In the study by Mackay et al.
(1993), plasma hyperosmolarity was not found with CI-977 until 120-180 min after
MCA occlusion which is likely to be outwith the therapeutic window of opprotunity,
and thus any action of diuresis is occurring at the limits or beyond successful
intervention (Mackay et al. 1993).
1.5.6. Calcium antagonists
Calcium channel antagonists have been employed in a number of studies with a view
to interrupting the biochemical cascade of events that calcium is believed to cause.
Careful consideration of calcium antagonists as a therapeutic approach for blockade
of increases in intracellular Ca2+ is important since modulation of CBF is a
mechanism by which calcium antagonists may mediate neuroprotection.
Furthermore, intracellular Ca2+ may increase due to stimulation of the sarcoplasmic
reticulum stores, via the IP3 receptor and the ryanodine receptor, so blockade of
VDCCs may attenuate only part of the ischaemia-induced Ca2+ entry. Conflicting
reports exist as to the contributions of VDCCs to events during ischaemia. The
spreading wave of depression that is thought to occur during ischaemia is believed to
be mediated by glutamate and K+ (Hansen 1985), the depolarisation consequent to
which should open VDCCs (Siesjo & Bengtsson 1989). However, spreading
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depression is in fact blocked by NMDA antagonists (Goroleva et al. 1987; Hansen et
al. 1988).
There are a large number of reports in the literature showing beneficial effects
of blocking Ca2+ entry using ligands selective for L, N & T Ca2+ channels in models
of stroke (Nakayama et al. 1988; Mossakowski & Gadamski 1990; Teasdale et
al. 1990; Kawamura et al. 1991; Morikawa et al. 1991; Shiino et al. 1991; Benham et
al. 1993; Valentino et al. 1993; Yamashita et al. 1993; Kashiwagi et al. 1994; Rami
& Krieglstein, 1994). However, for both NMDA antagonists and Ca2+ antagonists,
ameliorative effects are less commonly seen in global ischaemia, although some
studies have reported positive effects (Siembowicz & Hansen, 1978; Steen et al.
1985; Alps et al. 1987; Lin et al. 1990). Using Locke-type channel blockers,
Mohamed et al. (1985), Gotoh et al. (1986) and Jacewicz et al. (1990) showed that
nimodipine reduces infarct size when administered prior to MCA occlusion, while
Sauter & Rudin (1989) using isradipine demonstrated infarct reduction by -50%
following MCA occlusion in SHRs. The L-type blockers have been most extensively
used, although N-selective antagonists have proved effective (Yenari et al. 1996),
and Ito et al. (1994) reviewed a T-type antagonist, U92032 (which is also an
antioxidant confusing interpretation) which, like many of the L-type blockers, was
found to reduce neurological deficits in a rodent model of cerebral ischaemia.
Blockade of Ca2+ entry to neurones may not be the only mechanism by which
VDCC antagonists are effective. Indeed, blockade of vasoconstriction (or
vasodilatation) of cerebral vessels may be another mechanism by which VDCC
blockers are effective (Gisvold & Steen, 1985). A number of studies have shown L-
type antagonists to improve CBF in peripheral areas (Meyer et al. 1990; Sauter &
Rudin, 1989). Ohtaki & Tranmer (1993) investigated local CBF changes and
neuropathological outcome following administration of the novel calcium antagonist
AT877. They found that AT877 significantly improved local CBF during MCA
occlusion, as well as improved neurological outcome. They further report that the
brain tissue within the ischaemic zone was salvaged by i.v. AT877 primarily through
its action to increase CBF. The results of the study by Takayasu & Dacey (1990)
with AT877 also propose a vascular effect suggesting the drug can improve cerebral
microcirculation since AT877 may produce greater vasodilatation on parenchymal
arterioles compared to other Ca2+ antagonists.
Consideration of the studies whereby CBF changes have been observed and
consequent reductions in infarct volume found, as well as the ability of the drug itself
to pass through the BBB must be addressed. Not all studies on CBF increases during
ischaemia report beneficial effects and not all Ca2+ channel antagonists increase CBF
(Siesjo 1992b).
1.5.7. NMDA and excitatory amino acid antagonists
The implication of EAAs, and glutamate in particular, in ischaemic cell death has
been discussed above. Significant understanding of the pharmacology of antagonists
at glutamate receptors has been achieved in the last two decades (Fagg, 1985; Mayer
& Westbrook 1987; Choi 1990; Lodge & Johnson 1990; Watkins et al. 1990).
Antagonists for the NMDA receptor and the AMPA receptor are currently the most
selective. The NMDA-receptor complex has so far yielded the most sites for
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pharmacological modulation. Non-competitive antagonists that block from within the
ion channel, and display use-dependence, include MK801 (dizocilpine) and
phencyclidine. The NMDA receptor also contains a site for the co-agonist glycine
(Johnson & Ascher 1987), and this seems to be where kynurenate acts. Other
potential sites for modulation include the zinc and magnesium sites. Competitive
antagonists for the NMDA receptor include AP5 (a phosphonate) and CPP, while
competitive antagonists for the AMPA receptor include CNQX and NBQX.
Antagonists acting at the NMDA receptor, both competitive (AP5, CPP,
CPPene) and noncompetitive (MK801) have been used in both global/forebrain
ischaemia and focal cerebral ischaemia models. In global or forebrain ischaemia,
neither type of antagonist have proved consistantly successful or efficacious with
many studies showing no neuroprotective effects (Buchan et al. 1991; Fleischer et al.
1989; Lanier et al. 1990). However, a number of reports have shown neuroprotection
with these drugs in such models (LePeillet et al. 1992; Nellgard & Wieloch, 1992).
NMDA receptor antagonists have demonstrated greatest efficacy in focal cerebral
ischaemia models (Ozyurt et al. 1988; Park et al. 1988; Buchan et al. 1990; Choi,
1990; Gill et al. 1991). In the study by Gill et al. (1991), using a MCA occlusion
model, MK801 was found to reduce ischaemic damage volumes by 60% in the
cerebral cortex.
Whilst in vitro and in vivo work suggest that glutamate antagonists of the
NMDA and AMPA receptors are neuroprotective in many models, the mechanism of
action remains elusive. Uematsu et al. (1991) reported the mechanism to be due to
reducing intracellular Ca2+ changes and alteration of the NAD/NADH redox state, but
blockade of Ca2+ overload may not explain the mechanism by which such drugs exert
their effects. Buchan et al. (1989) suggests the neuroprotective effect of MK801 in
focal cerebral ischaemia may be due to a drug-induced increase in CBF (Gill et al.
1991), whilst physiological effects of hypothermia have been demonstrated for
MK801. Furthermore studies have demonstrated that the neuroprotective capacity of
NMDA receptor antagonists may be facilitated by producing hypothermia in
animals, although other reports show contradictory evidence (Kochhar et al. 1991).
1.5.8. Nitric oxide
NO has been postulated as having a role in the pathogenesis of brain damage during
ischaemia (Dawson et al. 1992). Low doses of nitroarginine compounds, which
competitively inhibit NOS, has been shown to reduce infarct volume in models of
focal cerebral ischaemia in rats (Buisson et al. 1992; Nagafuji et al. 1992; Trifiletti,
1992; Dawson et al. 1994), cats (Nishikawa et al. 1993) and mice (Nowicki et al.
1991). However a number of studies have also reported increases in infarct volume
with NOS inhibition (Yamamoto et al. 1992 Zhang & Iadecola, 1993; Kuluz et al.
1993; Morikawa et al. 1994), while in some studies no change occurred with NO
inhibition (Dawson et al. 1992; Morikawa et al. 1994). Furthermore, NO donors such
as SIN-1 and L-arginine have been shown to be neuroprotective in stroke models
(Zhang & Iadecola, 1994; He et al. 1995), although again, contradictory findings
have been reported (Prado et al. 1996).
These discrepancies may be explainable due to the multiplicity and diversity of
physiological and pathophysiological actions of NO (Dawson, 1994) and possibly
differences in experimental protocol. Perhaps the most important of these is blockade
of NO-mediated vasodilatation which may reduce CBF to cerebral tissue and
exacerbate injury (Dawson, 1994). Evidence for a precise role of NO in control of
CBF remains to be defined (Iadecola et al. 1994). However, NOS containing
endothelial cells in the cerebral vasculature and NOS containing adventitial fibres
(from the cranial autonomic ganglion) have been demonstrated (Nozaki et al. 1993;
Irakura et al. 1994; Pelligrino et al. 1993; Macrae et al. 1993). NO is clearly not the
only mediator of cerebral vasodilatation since autoregulatory responses and perhaps
those to hypoxia are not accounted for by NO effects, and NO may serve different
roles according to prevailing conditions (Iadecola et al. 1994).
Selective inhibitors, and transgenic animals deficient in a particular form ofNOS
have been developed to investigate the relative contribution of different NO pools to
stroke outcome. These studies have determined that whilst selective neuronal NOS
and inducible NOS inhibitors or knockout mice have smaller infarct volumes,
endothelial NOS inhibition or knockout aggravates ischaemic damage (Margaill et
al. 1997; Iadecola et al. 1997; Hara et al. 1996; Zhang et al. 1995). This suggests that
with production of more specifc NO inhibitors, targetting may allow therapeutic
isolation of the detrimental actions ofNO in stroke.
1.6. Endothelin
1.6.1. Discovery
Endothelins are a family of peptides with potent vascular actions that now occupy a
central position within the fields of cerebrovascular, pulmonary, cardiovascular, renal
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and hepatic disease research. The rate of discovery and insight has been dramatic and
the field is of direct importance to stroke research, not simply because of its possible
involvement in aspects of the pathophysiology of the disease, but in its application as
a tool to produce focal cerebral ischaemia. The origins of the discovery of endothelin
can be traced back to the work by DeMey & Vanhoutte (1983) & Rubanyi &
Vanhoutte (1985) examining the role of the endothelium in the facilitation of
contractile responses of isolated arteries, and Hickey et al. (1985) began work to
isolate this contractile substance.
1.6.2. Isolation and sequence cloning
Breakthrough in the endothelin story came as a consequence of the seminal paper by
Yanagisawa et al. (1988). They isolated a substance from the cultured supernatant of
porcine ECs. They discovered a 21-amino acid vasoconstrictor peptide, which they
named endothelin (ET), of Mwt. 2,492, which had free carboxy- and amino- termini
and had two disulphide bonds. They furthermore cloned the precursor peptide
(known as preproendothelin), and identified regional homology to the sarafatoxins
(SFXs) venom from the burrowing asp Atractaspis engaddensis. They also
determined the converting enzyme for the precursor peptide to be a zinc-containing
metalloprotease which was inhibited by phosphoramidon. The ECS0 for ET in a
porcine coronary artery assay was 4±2.2xlO"'°M, at least one arder of magnitude
lower than any other vasoconstrictor including angiotensin II, and as such has
established endothelin as the most potent vasoconstrictor peptide. Subsequently, a
family of endothelins has now been discovered within the human genome, and
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named endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3) (Inoue et
al. 1989). All are very similar at the 21 amino acid level, with more significant
sequence divergence at stages prior to final cleavage to form ET. Figure 1 illustrates
the primary amino acid sequence of the three ET isopeptides. All ET isopeptides are
derived from separate pre-proETs, which are processed by endopeptidases to
propeptides of 37-41 amino acids (Big ETs) (Rubanyi & Polokoff, 1994). The
carboxy terminus is the most highly conserved region between isopeptides, whilst
residues 4-7 make up the most variable region with the cysteine disulphide bridges
being between Cys1 & Cys15 and Cys3 & Cys" (Rubanyi & Polokoff, 1994).
Potent vasoconstriction was not the only action of ET, with the demonstration by
Warner et al. (1989) that low doses of proET induced vasodilation, although this
was not seen at higher doses. The significance of this finding would prove a key
point in the pharmacology of ET. Research into the structure-activity relationship of
these vasoconstrictor peptides began by use of substitutions and by truncating
peptides. Substitution of the cysteine residues for the pseudoisoteric amino acid
alanine were made and the peptides studied in a number of in vitro, in situ and in vivo
models. Work by Hiley et al. (1989) & Douglas & Hiley (1991) determined that
vasoconstrictor actions of ETs were not dependent on retention of the two sulphur
bridges, with [Ala3'"]ET-l and [Ala''15]ET-l, acting as vasoconstrictor agents in the
preparations studied, with only some loss of potency. Only the ET-1 peptide with all
cysteine residues substituted ( [Ala1'3'11'15] ) lost vasoconstrictor activity, but still
potentiated ET-1 responses when administered together. Furthermore, Hiley et al.


































and that, as opposed to constrictor activity, retention of sulphur bridges was
necessary for this action. Evidence that ET-1 released EDRF (either directly or as a
consequence of downstream effectors), was supported by the demonstration that
removal of the endothelium increased the pressor activity of ET in vitro.
1.6.3. Receptor cloning
Hiley et al. (1990) furthered initial study of the Ala-substituted ET compounds with
work using both the Ala-substituted peptides and truncated peptides in the rat
isolated superior mesenteric bed. The work confirmed functional studies suggesting
ET receptor heterogeneity, by showing differential orders of potency for
vasodepressor action over vasoconstriction with these peptides. While Ala-
substituted ET-1 (and a truncated ET]6.20) produced pressor responses, both
disulphide bonds were required for endothelium-dependent relaxation in the
mesenteric vascular bed. This suggests a differing pharmacophore within receptors
linked directly to constrictor actions and those linked to relaxation. The order of
potency for constriction in most models studied was ET-l=ET-2>ET-3, whilst
vasodilator responses showed no isopeptide selectivity.
ET receptor heterogeneity was confirmed conclusively by molecular biology
with the cloning of cDNAs encoding an isopeptide selective and non-isopeptide
selective receptors. Arai et al. (1990) reported the cloning of a cDNA for an ET
receptor which exhibited transmembrane topology similar to the G-protein coupled
receptors (GPCRs) with an unusually short third intracellular loop, and a long
extracellular N-terminal sequence. The cDNA was 3,216 nucleotides long which
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encoded 427 residues. Cos cell expression of the cDNA yielded an "ET-l-selective"
receptor which bound ET-1 with a Ki of 0.92nM but the Ki for ET-3 was 900nM.
Sakurai et al. (1990) cloned a second, non-selective, ET receptor from rat lung
and transfected a cDNA library into COS-7 cells producing a single receptor which
consisted of 415 residues, Mwt. of 46,901, and the familiar transmembrane topology
of GPCRs. The clone was designated as the ETB receptor and was suggested to be the
receptor mediating the vasodilator actions of ETs, at which ETs were equipotent.
Studies have subsequently demonstrated that ETB receptors are activated at lower
concentrations than the ETA receptor subtype (Willette et al. 1990).
1.6.4. Mechanism of action
The production of ETs may be regulated by a range of agents, although research has
not yet built a complete understanding. In the cerebral circulation, the production of
ETs can be regulated by agents such as thrombin, dopamine, bradykinin and
angiotensin II (Salom et al. 1995). Other factors determined to regulate ET
production include cytokines such as TNFs and interleukin-1 (IL-1), and ET-3 may
also control the release of ETs (Yokokawa et al. 1991). Receptor expression has been
shown to be subject to ligand-induced regulation, whereby ET receptors are
internalised following ligand binding, although pathophysiological conditions can
alter ET receptor number (Liu et al. 1989; Hirata et al. 1988)
Cellular localisation of ET receptors is heterogeneous (Salom et al. 1995). The
vasoconstrictor responses are mediated by ETA and ETB receptors are localised to the
vascular smooth muscle, whilst vasodilator responses are thought to be mediated by
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receptors, predominantly of the ETB subtype, located on the endothelium of vessels
(Salom et al. 1995). Association of ET-1 to available membrane receptors is a rapid
event, despite contraction developing slowly (Marsault et al. 1993). Binding of ET
isopeptides to ET receptors is essentially irreversible (Marsault et al. 1991), and the
ability of ET receptor antagonists to inhibit the responses of ETs decreases with
incubation time. Indeed, in the study by Wu-Wong et al. (1995), incubation of excess
ET-1 for 22 hours after [125I]ET-1 had been exposed to rat pituitary cells for 2 hours
period, failed to displace any bound [l25I]ET-l.
Research is building a comprehensive explanation of the mechanism by which
ETs mediate their actions. Both the vasodilator and vasoconstrictor responses to ETs
are mediated in part via an increase in intracellular Ca2+. Intracellular Ca2+ stores are
mobilised by IP3 via PLC activation via the GPCRs of ETs. This constitutes the
earlier phase of response to ETs. Plasma membrane depolarisation is believed to
occur leading to opening of the L-type Ca2+ channels facilitating delayed phase Ca2+
entry. This late phase entry explains a number of findings that the effects of ETs are
either abolished (Saito et al. 1989) or greatly reduced (Jansen et al. 1989; Asano et al.
1990) in the absence of extracellular Ca2+ medium, and why L-type blockers often
attenuate rather than abolish responses to ET (Rubanyi & Polokoff, 1994). The
vasodilator action of ETs are also produced by Ca2+ elevations due to ET receptor
activation, but these receptors are located on endothelial cells, and the rise in
intracellular Ca2+ activates the nitric oxide synthase enzyme. The nitric oxide then
diffuses to the SMCs overlying these cells to produce the transient relaxations seen
with ET. More recently ET receptors have been identified as being linked to release
of prostanoids (TxA2 and PGI2) via a GPCR linked to PLA2 (Rubanyi & Polokoff,
1994). ET-1 has also been demonstrated to be linked to PKC activation, which in
turn may regulate a number of downstream effectors such as Na+-H+ exchange and
nuclear events (Rubanyi & Polokoff, 1994).
The mechanism mediating the extreme duration of action of ET-mediated
vasoconstrictions is still poorly understood. However, studies have suggested that the
explanation may reside in the rapid process of receptor internalisation. Studies have
demonstrated that ET responses undergo quite rapid tachyphylaxis (Sudjarwo et al.
1994; Feger et al. 1994; Kitazono et al. 1995b), and are internalised following
binding. However, Marsault et al. (1993) proposed that this system of internalisation
followed by externalisation may account for the maintained action of ETs (Marsault
et al. 1993). However, the details of how this sustains ET actions is yet to be fully
addressed.
ETs have also been determined to possess long-term mitogenic actions on some
cell types. ET-1 has been shown to be a weak mitogen for smooth muscle cells in
culture and certain types of glia (Rubanyi & Polokoff, 1994). The signalling pathway
for this function is poorly defined but may involve PKC and tyrosine kinases
(Simonson & Dunn, 1990; Rubanyi & Polokoff, 1994). Figure 2 outlines a simplified
mechanism for typical smooth muscle effects of the ETs, and summarises some of
the processing and downstream actions of ET isopeptides.
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Following establishment of receptor heterogeneity, ETA and ETB receptors have been
documented throughout many tissues studied and in most mammalian species
investigated (Rubanyi & Polokoff, 1994). ET-1 is a full agonist on both ET receptors
and since an ETA-selective agonist is still unavilable, determination of receptor
pharmacology based on ET-1 effects alone is not possible. However, the
development of specific receptor antagonists has facilitated the determination of the
role of ETa receptors. BQ123, modified from the isolated cyclic pentapeptide BE-
18257B, has been the most extensively researched ET receptor antagonist (Rubanyi
& Polokoff, 1994). Subsequent structure activity studies led to a series of potent and
selective ETA receptor antagonists including FR139317, a linear tripeptide (Sogabe el
al. 1993).
ETa receptor antagonists have elucidated a broad range of functions mediated by
the ETa receptor. Most important of these is the mediation of sustained smooth
muscle contraction in the majority of systems studied including coronary & cerebral
blood vessels, kidney, lung, gastrointestinal tract and liver (Rubanyi & Polokoff,
1994). ETa receptors have also been identified as mediating the potent neuronal
actions of ETs. Buchan et al. (1994) characterised the ET receptor in the human
isolated pulmonary artery (a potential site for any ET involvement in pulmonary
hypertension), finding ET-1 had much greater efficacy than ET-3. This would
suggest the involvement of the ETA receptor, which was confirmed by the finding
that the ETB - selective agonist SFXs6c had no effect, while BQ123 produced
sumountable antagonism of ET effects (a shallow schild plot might suggest receptor
heterogeneity). Thus an ET receptor antagonist may in the future be a therapeutic
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target for treatment of pulmonary hypertension. Bosetan (Ro 47-0203) has been
extensively used in functional studies, being a mixed ETA/ETB antagonist, and was
employed by Lawrence & Brain (1994) with BQ123, an ETA selective antagonist, to
identify the receptor mediating intradermal local microvascular responses to ET-1
and ET-3. Consequently, they determined this to be an ETA-mediated event since
BQ123 was more effective on ET-1 mediated responses, while neither antagonist was
as effective at blocking ET-3-induced vasoconstriction. Furthermore, neither
antagonist changed basal flow alone (as determined by 133Xe clearance), which
represents further evidence against an homeostatic role for endogenous ET. Despite
extensive therapeutic indications, the use of ETA receptor antagonists outside of
research is still very limited.
1.6.6. Pharmacology of ET receptors (2): ETB receptors & responses
Whilst ETb receptors were originally defined as receptors mediating the vasodilator
response to ETs, there has emerged a body of evidence implicating ETB receptors in a
range of actions including vasoconstriction. Unlike the ETA receptor, selective
agonists are available for the ETB receptor including SFXs6c, BQ3020 and IRL1620
(James et al. 1993; Nambi & Pullen, 1995; Widdowson & Kirk, 1996).
As with ETa selective ligands, ETB receptor selective ligands have been
developed from structure activity studies on ETs. Subsequently, selective antagonists
for the ETb receptor have been described including RES-701-1 and IRL1038
(Sudjarwo et al. 1994; Yoneyama et al. 1995). The use of selective ligands has
facilitated elucidation of the distribution and function of ETB receptors, which have
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been identified in most tissues studied and have confirmed that these receptors
mediate constriction in some tissues and may have a role in pathophysiological states
(Rubanyi & Polokoff, 1994; Salom et al. 1995).
1.6.7. Pharmacology of ET receptors (3): Atypical receptors & responses
A number of studies have now suggested that the classification of ET receptors into
ETa and ETB is simplistic and does not adequately explain many findings (Bax &
Saxena, 1994). Further subtyping of both receptors has now been proposed, as well
as the existence of a third (ETC) receptor.
In the study by Sudjarwo et al. (1994), utilising specific receptor antagonists for
ETa and ETB receptors on a saphenous vein preparation, they identified subtypes of
both ETa and ETB receptors based on agonist and antagonist selectivity and potency.
Subsequent studies have delineated ETA and ETB receptors into ETAI and ETAI1, with
similar classification of ETB into ETB1 and ET0I1 (Sudjarwo et al. 1994; Yoneyama et
al. 1995). These receptor classifications remain to be widely adopted in the absence
of molecular studies and the cloning of receptors.
1.6.8. Physiological implications
Currently, the evidence for a physiological role for ETs is poorly supported by
experimental evidence (Rubanyi & Polokoff, 1994), and there is no evidence to date
of a role for ETs in the physiological regulation of the cerebral circulation (Patel. et
al. 1996a; Salom et al. 1995), although some evidence suggests that ETs could play a
role in blood pressure maintenance (Veniant et al. 1994). However, a number of
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findings have begun to shed some light on this, and postulated roles include the
maintenance of basal vascular tone, water balance as well as roles in paracrine,
autocrine & endocrine signalling (Rubanyi & Polokoff, 1994).
1.6.9. Pathophysiological implications
By contrast to a physiological or homeostatic role, evidence has been rapidly
accumulating that ETs have a role to play in pathophysiological events.
Subsequently, pathophysiological roles have been proposed for ETs in vasospasm
(coronary & cerebral), hypertension (systemic & pulmonary), and ischaemia
(myocardial, cerebral & renal) (Rubanyi & Polokoff, 1994).
Work by Hieda & Gomez-Sanchez (1990) showed hypoxic exposure of calf
coronary artery ECs produced an increase in ET immunoreactivity in the media.
Interestingly, Vanhoutte et al. (1989) had argued that ET is not the mediator of the
acute hypoxic vasoconstriction (which was the basis for its original discovery) since
the response to hypoxia is too rapid.
Hypertension as a pathological sequelae to elevated ET levels has received
support. Nakajima et al (1994) demonstrated ET-1 immunoreactivity in the
cerebrospinal fluid (CSF) of hypertensive patients, as well as elderly patients with
multi-infarction dementia, and have elucidated a correlation between ET-1 levels,
hypertension and cerebrovascular injury. However, questions remain as to the
physiological relevance of such levels. Indeed, elevated ET-1 concentrations were
only around lOpM, levels only just in the active range. However, ET antagonists
were effective in attenuating the reduction in the diameter of the basilar artery which
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occurs with injection of autologous blood, in dog models of subarachnoid haeorrhage
(Nirei et al. 1993; Itoh et al 1993). Studies have also demonstrated that ETs may
contribute to infarct size in a number of organs including the heart and kidney
(Watanabe et al. 1991; Kon et al. 1991).
Pathophysiological roles for ETs are also inferred by reduced levels of ETs in
depressed patients (Hoffman et al. 1989), and in asthmatic patients, ET levels are
increased in the pulmonary lavage fluid (Mattoli et al 1991), whilst a role in the
genesis or maintenance of pulmonary disease is being investigated. A role in tumour
growth is also suggested by the finding that ET levels are elevated in cancer tissue
(Yamashita et al 1991). ET-1 levels have also been shown to be elevated in patients
with essential hypertension (Nakajima et al. 1994). However, elevated levels of ETs
do not allow the determination of cause or effect, or indeed whether such ET levels
are detrimental or indeed sufficient to be of pathophysiological significance.
The evidence for a pathophysiological role for ETs in cerebral ischaemia has
received considerable support. ET-1 levels have been shown to be much higher in
humans who have undergone cerebral ischaemia, SAH and multi-infarct dementia
(Hirata et al. 1990; Suzuki et al. 1990; Ziv et al. 1992; Nakajima et al. 1994). ET-3
levels have also been shown to be elevated in patients with SAH, vasospasm and
head injury (Kraus et al. 1991; Salom et al. 1995). In experimental ischaemia,
ischaemic tissue ET-1 levels are found to be elevated following MCA oclusion
(Barone et al. 1994), whilst ETA receptor antagonists have been shown to reduce
ischaemic damage following MCA occlusion (Patel et al. 1996b).
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1.6.10. Cerebral circulation
Early studies showed that ET-1 was capable of producing prolonged vasoconstriction
and reducing cerebral blood flow to ischaemic levels when injected into the brain
parenchyma (Fuxe et al. 1992), intracisternally (Mima et al. 1989), or when applied
directly onto cerebral blood vessels (Robinson & McCulloch, 1990; Robinson et al.
1990). This was supported by findings in vitro in which ET-1 produced potent and
prolonged constriction of cerebral blood vessels (Jansen et al. 1989; Saito et al.
1989; Asano et al. 1990). The potency and duration of ET-l-induced
vasoconstriction has led to its use in models of stroke as an agent capable of
producing focal cerebral ischaemia (Robinson et al. 1990; Sharkey et al. 1993).
Research into the effects of ETs on the haemodynamics of the cerebral
circulation began in 1990, with the study by Robinson & McCulloch on the
contractions produced by ET-1 on feline cortical vessels. This in situ study showed
these, vessels like those in the periphery, to be sensitive to ET-1. Resistance vessels
responded with vasoconstriction as did the capacitance vessels. Laser-Doppler
flowmetry was used in the study by Willette et al. (1990) in a subsequent study of
the effects of ETs on the cerebral circulation in the rat. The rat cerebrovasculature
responded to ET-1, with dilatory as well as constrictory responses of the
microvasculature depending on dose and administration (vasoconstriction only
prominent at doses >300pM). The BBB seems to limit effects of ETs on
cerebrovascular smooth muscle, and circulating ETs are thus unlikely to have
pathophysiological implications for the cerebrovasculature, although this may change
following focal cerebral ischaemia (Betz et al. 1994). The ET receptors mediating
vasoconstrictor actions are solely located on the smooth muscle cells (SMCs), and, at
least in the case of the cerebral circulation, responses to ET are likely to be minimal
if administered intraluminally due to the effect of the BBB.
1.7. MCA OCLUSION BY INTRACEREBRAL ET-1
1.7.1. The model
The study by Robinson et al. (1990) demonstrated the ability of ET-1 to cause
sustained constriction of the rat MCA and produce ischaemic brain damage similar to
that following permanent MCA occlusion. This model involved the transorbital
surgical exposure of the MCA. However, surgical exposure of the MCA has
drawbacks in terms of technical requirements and physical damage to facial structure,
as discussed previously. In the study described by Sharkey et al. (1993), ET-1 was
injected intracerebrally via a previously implanted cannula. This required only a
small craniotomy and injection of a small volume of ET-1 into the outer layers of
cortex adjacent to the MCA. [14C]iodoantipyrine autoradiography demonstrated that
CBF was profoundly reduced within the vascular territory of the MCA. Quantitative
histopathology subsequently confirmed extensive infarction within the vascular
territory of the MCA (Sharkey & Butcher, 1994; Sharkey & Butcher, 1995). Animals
showed good weight recovery and consequently the model has proved useful in
behavioural analysis (Marston et al. 1995). A further advantage of this model was the
ability to induce MCA occlusion in conscious animals, eliminating confounding
influences of anaesthetics (Sharkey et al. 1993). Studies validated the model by
demonstrating the neuroprotective efficacy of MK801, a gold standard
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neuroprotectant in models of focal cerebral ischaemia (Sharkey & Butcher, 1995).
Furthermore, Sharkey & Butcher (1994) and Butcher et al. (in press), have
demonstrated the neuroprotective profile of FK506.
1.7.2. Aims of thesis
Many characteristics of this model have been studied including the initial ischaemic
insult, histopathological outcome and efficacy as a screening tool for putative
neuroprotectants. However, key characteristics have yet to be addressed. Amongst
these are the optimisation of ET-1 dose and injection volume. Furthermore, the
duration of ischaemia has not been documented in this model. Whether this model
represents a permanent or transient MCA occlusion, and if reperfusion does occur, is
this extensive and does it have any pathophysiological significance, must also be
addressed. Finally, and central to this thesis is the question of whether the ischaemic








The initial studies described in this thesis address the existing model of MCA
occlusion by intracerebral ET-1 injection. Previous studies with this model did not
address in detail the optimal dose and injection volume of ET-1. A narrow range of
doses (60 and 120 pmols) have been used, and the effect of injection volume has not
been reported (Sharkey et al. 1993; Sharkey & Butcher 1994; Sharkey & Butcher
1995; Marston et al. 1995). Furthermore, changes in animal supplier and equipment
since the original studies, necessitated model optimisation.
2.2. Methods
2.2.1. Surgical techniques
All animals used throughout these studies were supplied by Charles River, and
except for section 4.2.3., rats were of the Sprague Dawley (SD) strain. Animals were
allowed free access to food and water both before and after surgery, and were
maintained in a thermostatically controlled (22±2°C), air conditioned, housing
facility on a 14:10 h light/dark cycle (light on 05:00 h) unless otherwise stated. All
surgical procedures were performed under asceptic technique. Instruments and non-
sterile items (e.g. scalpel blades) were routinely immersed in a sterilising fluid
(Novasapa) and/or placed in an instrument steriliser at 200°C prior to use. Animals
were returned to clean cages containing bedding materials following surgery after a
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recovery period in an incubator which maintained normothermia until recovery from
anaesthesia.
Unless otherwise stated, surgical anaesthesia was induced in 5% halothane in a
nitrous oxide: oxygen mix (80:20 v/v). Following induction, animals were
maintained at 1-1.5% halothane in the same nitrous oxide: oxygen mix. Rectal
temperature was maintained at 37.5±0.5°C by a rectal probe connected to a
thermostatically controlled heating blanket (CMA) throughout all surgical
procedures, unless otherwise stated. Following induction of anaesthesia, the scalp
was shaved, and the animal was placed in a stereotaxic frame (Kopf instruments). A
midline incision was made by a scalpel blade, the skin and periosteum was cut and
retracted. Bregma was located and the desired stereotaxic target co-ordinates marked
with a pen on the surface of the skull. A craniotomy (2mm dia.) was then performed
over the site using an electric dental drill. The drill site was cooled and irrigated with
saline to prevent thermal damage to the underlying brain tissue. Following
craniotomy, the dura was incised and reflected using a hooked needle. The cannula
was then lowered slowly to the predetermined co-ordinates and injections made (lpl
infused per 90 seconds). Following the last injection, the cannula was left in situ for a
further five minutes before being slowly withdrawn. The scalp wound was then
sutured (Ethicon 4/0 silk), the animal was removed from the stereotaxic frame and
placed in an incubator. In all studies employing intracerebral injections, separate
injection cannulae were made for every drug used.
2.2.2. Histology
92
In studies where the volume of ischaemic brain damage was determined, animals
were allowed to recover for three days unless otherwise stated. Previous studies in
this model have determined that the volume of ischaemic brain damage does not
increase between three and seven days post-occlusion and therefore three days was
considered the most efficient time to allow for the lesion size to be maximal (Sharkey
& Butcher 1995). Shorter time periods may curtail maturation of a lesion as
ischaemic damage is reported to progress for at least 1 day in studies where ET-1 was
applied to the exposed MCA (Dawson et al. 1993).
Three days following surgery, animals were deeply anaesthetised by
intraperitoneal injection of pentobarbital (50mg/kg), and perfused transcardially. This
procedure involved exposure of the thoracic cavity, insertion of a needle connected to
a pump into the apex of the left ventricle and incision of the right atrium. Rats were
perfused initially with 20mls of heparinised phosphate buffered saline (PBS) (10
IU/ml), followed by 180 mis of 4% paraformaldehyde in PBS (see Appendix B).
On completion of perfusion, the brain was carefully excised and placed into a
storage vial containing the paraformaldehyde/PBS solution in 20% sucrose and
stored at 2-5°C for at least 48 hours, unless otherwise stated. Brains were then
removed from storage, frozen at -42°C in isopentane, and mounted in a plastic
embedding matrix (Lipshaw) on a chuck. 20pm sections were cut at -20°C, and
collected on gelatine subbed slides and air dried at 20-30°C. All sections were stained
with thionin (0.01%). Sections were dehydrated in ethanol, the lipid removed in
xylene and then rehydrated prior to immersion in the 0.01% thionin solution for 20-
30 minutes. Sections were then differentiated in 0.2% acetic acid, dehydrated again
and then returned to xylene, and subsequently cover slips adhered to the slides with
DPX. Sections were examined under a light microscope (Leitz Laborlux) at eight
predetermined levels and the volume of ischaemic damage quantified by volumetric
analysis according to the principles described by Osbourne et al. (1987).
The mathematical model used to calculate the volume of damage accounts for
brain shrinkage and/or distortion, that may occur due to oedema and following
perfusion fixation. Ischaemic brain damage was annotated onto enlarged diagrams of
the brain at eight stereotaxic levels from frontal cortex (bregma +3.Omm) at its most
rostral, to occipital cortex (bregma -7.0mm) at its most caudal. The area of infarct
was then cut out and weighed, and quantification of the ischaemic lesion calculated
by the equation below:
T,.„
£ (A„., x T„) + ((A„ - An_,) TjT„)x 0.763
where:
T = distance between sections (thickness)
A = area of ischaemic damage
0.763 = correction factor
The correction factor is determined by:
1) ratio of enlarged section to standard brain size
2) ratio between the weight of tissue to paper for a given area
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The equation therefore integrates the cross sectional areas, once corrected for the
enlargement factor, with the distance between levels, and has previously shown to
correlate well to the same procedure calculated on an image analysis system (M4
MCID). Ischaemic damage is determined as volume, in cubic millimeters (mm3) for
each animal and determined separately for neocortex and striatum, and in some cases
the hemispheric volume of damage was calculated.
2.2.3. Experiments (1): Optimisation of previous co-ordinates.
Previous studies with this model had used SD rats from Harlan Nolak within the
range 285-315g (Sharkey et al. 1993). However, on beginning this project the routine
supplier was Charles River, and a weight range of 280-320g was used. Previous
studies have shown that strain and supplier differences can affect the stereotaxic
position of brain structures relative to standard atlas references. Furthermore a
different sterotaxic frame to that used previously would be used. The first study
therefore determined whether the previous co-ordinates were still suitable. Microlitre
indian ink injections were employed to determine if co-ordinate modifications were
required. Using cadavers of SD rats and following determination of bregma, a
craniotomy was performed and a 28 gauge cannula was lowered to the previous co¬
ordinates and 2pi of indian ink injected. Following injection brains were immediately
removed. The brains were sectioned and the ink spot examined under a microscope.
Co-ordinates were altered by visual determination and by using the rat brain atlas of
Watson & Paxinos (1986).
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2.2.4. Experiments (2): Dose response relationship
In order to determine the minimum dose sufficient to reliably cause the MCA
occlusion-like pattern of histological brain damage, a range of ET-1 doses were
studied. Animals underwent surgery as described in section 2.2.1. Following
craniotomy, a 28 gauge steel cannula was then lowered 8.7mm below skull and
vehicle or 10,33,100 or 300 pmols of ET-1 were injected in 2pl volume. Animals
were allowed to recover for three days before perfusion fixation and histological
determination of ischaemic brain damage as described in section 2.2.2..
2.2.5. Experiments (3): Injecton volume
Determination of an optimal volume was assessed by injecting ET-1 (100 pmols) in
volumes of 1,2 or 3pi. Animals underwent stereotaxic surgery and histological
analysis as outlined in section 2.2.1. and 2.2.2.
2.2.6. Experiments (4): Targeting accuracy
In these studies ET-1 was injected 1mm away from the standard co-ordinates. This
was to determine the stereotaxic accuracy required to reliably cause MCA occlusion
and provide information as to the surgical skill level required. Second, to confirm
that the ischaemic damage following ET-1 injection originates predominantly from
an action on MCA located ET receptors and not simply due to intraparenchymal
effects of the type previously reported (Fuxe et al. 1992) Stereotaxic surgery and
histological analysis was performed as outlined in section 2.2.1. and 2.2.2. ET-1 (100
pmols in 2pl) was injected 1mm medial, caudal or dorsal to the standard co-
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ordinates. A 1mm rostral injection co-ordinate was not included since the skull
narrows rostral to the optimal co-ordinate site and the craniotomy site would miss the
skull edge.
2.2.7. Statistical analysis
All data from these studies were analysed by analysis of variance (ANOVA) on ranks
with a post hoc Dunn's method test to determine differences between groups.
Statistical significance was accepted at the 5% (p<0.05) level.
2.3. Results
2.3.1. Optimal co-ordinates
Following microscopic analysis of cerebral cortex from rats injected at a range of
stereotaxic co-ordinates, the optimal co-ordinates that delivered the ink to <0.5mm
from the MCA were determined. It was also found desirable to lower the tooth bar.
This allowed a slightly more caudal craniotomy to be performed, while avoiding the
skull edge, which narrows close to the AP co-ordinate. Consequently the vertical
depth for the cannula was increased to compensate for the greater tissue penetration
depth consequent to this. Results of the study comparing previous co-ordinates for
the new variables are shown below:












Quantitative histopathology determined that intracerebral microapplication of ET-1
in the range 33-300 pmols, yielded a pattern and volume of damage similar to that
reported previously (Figure 3). Damage extended from occipital cortex at its most
caudal, to frontal cortex at its most rostral, with concommitant damage to medial and
lateral striatum. This damage was confined to the vascular territory of the MCA and
only 1 animal, in the 300 pmol group, exhibited damage in the hippocampus and
thalamus, outwith the MCA-territory. The volume of hemispheric ischaemic brain
damage was not significantly different between groups over this dose range, but
damage was significantly greater than in the sham-lesioned animals in both cortex
and striatum (p<0.05). At 10 pmols, brain damage was significantly reduced
compared to higher ET-1 doses (p<0.05), and consisted predominantly of cannula
damage around the injection site. Both cortical and striatal damage in the 10 pmol
group were not significantly different from that observed in the sham-lesioned
animals (p<0.05). Figure 4 shows resolution of ischaemically damaged cerebral
cortex following ET-1-induced MCA occlusion, compared to cortex from sham
lesioned animals.
2.3.3. Injection volume
Varying the injection volume between l-3pl had no significant affect on the pattern















































Figure 3. Dose-response relationship for ET-l-induced MCA occlusion. 10 (n=l 1),
33 (n=12), 100 (n=l 1), 300 (n=13) pmols or vehicle in 2pl was injected. Ischae-
mic damage was determined for cortex (top) and striatum (bottom). Data are
presented as mean ± s.e.mean. Ischaemic damage was significantly reduced in the
10 pmol group, and not significantly different from vehicle injection.*R=<0.05.
Figure 4.
Light microscope photographs of (Top) thionin-stained ischaemically damaged
cerebral cortex three days after MCA occlusion by intracerebral injection of 100
pmols ET-1, and (bottom), cerebral cortex from vehicle injected sham animals.











































Figure 5. Effects of infusion volume on ET-1 induced MCA occlusion. ET-1 (100
pmols) was injected in 1 (n=12), 2 (n=12) or 3 (n=12) microlitre volume. Ischae-
mic damage was determined for cortex (top) and striatum (bottom). Data are
presented as mean ± s.e.mean. No significant differences were found between
treatments.



































Figure 6. Effects of stereotaxic injection position on ET-1-induced MCA occlu¬
sion. ET-1 (100 pmols in 2pl) was injected at the optimal coorodinate (n=l 1) or
1mm medial (n=10), caudal (n=10) or dorsal (n=10) to the optimal coordinates.
Ischaemic damage was determined for cortex (top) and striatum (bottom). Data
are presented as mean ± s.e.mean. ET-1 injection 1mm away from optimal co¬
ordinates reduced ischaemic damage compared to the standard injection site
*.P=<0.05 compared to control.
the characteristic pattern of MCA occlusion-induced brain damage was seen in all
groups.
2.3.4. Targeting accuracy
Injection of ET-1 into cortical tissue 1mm medial, caudal or dorsal to the optimal co¬
ordinates, decreased the volume of consequent brain damage. Ischaemic brain
damage was significantly reduced in both cortex and striatum at each co-ordinate,




The present studies optimised the model for male SD rats (Charles River) within the
weight range 280-320g. Previous studies with this model utilised a different supplier,
stereotaxic frame and slightly different weight range. Consequently experiments
were performed to determine if a new supplier, frame and weight range might
compromise MCA targetting accuracy. Indeed, the previous injection co-ordinates
delivered the ink injection slightly dorsally and caudally. This position was changed
following the co-ordinate optimising studies to produce the new co-ordinates
presented. Following co-ordinate optimisation, dose and injection volume for ET-1-
induced MCA occlusion were addressed. The results from these studies outline the
optimal dose range and injection volume. We observed that using 33-300 pmols, and
with a 1-3 pi infusion, ET-1 produced a large ischaemic lesion comparable to
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previous studies using this model (Sharkey et al. 1993; Sharkey & Butcher 1994;
Sharkey & Butcher 1995). Brain damage was restricted to tissue within the vascular
territory of the MCA.
Quantification of ischaemic brain damage requires the careful consideration of
the criteria for defining irreversibly damaged cells (Nedergaard, 1988). Parameters
such as energy depletion or electrical silence are consequently not useable indices
(Nedegaard, 1988). An area of ischaemically affected tissue must be examined for
cellular signs of irreversible damage that may be termed ischaemic brain damage or
"infarct". A cerebral infarct is defined as an area of tissue within which all cells, of
neuronal, glial and vascular nature have undergone necrosis (Brierly & Graham,
1984). However, in light of the potential contribution made by apoptosis to ischaemic
cell death following focal cerebral ischaemia, such a definition must be adjusted
accordingly.
In the hours following MCA occlusion, cells within the MCA territory decrease their
ability to take up histological dyes (such as thionin and haemotoxylin & eosin). Cells
appear pale and swollen, with evident chromatin dipersal. In areas initially
penumbral to the core, neurons appear shrunken with basophilic cytoplasia. These
cells later loose their cellular identity in the days following occlusion and the area
surrounding the ischaemic tissue becomes more demarcated.
Figure 7 shows the sharp demarcation of ischaemically damages tissue to normal
brain tissue, with only a very narrow band of scattered dead neurones, found in the
present studies. This pattern of ischaemic damage is similar to that found following
surgical exposure via the subtemporal approach whereby the MCA is occluded
Figure 7.
Demarcation of boundary between ischaemically damaged and normal cortex from
animals perfusion fixed three days after ET-1 -induced MCA occlusion.
Magnification = x 200
102
Border between ischaemic
and normal cortical tissue
proximal to the circle of Willis. This suggests that brain damage in the ET-l-model
results from occlusion of the MCA, proximal to the striate branches, which is
supported by the extensive damage noted in the striatum. This pattern contrasts with
studies where the MCA was occluded by an intraluminal filament, where damage is
often found in structures outwith this vascular field such as the thalamus and
hippocampus (Koizumi et al. 1986). Furthermore, this model frequently incurs
damage to the hypothalamus leading to problems in thermoregulation (Zhao et al.
1994), which are avoided by this approach.
The volume of brain damage was not significantly different from sham-lesioned
animals when 10 pmols of ET-1 was injected. This suggests that either 10 pmols of
ET-1 does not constrict the MCA sufficiently to occlude the vessel, or that the
duration of occlusion is insufficient to produce ischaemic damage. These results
support an all-or-none response. There was not a statistically significant dose
dependent increase in infarct size within the effective range. It might be expected that
with increasing dose, the duration of occlusion would increase with subsequently
lager infarct volumes. In previous studies in which ET-1 was instilled onto the
surgically exposed MCA (Macrae et al. 1993), a dose-response relationship was
reported with increasing dose. The explanation for this difference is unclear.
However, in the study by Macrae et al. (1993), whilst increasing dose produced a
graded ischaemia, severe reductions in CBF (<50% of control) in the lowest effective
dose group (10"7M) were of short duration (-30-60 minutes) whilst all other doses
(10"6 to 10"4M) produced a severe ischaemia of more than 3 hours duration. It is
conceivable that this is reflected to an extent in the present data, whereby the lowest
dose (10 pmols) did not effectively produce ischaemia severe enough to produce a
lesion, above which the insult was essentially the same irrespective of dose.
The injection volume does not appear to be critical in this model, because
similar lesions resulted when 100 pmols of ET-1 was injected in 1-3pi volume,
although larger injection volumes would be expected to reduce any errors in ET-1
delivery consequent on inter-animal variations. In other studies, ET-1 was infused
one millimetre medial, caudal or dorsal to the optimal site. That this procedure
resulted in only a focal lesion confirms two points. First, the volume of ischaemic
brain damage produced by infusion of ET-1 at the optimal site must be a direct
consequence of occlusion of a major cerebral artery, and second, that careful and
precise stereotaxic surgery is required to produce a reliable occlusion of the MCA.
Animal exclusion criteria were established as a consequence of preliminary
studies that suggested inter-animal variation in the MCA position leads to occasional
"misses" in which the volume of ischaemic damage was <10mnf in the cortex and
absent in the striatum, suggesting failure of ET-1 to reach the MCA. Flowever,
exclusion based simply on no striatal damage and <10mm3 of cortical damage was
deemed insufficient since the dose and volume were being varied in these studies.
Consequently an additional criterion was included as a safeguard. The MCA was
marked using indian ink prior to cryostat sectioning. Since the injection cannula tract
was found to be visible on a small number of consecutive sections during sectioning,
the distance between the MCA and injection site could be determined. If the cannula
injection site was >500pm distant to the MCA, this represented an additional
exclusion criteria. If an animal fulfilled both lesion volume and cryostat-determined
target inaccuracy criteria, an animal was excluded. These criteria were applied to all
studies performed. Approximate rates of exclusion were -10% or less per treatment
for subsequent studies.
In conclusion, these studies demonstrate that there is a relatively broad dose
range over which ET-1 effectively causes MCA occlusion. Increasing the dose above
100 pmols does not increase the subsequent volume of ischaemic brain damage. The
lesion reliability and volume appears to be independent of injection volume within
the range 1-3 pi. However, a 2-3 pi volume is likely to avoid any "misses" arising
from stereotaxic inaccuracy or interanimal variability as the ET-1 diffusion would




CHAPTER 3. CHARACTERISATION OF ET-1-INDUCED MCA
OCCLUSION MODEL
3.1. Introduction
3.1.1. Model verification by characterisation
Whilst the ET-1-model has been characterised in terms of histopathological end-
point at 3 & 7 days (Sharkey & Butcher, 1995), and local CBF at 10 minutes post
occlusion (Sharkey et al. 1993), a number of other parameters should be assessed in
the process of model characterisation. Of these, perhaps the most important relating
to this model is the temporal profile of ischaemia. Since MCA occlusion is not
performed by physical means whereby a clip or filament occludes blood flow, the
duration of ischaemia cannot be automatically inferred. Whilst the volume of
ischaemic damage reported for this model is consistent with that following
permanent occlusion of the MCA (Sharkey et al. 1993), model characterisation
requires an assessment of the duration of ischaemia following ET-1 injection. In the
model of ET-1-induced MCA occlusion in which ET-1 was applied to the surgically
exposed MCA (Robinson et al. 1990), hydrogen clearance measurement of CBF
demonstrated recovery of blood flow within a l-4hr period according to dose
(Macrae et al. 1993). This finding is significant in the context of this model. One
requirement of focal cerebral ischaemia models is the control of the duration of
occlusion. Available data suggest that if ischaemia lasts three hours or more, the
resulting damage is not different from a permanent occlusion (Kaplan et al. 1994).
Elowever, if the duration of occlusion is less than three hours, in functional terms the
model may represent one of ischaemia with reperfusion. By contrast, if ischaemic
severity remains essentially unchanged for a duration of 3 hours or greater, then the
model will constitute one of permanent MCA occlusion in pathophysiological terms.
Whilst models of MCA occlusion that employ snare ligatures or the filament
approach demonstrate "square wave" patterns of flow reduction and return on release
of occlusive procedure (Yang et al. 1994), Macrae et al. (1993) showed that at the
lower doses of ET-1 gradual reperfusion was seen in this model of MCA oclusion.
Consequently, in this section of model characterisation, three methods were
employed to determine the duration of ET-1-induced ischaemia. These were the
monitoring of cortical tissue perfusion velocity by laser Doppler flowmetry, striatal
measurement of oxygen tension and [l4C]iodoantipyrine autoradiography of local
CBF, three hours after ET-1-induced MCA occlusion. As described above, brain and
body temperature can critically affect the outcome of both global and focal cerebral
ischaemia, and this parameter was evaluated using an intracranial thermistor.
Furthermore, the relationship between body and brain temperature was addressed.
3.1.2. Ottosensor probes
The study utilised miniature multiple thin-film recording probes (Ottosensors Corp.).
These microprobes were employed to measure changes in cerebral temperature and
oxygen tension within the striatum following ET-l-induced MCA occlusion, and
have previously been validated in studies using a model of forebrain ischaemia
(Freund et al. 1993). The "T.O.P." probe has six sensors, two temperature, two
oxygen and two that measure electrical potential, mounted on a glass substrate. The
recording area is ~16mm long and 400pm wide x 100pm thick. The probe is
connected via a stereotaxically manipulated holder to an interface unit comprising
temperature, oxygen & potential modules, as well as an LCD display module. The
probes are rinsed with a solution of acetone and ethanol immediately prior to
stereotaxically lowering into the brain parenchyma. The probes gives voltage
readings of the concentration of oxygen reacting on their surface, and readings are
linear such that voltage can be converted to actual oxygen readings by constructing a
straight line between readings from known solutions. The temperature sensors were
factory calibrated to read absolute temperature.
3.1.3. Laser Doppler flowmetry
The capability to measure changes in CBF is of central importance in many aspects
of stroke research. Whilst the technique of [14C]iodoantipyrine autoradiography
gives a quantifiable measure of local CBF in terms of volume per unit time (e.g.
ml/lOOg/min), it allows only single time points to be studied. Methods for continuous
measurement of flow changes offers a greater degree of flexibility and versatility in
research. Among methods employed for repeated measurements of local CBF are the
hydrogen & xenon clearance, the microspheres technique and MRI & PET. However
these techniques hold a number of drawbacks such as limitations in rapid flow
change monitoring and continuous time point sampling (Skarphedinsson et al. 1988).
Nilsson et al. (1980a, 1980b) introduced a new method which allowed
measurement of local changes in CBF in a continuous fashion, and was capable of
monitoring rapid changes. The method was based on the principal of Doppler
(frequency) shifted light. The term laser Doppler flowmetry (LDF) was coined for
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the instrument which uses the frequency broadening of a laser beam back-scattered
from moving formed elements of the blood (predominantly red blood cells)
(Skarphedinsson et al. 1988). The signal is determined on the linear relationship
between the relative portion of Doppler-shifted light and the volume fraction of
moving red blood cells in the measured tissue, and the relationship between the red
blood cell velocity and mean Doppler frequency. Thus, light which is reflected from
moving formed elements of the blood produces an altered signal relative to the light
received from blood cells and other tissue elements not moving. The output signal of
the flowmeter is obtained by real time computation of the number of red blood cells
multiplied by their velocity (or red cell flux) (Skarphedisson et al. 1988).
The main drawback with the technique is that the Doppler signal values cannot
reliably be assumed as CBF in ml/g tissue/min in the way that [14C]iodoantipyrine is
quantified (Kirkeby et al. 1995). A number of studies have suggested LDF can be
calibrated for measurement of absolute CBF (DiResta et al. 1987; Eyre et al. 1988;
Lindsberg et al. 1989; Fabricus & Lauritzen 1996). However, these studies
determined that such absolutes are only valid when CBF and the brain region is the
same in every animal, and baseline values are identical (Fabricus & Lauritzen, 1996).
If the probe site is chosen irrespective of baseline values, numerical LDF values will
vary accordingly. Consequently, studies employ a strategy for showing relative
changes in blood flow. i.e. the LDF values are expressed as % of baseline. This point
will be addressed in detail below, and with reference to research findings. Studies
also point out that LDF should only be applied to microcirculatory recordings and
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not used to record arterial flow for which Doppler sonography is the appropriate
technique.
The original technique of LDF was designed for measurement of human skin
blood flow and Riva et al. (1972) were the first group to employ LDF for blood flow
measurements. LDF has since been employed to measure changes in blood flow in
tissues as diverse as the spinal cord (Lindsberg et al. 1989), intestinal wall & mucosa
(Ahn et al. 1985; Feld et al. 1982), renal cortex (Stern et al. 1979) and cerebral
cortex (Dinargl et al. 1989; Florence & Seylaz 1992; Takagi et al. 1994a; Kadoya et
al. 1995; Zhang et al. 1997).
Validation by comparison with established or similar techniques is essential in
adopting and deploying a novel technique. LDF has been validated by comparison to
known techniques under experimental conditions. Fabricus & Lauritzen (1996)
addressed the question of whether changes of CBF measured by LDF correlates with
CBF changes measured by [14C]iodoantipyrine in order to determine the valid
approach to recording and interpreting LDF values. They found that the numerical
values recorded by LDF correlated poorly to [14C]iodoantipyrine values calculated
from simultaneous recordings at the same site (i.e. LDF units vs. ml lOOg"1 min"1),
concluding that it would be invalid to convert LDF values to absolute CBF. Dinargl
et al. (1989) also addressed this point. As with the study of Fabricus & Lauritzen
(1996), a poor correlation between absolute CBFldf (CBF measured by LDF) and
absolute CBFIAP (CBF measured by IAP), was noted. While concluding that LDF is
inaccurate for determination of absolute local CBF in flow units, they found changes
in CBFldf and CBFIAP (with values expressed as % of baseline) correlated well.
Absolute values were highly dependent on probe placement and position and
therefore absolute values were not considered a true reflection of CBF. Dinargl et al.
(1989) offer a number of possibilities for the discrepancy between absolute CBFldf
and CBFiap. First, avoiding larger vessels is problematic given the density of the
microvasculature and the size of the probe, but placement in proximity of larger
arteries and veins contributes distortion of the LDF signal. Other contributing factors
include microregional variations in perfused capillaries (Kuschinsky et al. 1987;
Tyson et al. 1987; Dinargl et al. 1989) and differences in local haematocrit
(Mchedlischvili, 1986; Dinargl et al. 1989). Both these may influence the LDF signal
magnitude. By contrast, local CBF may be recorded consistently by
[,4C]iodoantipyrine despite differences in haematocrit, flow velocity and capillary
recruitment, although CBFldf might be different in two adjacent regions since all
these factors can affect the LDF signal to a different degree (Dinargl et al. 1989).
Like Dinargl et al. (1989), Fabricus & Lauritzen (1996) found that the ratio of
CBFldf correlated better with the ratio of CBF,AP values between the two
hemispheres, and thus under "normal" conditions relative changes of LDF are useful
for studies of dynamic changes in CBF. They also found that at increased CBF
levels, LDF recorded values greater than CBFIAP. Thus, it seems in non-physiological
conditions with high CBF, LDF may tend to overestimate CBF.
A number of studies have also examined CBF as recorded by LDF and
compared it to values obtained with the microspheres technique (Eyre et al. 1988;
Lindsberg et al. 1989; Kirkeby et al. 1995). In the study by Kirkeby et al. (1995),
they found that as with [14C]iodoantipyrine, correlation between LDF and
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microspheres was not found when LDF values were used as absolute CBF. However,
when percent change from baseline was used in the calculation for both LDF and
microspheres, a significant correlation was found, although this correlation was
weaker than for [14C]iodoantipyrine. This group concluded that LDF, with values
expressed as % change, provides a valid method for studying local microcirculatory
changes in the brain.
Another common method for repeated measures of local CBF is the hydrogen
clearance technique (Haining et al. 1968). This technique is quantitative in terms of
local CBF in ml/lOOg/min and has been employed as a technique to determine CBF
in a number of models of focal cerebral ischaemia (Heiss & Rosner, 1983; Macrae et
al. 1993). Skarphedisson et al. (1988) compared CBF measurements between LDF
and the hydrogen clearance technique, although other studies have been carried out
(Diresta et al. 1987; Reith et al. 1994). While this study does not attempt to correlate
actual values, when expressed as a % of control, both LDF and H2 clearance
correlated well over a broad range.
Various studies therefore support the use of LDF for obtaining continuous
estimates of CBF changes, although restrictions in interpretation must be addressed.
For example, since the volume of tissue sampled cannot be quantified in vivo, LDF
values cannot be quantified in terms of ml/g tissue/min. Rather LDF values should be
expressed and evaluated as % change from control or baseline and consequently
results correlate well with other established techniques for measuring CBF (Fabricus
& Lauritzen 1996). Furthermore, despite a number of groups referring to LDF
recording "CBF", the technique really measures red blood cell flux, and not whole
not whole blood flow/CBF, and should be referred to appropriately. LDF use in
research has expanded due to a number of favourable advantages over some of the
techniques mentioned in the previous section, including:
1. LDF implies no trauma to the brain, unlike H2 clearance, with the exception of
when used intracerebrally (Skarphedisson et al. 1988).
2. LDF allows continuous changes in blood flow to be studied, avoiding the single
time point nature of techniques such as [14C]iodoantipyrine autoradiography and
microspheres (Kirkeby et al. (1995).
3. Simplicity of use. This may not appear to be of importance in some respects, but
the ease of use with which it can be applied and the lack of need for i.v. injections,
electrolysis and extensive post-study analysis (such as with [14C]iodoantipyrine),
is an aid in simplifying the job of the researcher.
As with any technique, the protocol for using LDF is important, and establishing
continuity in the use and approach to measurement reduces study-to-study variation
and increases comparability between research findings. In table 2, the various
procedures and protocols used by groups utilising LDF in cerebrovascular research
are listed. This includes factors such as the recording site, condition of the dura and
data interpretation and representation.
LDF has been employed in an extensive range of studies into CBF
autoregulation & the coupling of blood flow to metabolism (Iadecola & Reis, 1990;
Nakai et al. 1983; Mraovitch et al. 1986; Paulson et al. 1990; Florence & Seylaz,
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as the hypercapnic response of CBF (Haberl et al. 1989) and the effects of
anaesthetics on CBF (Lee et al. 1994; Hudetz et al. 1995).
LDF has been applied in cerebrovascular disease research to monitor CBF
changes following experimental cerebral ischaemia, and therefore represents a potent
tool in such studies, with pre and post occlusion real time measurements of changes
in cerebral microcirculation. Furthermore, with the growing emphasis on
experimental reperfusion models, LDF can not only confirm successful occlusions,
but also monitor CBF recovery during reperfusion. Dinargl et al. (1989) were the
first group to assess LDF in a model of MCA occlusion. Ischaemic CBFldf (MCA
occluded by transorbital approach) averaged 33% of preocclusion values with some
hyperaemia on reperfusion (120-141%). Subsequently, a number of studies have
applied LDF in focal cerebral ischaemia studies (Dalkara et al. 1994; Reith et al.
1994; Morimoto et al. 1996; Zhao et al. 1997). Studies have examined the effects of
glutamate release (Takagi et al. 1994a), hypothermia and mannitol (Karibe et al.
1995), ET receptor antagonists (Patel et al. 1996b), ICAM-1 null mice (Connolly et
al. 1995) and zinc protoporphyrin neuroprotection (Kadoya et al. 1995). The parietal
cortex is the most commonly studied brain tissue region in studies that employ LDF
to monitor CBF following MCA occlusion, and the experimental protocol applied in
the present studies has combined many of the common experimental practices.
3.1.5. [14C]iodoantipyrine autoradiography
The quantitative measurement of local CBF within discrete brain regions developed
from work by Kety (1951), on the principles of inert gas exchange between blood
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and tissues (Sakurada et al. 1978). The approach was based on the Fick Principle,
that the rate of change of a chemically inert tracer substance in a given tissue is equal
to the difference between the amounts brought to the tissue in the arterial supply and
removed by the venous supply (Sokoloff, 1986). A freely diffusible tracer in the
blood will be in near instantaneous equilibrium with brain tissue, permitting the
measurement of regional blood flow from the rate of accumulation of the tracer in the
brain. These basic principles of tissue-tracer equilibration were first applied to the
measurement of local CBF using [131I]trifluoroiodomethane in the cat (Landau et al.
1955; Freygang & Sokoloff, 1958; Kety 1960), but the mathematical calculation
permitted techniques such as CF3I, 85Kr, 133Xe and hydrogen clearance to measure
blood flow (Landau et al. 1958; Glass & Flarper 1963; Purves, 1972). The original
method involved the intravenous infusion of [131I]trifluoroiodomethane for 1 min
during which, timed arterial samples were taken from which the arterial blood
concentration could be later calculated. The animal was then decapitated and the
brain frozen in liquid nitrogen, sections taken and autoradiographs produced by
incubation with X-ray film, whilst maintaining the tissue at -75°C to prevent loss of
the volatile tracer. Distribution of the tracer reflects perfusion rates and
autoradiograms were pictorial representations of the CBF in various brain structures
(Sokoloff, 1986):
The original operational equation was:
T
Ci (T) = XK \ Ca e"K(T"t,dt
o
where Ci(T) was the tissue concentration of the tracer at a given time T after tracer
introduction, X was the tissue:blood partition co-efficient, CA the arterial tracer
concentration, t was the variable, time. K was defined as equal to mF/WA, where
F/W is the rate of CBF per unit mass of tissue and m equalled a constant between 0
and 1 that represented the achieved tracer diffusion equilibrium from arterial to
venous passage (1 in the absence of diffusion limitation or arteriovenous shunts that
are absent in the cerebral circulation). If m=l then blood flow can be calculated from
the time of tracer infusion onset, arterial tracer concentration history and the
tissue:blood partition coefficient (Sakurada et al. 1978).
[l3lI]trifluoroiodomethane was a freely diffusible, chemically inert stable tracer
which had a value for m as close to 1 as possible, but suffered disadvantages. These
included a short half life, requiring regular synthesis & complex chemical
purification, the poor resolution characteristic of [12T] iodine-labelled tracers,
alterations in blood soluability with haematocrit, variations in the blood/tissue
partition coefficient from region to region & animal to animal and the inconvenience
associated with assaying a volatile tracer (Reivich et al. 1969; Sakurada et al. 1978;
Sokoloff, 1986). Consequently a commercially available, non-volatile [l4C] tracer
was sought of which [14C]antipyrine seemed to satisfy the requirements (Sokoloff,
1986). However, uptake of this tracer was found to be diffusion limited, leading to
CBF values considerably less than those obtained from studies with inert gases
(Sakurada et al. 1978). Use of 4-iodo-[N-methyl-14C]antipyrine ([l4C]iodoantipyrine)
circumvented the limitations of [14C]antipyrine possessing 1) isotope stability 2) high
oil/water partition coefficient to make it more freely diffusible and 3) a blood/brain
partition coefficient determined as 0.78-0.8 that was uniform throughout the CNS
and did not vary with haematocrit (Sakurada et al. 1978; Sharkey, 1986; Sokoloff,
1986).
Jay et al. (1988) described a correction factor for use of the [14C]iodoantipyrine
with small animals such as the mouse. Errors in the original technique arose when
applied to small rodents consequent to the relatively low diameter/length ratio of
arterial catheters, leading to errors in the time course of [14C]iodoantipyrine
concentration in the arterial blood. Two types of arterial sampling distortion occur
arising from the delay in the passage of blood from the distal end of the catheter and
a washout effect arising from dilution of arterial tracer due to dead space within the
catheter (Jay et al. 1988).
[l4C]iodoantipyrine autoradiography has successfully been used to measure local
CBF, producing accurate blood flow maps of multiple levels of brain tissue at a
resolution of ~100pm, which is at least an order of magnitude lower than PET and
two orders below current MRI resolution. Furthermore, the technique has been
extensively applied to research into cerebral ischaemia.
3.2. Methods
3.2.1. Indwelling cannula system
In these studies of the characteristics of ischaemia following ET-1 -indued MCA
occlusion, an indwelling cannula system was used. An indwelling cannula was
employed in the original studies with this model when ET-1 was injected in
conscious animals. Two factors prevented the use of a stereotaxically lowered
injection cannula in these studies. The holder for the intracerebral probes was too
bulky to allow for both a stereotaxically controlled probe placement and a
stereotaxically controlled injection needle. Such spatial limitations required an
implanted cannula to be used, removing the need for stereotaxic control of the ET-1
injection during intracerebral recordings. The second need for the indwelling cannula
system for ET-1 injections arises from the use of LDF. Lowering of a stereotaxically
controlled injection needle through the brain parenchyma caused significant
deflections of the LDF baseline prior to ET-1 injection in preliminary studies. The
use of an indwelling cannula into which the injection cannula could be placed
prevented any disturbance of LDF signal prior to ET-1 injection.
Animals were implanted with an indwelling cannula 5-10 days prior to study
according to a modification of the method described by Sharkey et al. (1993).
Animals were anaesthetised, placed in a stereotaxic frame and rectal temperature
maintained at 37-38°C. After a midline incision, a craniotomy was performed (co¬
ordinates from bregma; AP=0.9mm, L=-5.2mm), four surgical screws fixed to the
skull and an indwelling cannula (26 gauge with a 31 gauge dummy cannula), cut to
8.5mm, lowered 8.2mm below the skull. The cannula was fixed to the skull by dental
cement, the wound sutured (Ethicon 4/0 silk) & sprayed with an antiseptic, and the
animal returned to its cage and allowed to recover. Injections were made by
withdrawing the dummy cannula and inserting a 31 gauge injection cannula, cut to
9.2mm, which would project below the indwelling cannula to the same co-ordinate
site as the stereotaxically lowered cannula reached. The ~0.7mm projection of the
injection cannula below the guide ensured injections were made into "undamaged"
tissue. Figure 8 illustrates the in situ recording procedure used in studies with
ottosensors probes.
3.2.2. Intracerebral oxygen & temperature
Freund et al. (1993) determined that halothane was not a suitable anaesthetic to use
with the Ottosensors probes, as this interfered with the oxygen sensor. This was also
noted in preliminary studies (data not shown). Consequently, isoflurane, another
volatile anesthesic commonly used in in vivo studies, was employed.
It was found that a given probe gave inconsistencies in oxygen tension calibration
under the approved calibration protocol between studies, so voltage readings were
used directly and changes in oxygen expressed as relative (%) changes from pre-
MCA occlusion values (taken as 100%-baseline, not 100% oxygen). Temperture
probes were calibrated against 2 mercury and 4 electronic thermometers in reference
solutions of ACSF within a 32-39°C range, and corrected where necessary.
Following surgery to implant indwelling cannulae, animals were allowed to
recover for 5-10 days. On the day of study, rats were reanaesthetised for the duration
of the study (this time with isoflurane since the probes do not work with halothane)
and placed in the stereotaxic frame. A craniotomy was performed (AP=+1.0mm; L=-
2.0 to bregma) and the probe (with its chamber filled) lowered 5-7mm into the
striatum to begin recordings.
Oxygen tension and brain temperature readings were recorded from both sets of
sensors for 15-30 minutes before ET-1 (450 pmols in 3pl) injection (lpl/90 seconds)
via a 31 gauge injection cannula (9.2mm) inserted into the lumen of the indwelling
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cannula following removal of the dummy cannula. This dose of ET-1 is in fact higher
than was determined as necessary during the early characterisation experiments.
However preliminary experiments determined the 100 pmol in 2pl injection was
unreliable in occluding the MCA using indwelling cannulae. Indeed, in preliminary
studies only 1 in 6 studies (17%) showed successful MCA occlusion or signs of
ischaemia on inspection of brains. By comparison the higher dose was successful in
all experiments. The lower success rate was likely to be a consequence of the use of a
guide cannula and the time between implantation and study, with reduced stereotaxic
control, small lateral movement of the guide cannula in situ and the re-entering of the
rat into the stereotaxic frame. Ischaemic brain damage was therefore quantified in
animals three days after injection of 450 pmols in 3pi according to the experimental
protocol of section 2.2.1. and 2.2.2.
Following completion of the ET-1 infusion, the injection cannula was removed
(5 minutes after last injection) and readings continued for 3 hours. After three hours,
the rat was killed while still under anaesthesia and the brain dissected to confirm
successful MCA occlusion. This involved microscopic inspection of the MCA
vascular territory to determine tissue pallor.
3.2.3. Laser Doppler flowmetry
An indwelling cannula was implanted 5-10 days as described in section 3.2.1.. On
the day of study, animals were anaesthetised with halothane and placed in a
stereotaxic frame. A craniotomy was performed over the parietal bone following
gentle displacement of the top edge of the temporalis muscle. A drop of artificial
121
cerebrospinal fluid (ACSF) (for composition see Appendix B) at room temperature
was added to the craniotomy site. ACSF was found to have no effect on the LDF
signal (preliminary studies). A LDF probe (24 gauge) was advanced to just touch the
surface of the cortex, and LDF recordings (Transonic systems Inc.) were made for
15-30 minutes prior to ET-1 injection. ET-1 (450 pmols in 3pl) was injected, and
recordings were made for 3hours. The animal was then killed and a zero flow value
recorded and deducted from the recorded signal. Brains were removed and the MCA
territory inspected under a microscope to confirm a successful ischaemic event. LDF
data were expressed as a % change from baseline. Figure 9 illustrates the in situ
recording procedure used in LDF studies.
3.2.4. [l4C]iodoantipyrine autoradiography
Animals were anaesthetised and polyethylene catheters (15cm long) were inserted
into both femoral arteries and veins to permit the continuous monitoring of mean
arterial blood pressure (MABP), the repeated sampling of arterial blood, and the
administration of [l4C]iodoantipyrine. The wounds were infiltrated with anestheic gel
(2% xylocaine) and sutured. The animals were then placed in a sterotaxic frame and
the MCA occluded by intracerebral ET-1 injection as described in section 2.2.1.
Briefly, following a craniotomy, a 28 gauge cannula lowered 8.7mm below skull and
100 pmols of ET-1 in 2pl, or vehicle (sham animals) in 2pl was injected (lpl/90sec),
the cannula left in situ for 5 minutes and then slowly withdrawn. Whilst still under
anaesthesia, animals were placed in a plaster-of-Paris cast and secured firmly to a















pressure monitor and allowed to recover from anaesthesia, whilst being maintained
normothermic by a heating lamp and rectal probe. The experiment was performed
three hours following the first ET-l/saline injection. Blood gases & blood pH (Ciba
Corning model 238) and plasma glucose (Beckman glucose analyser 2) were sampled
immediately prior to beginning the blood flow measurement. Local CBF was
measured according to a modification of the original method of Sakurada et al.
(1978). Briefly, a ramped infusion of [14C]iodoantipyrine (4.62 MBq/kg (50pCi) in
lml saline) was administered via the left femoral catheter over a 40 second period.
14-19 timed samples were collected on pre-weighed filter paper discs from the free
flowing right arterial catheter. An example of an arterial input function for [14C]-
iodoantipyrine loading is shown in Figure 10. Radioactivity in disintegrations per
minute (DPMs) were calculated per sample weight and plotted against the time the
sample was collected. At the end of the infusion period, the animal was killed by
decapitation, the brain excised and frozen in isopentane (-42°C). The frozen brain
was transferred to a bed of dry ice where it was afixed to a swivel headed microtome
chuck with a plastic embedding matrix (Lipshaw). The brain was then stored at -70°C
until sectioning (within 48 hrs). The filter paper discs were re-weighed, 400pl of
hydrogen peroxide (40% v/v) added to bleach the colour and 10 mis of scintilation
fluid added to each vial. The [14C] concentration was then calculated by scintillation
spectrometry.
From each brain, 200 coronal brain sections (20pm) were collected on glass
cover slips and rapidly dried on a hot plate (70°C). Autoradiograms were prepared by
affixing the coverslips to card, and then sections were exposed to blue-sensitive X-
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Figure 10. Graph illustrating an arterial input function. A ramped infusion of
[,4C]iodoantipyrine was delivered intravenously over 35-40 seconds during which
timed arterial samples are taken
ray film (Kodak SB-5) along with a series of l4C-labelled standards (concentration
range 44-2500 nCi/g tissue equivalents) in light-tight cassettes. These standards
include a blank and eight standards with progressively increasing l4C concentrations
calibrated to equivalent 14C concentration in brain sections of 20pm thicknes. Films
were exposed for 6-7 days and processed according to manufacturer's instructions.
Analysis of autoradiograms was performed on a computer-based image analysis
system (M4 MCID), following construction of a calibration curve from densitometric
measurement of the standards. An accessory file contains the sampling time, sample
volume, correction factor and DPM counts from the timed arterial samples, which are
integrated into the equation below. Identification of brain areas was made with
reference to the atlas of Paxinos & Watson (1986). Bilateral optical density
measurements were made from twenty-nine brain regions. Measurements from 4-6
brain sections were analysed per region of interest, and calculation of local CBF
made from the optical density value by reference to a calibration curve constructed
from the [14C] standards, and from the local [I4C] concentration, the history of [14C] in
arterial blood and the tissue blood partition coefficient for [14C]iodoantipyrine (0.79)
using the equation derived of Sakurada et al. (1978) with the correction factor for
distortion of the arterial cathater input function (0.184) of Jay et al. (1988):
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Ci (J) is the concentration of tracer in tissue at a given time (T) following tracer
injection
C'a is the concentration of tracer in the arterial blood
t is variable time after correction (0.184 x catheter flow rate) for the transit time
through the catheter.
K is a constant defined as mF where m=l (diffusion of tracer across BBB)
and WA, F/W is the rate of blood flow per unit mass of
tissue
A, is the tissue/blood partition coefficient for the tracer (0.79)
Local CBF within 8 flow thresholds from 0-25 ml/lOOg/min up to flows
>250ml/100g/min was also determined by setting flow thresholds and measuring
hemispheric, cortical and caudate nucleus blood flow at the level of the steroetaxic
injection site (~lmm rostral to bregma).
[I4C]iodoantipyrine studies were performed with the assistance of Dr. J. Sharkey of
the Fujisawa Institue of Neuroscience, University of Edinburgh.
3.2.5. Statistical analysis
All data are shown as mean ± s.e.mean. Temperature and oxygen data were analysed
using two-way ANOVA with post-hoc Tukey test, while LDF studies were analysed
with one-way ANOVA.
Physiological variables were compared by Students T test. Ipsilateral and
contralateral local CBF within 29 specific brain regions following
[I4C]iodoantipyrine autoradiography in ET-1 -induced MCA occluded animals were
compared to sham operated controls by Student's T test. The % of ipsilateral and
contralateral hemisphere, cortex and caudate nucleus within 8 specific flow
thresholds were compared against flow in sham operated animals by Student's T test.
3.2.6. Experiments performed
Four studies were performed:
1) Body temperature vs brain temperature. Body temperature was varied over the
range 30-40°C and corresponding brain temperature recorded in non-MCA
occluded animals.
2) Brain temperature and oxygen tension were recorded following ET-1-induced
MCA occlusion within lateral striatum.
3) Temporal profile of ischaemia following ET-1-induced MCA oclusion was
recorded by LDF
4) [l4C]iodoantipyrine autoradiographical determination of local CBF three hours
following ET-1 injection. Local CBF for sham and MCA occluded animals was
also used to determine the % of hemisphere, neocortex and caudate nucleus
within 8 flow thresholds.
3.3. Results
3.3.1. Body & brain temperature
Calibration of temperature sensors in ACSF demonstrated a linear and parallel
relationship for the two temperature sensors "a" (proximal) and "b" (distal) in the
range 30-40°C. (r2(a)=0.98 slope a=1.07±0.02; r2(b)=0.98 slope b=1.12±0.02). Since
changes in temperature for the probe are linear, a correction factor could be simply
based on the mean differences between the sensor readings and the rectal probe
readings rather than on the differences of slope between sensor and probe readings.
This would have required back calculation to absolute zero and a correction factor
that took into account slope divergence at different temperatures. Thus the mean
differences between sensor readings and the reference electrodes over the range 32-
39°C were calculated and then sensor readings corrected where appropriate.
The results for striatal temperature in the range 32-39°C from both probe sensors
are plotted in figure 11, against corresponding body temperature. Linear regression
gave a r2 value of 0.96 and slope of 1.03, demonstrating a linear correlation between
core body temperature and (non ischaemic) brain temperature in the 32-39°C range.
3.3.2. 450 pmols in 3pl
Injection of 450 pmols ET-1 in 3pl (n=9) produced an hemispheric ischaemic brain
lesion of 159 ± 18mm3. This volume was not significantly different to that seen
following injection of 33-300 pmols ET-1 in 2pl.
3.3.3. Cerebral temperature
Striatal temperature and rectal temperature remained between 37-38°C for the
duration of recordings with mean values of 37.6±0.03°C and 37.5±0.03°C
respectively (Figure 12). Fluctuations in temperature across time were below the
limits of thermostatic control of the heated blanket (CMA specification ± 0.2°C).
Correlation between body and brain
temperature
Figure 11. Correlation between body and brain temperature over the range 30-
40°C. Body temperature was varied and striatal temperature simultaneously re¬
corded (n=4). A strong positive correlation was found. R2=0.96; slope=1.03.
Striatal and rectal temperature following
ET-1 -induced MCA occlusion
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Figure 12. Intracerebral temperature recordings from the striatum following ET-
1-induced MCA occlusion (n=3). Data are presented as mean ± s.e.mean. No
significant change in brain temperature occured following ET-1-induced MCA
occlusion, and no differences were found between striatal and rectal temperature,
throughout the 3 hour recording period.
3.3.4. Cerebral oxygen tension during stroke
Striatal oxygen tension remianed unchanged for the duration of recordings in non-
MCA occluded (vehicle-injected) animals. By contrast, in animals undergoing ET-1-
induced MCA occlusion, oxygen tension fell significantly (p=<0.05) within 15
minutes of ET-1 injection to 61% of baseline value (range 50-83%). Oxygen tension
was maximally depressed by 85% after 2 hours, remaining below 30% for the
duration of recordings and showing no significant recovery (Figure 13).
3.3.5. Cortical tissue perfusion (LDF) - 3hour recordings
LDF recordings from dorsal parietal cortex ipsilateral to the site of Et-1 injection
demonstrated that mean flow velocity was reduced by 86% (range 72-99%) within 5
minutes of vessel occlusion (Figure 14). LDF values remained depressed by greater
than 50% after 2 hours, and flow was still significantly reduced after 3 hours
(p<0.05).
3.3.6. Local CBF at 3hours
Physiological variables for sham and MCA occlusion animals are shown in Table 3.
Variables were within the normal limits for conscious animals and no significant
differences were found between sham and ET-1 treated animals for any of the
parameters studied.
Local CBF was found to be generally symmetrical between hemispheres and
between sham and MCA occluded animals in brain regions outwith the MCA
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Figure 13. Intracerebral oxygen tension recordings following ET-1-induced MCA
occlusion (n=5) or vehicle injection (n=8). Data are presnted as mean ± s.e.mean.
Whilst control recordings did not significantly change from baseline, oxygen ten¬
sion fell significantly within 15 minutes by 39%, and was maximally decreased by
85%, following ET-1 injection. *P=<0.05 compared to vehicle controls.
LDF profile of tissue perfusion velocity change following
ET-1-induced MCA occlusion
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Figure 14. Dorsal parietal cortex LDF recordings of perfusion velocity changes
following ET-1-induced MCA occlusion (n=5). Data are presented as mean ±
s.e.mean. LDF signal was reduced by 86% within 5 minutes of ET-1 (450 pmols
in 3pi), and remained depressed for three hours. *P=<0.05 compared to baseline.
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territory. Areas such as the pons, cerebellum and genu of the corpus callosum
demonstrated variations in local CBF of <10% between hemispheres and across
treatments. Furthermore, there were no significant differences between sham and ET-
1 treated animals in any structure contralateral to the side that underwent
intracerebral injections. Figure 15 shows pseudocolour transforms of local CBF
measured three hours after animals undergoing ET-1-induced MCA occlusion,
compared to vehicle injected controls. Note the profound reductions in CBF
throughout the MCA vascular territory at both representative stereotaxic levels .
Local CBF determined 3 hours following ET-1 induced MCA occlusion
demonstrated significant reductions in blood flow of up to 84% (piriform cortex) in
the ipsilateral hemisphere in a number of brain regions compared to sham operated
animals (Table 4). These included all cortical structures, except the midline structures
of the retrosplenial and cingulate cortices, and the lateral caudate-putamen. A number
of structures outwith the MCA vascular territory exhibited small CBF reductions and
included the globus pallidus and nucleus accumbens which were reduced by 27% &
43% respectively.
Local CBF at different flow thresholds within hemisphere, cortex and caudate
nucleus were calculated and data are presented in figures 16 (hemispheric), 17
(cortex) and 18 (caudate-putamen). Statistical analysis demonstrated a significant
shift towards the left througout the three sampled regions. Whilst there were no
significant differences in local CBF within any flow threshold for the contralateral
hemispheres, the % of ipsilateral hemispheric flow within specific thresholds were
significantly increased within the following 1CBF bands: 0-25, 25-50 & 50-75
Local cerebral blood flow three hours following
ET-1 -induced MCA occlusion
Sham MCA occlusion ET-1-induced MCA
at 3hours occlusion at 3 hours
Brain region Blood flow Blood flow Blood flow Blood flow
ipsilateral contralateral ipsilateral contralateral
Superficial cerebral structures
Medial prefrontal cortex 188±5 188±4 135±23a 156±25
Frontal cortex area 8 191±6 191±5 62±19*** 188±15
Frontal cortex area 10 184±6 186±5 39±9* ** 182±16
Piriform cortex 208±8 207±7 33±10*** 217±8
Somatosensory cortex 198±2 197±2 42±8*** 198±14
Cingulate cortex 226±8 224±7 216±28 224±27
Parietal cortex 202±6 200±6 66±10*** 216±17
Temporal cortex 193±6 192±6 64±10*** 215±12
Retrosplenial cortex 215±5 213±4 218±27 228±24
entorhinal cortex 140±8 136±9 54±10*** 145±10
Primary visual cortex 212±5 213±5 82±15*** 221±15
Deep cerebral structures
Genu of corpus callosum 52±2 51±2 46±9 47±8
Nucleus accumbens 109±6 109±6 63±12** 99±10
Caudate-putamen (dorso-lateral) 131±4 133±4 70±15* 139±11
Caudate-putamen (medio-lateral) 146±8 146±7 80±16** 149±10
Septal nucleus 98±7 98±6 98±13 97±15
Anterior-medial thalamic nucleus 194±7 194±7 173±17a 192±14
Ventrothalamic nucleus 149±5 149±6 136±13a 178±19
Subthalamic nucleus 147±3 146±5 148±12 167±14
Globus pallidus 101±4 103±4 74±8** 95±6
Hippocampal CA1 84±4 84±4 91±8 98±9
Dentate gyrus 114±4 109±3 122±9 125±10
Internal capsule 84±2 84±2 83±9 89±9
Lateral geniculate nucleus 162±3 158±3 158±12 179±21
Substantia nigra 130±10 131±9 150±16a 142±15
Cerebellum & pons
Pontine nucleus 111±6 112±7 111±7 114±8
Cerebellar white matter 45±2 45±2 44±5 43±4
Cerebellar grey (minimum) 103±1 104±1 108±6 109±6
Cerebellar grey (maximunm) 230±11 229±10 221±13 218±13
Table 4. Local cerebral blood flow (ml/lOOg/min) in 29 anatomically defined
regions of the brain, measured 3 hours after ET-1-induced MCA occlusion or sham
(saline) injection. Data are presented as mean ± s.e.mean. Student's T test.
*/)=<0.05. ***/>=<0.05. for comparison to ipsilateral sham animals. ano significant
difference.
ml/lOOg/min. By contrast, the % of hemisphere within the bands 100-150, 150-200,
200-250 and >250 ml/lOOg/min were significnatly reduced in MCA occluded
animals.
This pattern was identical to that seen for the cortex and caudate nucleus, whereby
the % of the region with the 0-75 ml/lOOg/min bands were increased, whilst above
lOOml/lOOg/min, the % of the region was significantly reduced compared to sham




In these studies, intracerebral 02 & temperature recordings, LDF and [14C]-
iodoantipyrine autoradiography were employed to determine the characteristics of the
ET-1-induced MCA occlusion model. In establishing a novel model of stroke, a
range of parameters should be examined in detail. This allows comparison to existing
models and consequently advantageous and disadvantageous aspects to be addressed.
These studies suggest that the duration of ischaemia is at least three hours, and that
this model is not associated with a reduction in striatal temperature. Intracerebral
temperature and oxygen tension were measured within the striatum, since
histopathological analysis in chapter 2 demonstrated that the region of the medial and
lateral caudate nucleus consistently exhibits ischaemic brain damage. LDF
recordings were only made from the parietal cortex, since preliminary studies
130

































































25-50 50-75 75-100 100-150 150-200 200-250 >250
Flow band
Figure 16. Comparaison of the % of ipsilateral (top) and contralateral (bottom)
hemisphere demonstrating local CBF within specific flow bands for ET-1 (n=8)
and sham operated (n=7). Data are presented as mean ± s.e.mean. *P=<0.05 com¬
pared to sham operated controls.
Cortical local CBF bands 3 hours following
ET-1-induced MCA occlusion
TPSTLATERAL
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Figure 17. Comparison of the % of ipsilateral (top) and contralateral (bottom)
cortex demonstrating local CBF within specific flow bands for ET-1 (n=8) and
sham operated (n=7) animals. Data are presented as mean ± s.e.mean. *P=<0.05
compared to sham animals























































0-25 25-50 50-75 75-100 100-150 150-200 200-250 >250
Flow band
Figure 18. Comparison of the % of ipsilateral (top) and contralateral (bottom)
caudater nucleus within specific local CBF bands for ET-1 (n=8) and sham oper¬
ated (n=7) animals. Data are presented as mean ± s.e.mean. *jP<0.05 compared to
sham animals.
Figure 15.
Local CBF determined by [l4C]iodoantipyrine autoradiography three hours after
intracerebral injection of 100 pmols ET-1 adjacent to the MCA. Pseudocolour
transforms represent local CBF at the level of bregma in (a) ET-1 treated & (b)
vehicle injected sham animals at the same level, and local CBF at the level of the
hippocampus (Bregma -4.0mm) in (c) ET-1 treated & (d) vehicle injected sham




determined the LDF signal from intracerebral recordings were unreliable (data not
shown).
3.4.2. Body/brain temperature correlation
We found in these studies that there is a linear correlation between core body
temperature and (non ischaemic) brain temperature in the 32-39°C range. Previous
studies have shown that whilst brain temperature may not be the same as body
temperature, there is a direct correlation between them, and the present data are
consistent with established findings (Ginsberg et al. 1992; Hasegawa et al. 1994),
validating these probes for application to subsequent studies.
3.4.3. Striatal temperature
LDF and intracerebral recordings were made from rats with implanted cannulae. As
mentioned, a higher dose and volume was employed in this study using an
indwelling cannula, to increase the MCA occlusion success rate. However,
histopathological analysis demonstrated that this higher dose and volume had no
significant effect on the volume and distribution of ischaemic brain compared to
injection of 100 pmol in 2pi using an acutely placed cannula. Intracerebral
recordings from the striatum following ET-1 -induced MCA occlusion determined
that temperature remained unchanged for 3 hours following ET-1 infusion. These
results contrast with findings in other models of MCA occlusion, in which the
procedures involved have been shown to either elevate (Zhao et al. 1994) or decrease
(Morikawa et al. 1992) brain temperature. However, studies have shown that the
striatal temperature may change by only 0.5°C or less following MCA occlusion
(Hasegawa et al. 1994). These differences may be due to a number of factors. First,
by contrast to the transorbital approach, occlusion of the MCA in this model
circumvents the need for a large craniotomy or displacement of the temporalis
muscle. Such surgical procedures may lead to brain cooling consequent on tissue
exposure. Second is the possible effect of residual flow within the vascular territory
of the MCA, insufficient to prevent ischaemic damage but sufficient to maintain
local tissue temperature. This is an important finding because reducing brain
temperature ameliorates brain damage from both focal and global cerebral ischaemia
(Buchan & Pulsinelli, 1990; Busto et al. 1987; Onesti et al. 1991; Xue et al. 1992),
while hyperthermia may exacerbate neuropathological damage (Chen et al. 1991;
Dietrich et al. 1990). Consequently, an advantage of the intracerebral ET-1 model is
that neuroprotection studies will not be confounded by changes in brain temperature.
3.4.4. Striatal oxygen tension
The duration of MCA occlusion-induced ischaemia was assessed by measuring
oxygen tension within the medial striatum. ET-1-induced MCA occlusion resulted in
profound reductions in striatal oxygen tension. This decrease was significant within
15 minutes, and continued to fall reaching a maximum of 85% reduced after 2 hours,
thereafter remaining essentially stable. There was no sign of recovery of oxygen
tension during the 3 hour recordings. By contrast, vehicle injection had no significant
effect on oxygen tension, and there was no significant deviation from baseline
recordings. Whilst oxygen tension is not a direct measure of CBF, it is a function of
the perfusion state in ischaemically challenged tissue. That oxygen tension declines
following MCA occlusion reflects the reduction in CBF to the tissue and the
ischaemic predicament of the brain parenchyma. Measurement of oxygen extraction
has been a principle method of assessing cerebral ischaemia using PET methods, and
has been addressed above.
Significant falls in brain oxygen levels following experimental cerebral
ischaemia have been reported previously (Crockard et al. 1975; Martin el al. 1982;
Nair et al. 1987; Freund et al. 1989; Liu et al. 1995 ) and the present data are
consistent with studies in which the MCA was occluded by intraluminal filament
(Back et al. 1994b) or transorbital approach (Zauner et al. 1995). These results
suggest that the duration of ET-1 -induced ischaemia is at least three hours.
3.4.5. Cortical perfusion velocity
LDF recordings from the parietal cortex extend the findings of the oxygen tension
recordings. The parietal cortex is commonly sampled in LDF studies (Dirnagl et al.
1989; Dalkara et al. 1994; Kadoya et al. 1995; Karibe et al. 1995; Takagi et al.
1994a) because this region consistently undergoes dense ischaemia following MCA
occlusion (Gartshore et al. 1996; Sharkey et al. 1994; Tamura et al. 1981b), and
reperfuses on cessation of MCA occlusion (Dirnagl et al. 1989; Karibe et al. 1995).
LDF has also been shown to be an accurate index of histological outcome (Soriano et
al. 1997). In these studies, LDF values (tissue perfusion units) were expressed as the
% change from baseline, which is accepted as the only valid method with which to
express LDF data (Fabricus & Lauritzen 1996).
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The reduction in parietal cortex flow of -86% within 5 minutes of ET-1 is
somewhat greater than that found using [14C]iodoantipyrine autoradiography (-60%
reduction) in an earlier study using this model (Sharkey et al. 1993), although this
may be adequately explained by experimental protocol differences, or the use of
anesthetics in the present study, which have significant effects on CBF. Data are also
comparable with LDF studies in which the MCA was blocked by an intraluminal
filament (Kadoya et al. 1995) or by electrocoagulation (Morikawa et al. 1992). Flow
returned gradually over the three hour recording period but still remained below 50%
after two hours, and significantly reduced compared to pre-ET-1 values after three
hours. This profile compares well to studies where ET-1 was applied to the exposed
MCA (Gartshore et al. 1996), in which "raTc-exametazime uptake in the parietal
cortex was reduced by 84% 5 minutes after ET-1 application and recovered to -40%
2 hours post ET-1. These findings suggest that CBF may return to structures within
the vascular territory of the MCA and some reperfusion may be a characteristic of
this model.
These results however do not entirely compliment the findings of striatal oxygen
tension, which suggested blood flow has not returned to the striatum after three
hours. This difference may be explained by the differential sampling sites. LDF was
recorded from dorsal parietal cortex which commonly lies within the ischaemic
penumbra (see table 2), and is close to the boundary between normal and ischaemic
tissue, such that CBF may return to this area in some cases. By contrast, the medial
and lateral striatum represent end-territory structures that do not receive significant
collateral perfusion from other vascular fields, and the low efficacy of
neuroprotectants to reduce ischaemic damage in the striatum has been attributed to
this (Nagasawa & Kogure, 1989; Sharkey & Butcher, 1994; 1995). These differences
are reflected in Figure 33, which is a pseudocolour transform of local CBF measured
by [14C]iodoantipyrine 3 hours following ET-1 induced MCA occlusion. A region of
hyperperfusion lies within the dorsal LDF sampling site (a), whilst no such
hyperperfusion is evident within the striatum. Consequently, the recording position
of the LDF probe means that sampling within this region may exhibit a greater
degree of reperfusion than core areas of the ischaemic territory.
3.4.6. Local CBF at 3 hours
Previous studies have determined that if ischaemia following MCA occlusion is of
three hours duration or greater, the pathophysiological outcome is not significantly
different to animals subjected to permanent MCA occlusion (Kaplan et al. 1994).
Consequently local CBF was determined 3 hours following MCA occlusion using the
technique of [14C]iodoantipyrine autoradiography, which is an established method for
quantitative determination of local CBF (Sakurada et al. 1978).
Twenty-nine brain regions were sampled in these studies which included
structures both within and outwith the vascular terrirory of the MCA as well as brain
regions with functional connectivity to regions within the MCA vascular field.
Generally, ipsilateral local CBF in ET-1 injected rats was not significantly different
to the contralateral side and was not significantly different to either ipsilateral or
contralateral CBF in sham animals. CBF within the pons, septum and cerebellar
white matter was very similar to that reported previously following MCA occlusion
in the rat (Tamura et al. 1981b) and was not significantly different to sham operated
animals or the contralateral hemisphere.
CBF was significantly reduced in all ipsilateral cortical structures studied except
midline structures such as the cingulate and retrosplenial cortices. These structures
receive CBF from the anterior cerebral artery and generally do not undergo
significant changes in local CBF following MCA occlusion (Tamura et al. 1981b;
Robinson et al. 1990). Local CBF in the frontal and parietal cortices 3 hours after
ET-1-induced MCA occlusion was in the range 33-66ml/100g/min, reductions of 63-
73%, which compares well to reductions of 82-83% found previously following
permanent MCA occlusion of 82-83% (Tamura et al. 1981b), and are almost
identical to those found in other models that have employed ET-1, where these
cortical structures exhibited reductions of 67-71% (Robinson et al. 1990). Local CBF
was reduced by 61% in the more caudal structure of the primary visual cortex, which
is in agreement with previous studies (Tamura et al. 1981b; Robinson et al. 1990).
This level of CBF reduction has been previously accounted for by this structure
receiving some CBF supply from the posterior cerebral artery (Tamura et al. 1981b;
Scremin, 1995). The extent of CBF reduction in areas such as the piriform cortex
(85%) and somatosensory cortex (79%) suggests that significant reperfusion has not
commenced 3 hours following ET-1-induced MCA occlusion. The somewhat higher
level of cortical CBF at three hours compared to 30 minutes post-MCA occlusion
(Tamura et al. 1981b) may be adequately explained by previous reports that CBF
may recover to an extent even following permanent (electrocoagulation) occlusion of
the MCA (Hakim et al. 1992).
These results contrast to the study by Gartshore et al. (1996) in which ET-1 was
applied to the exposed MCA. In their study, CBF had generally recovered to a
greater extent at two hours than was obserevd at three hours in this model. The
explanation for this is unclear but is likely to be due to differences arising from
injection of ET-1 intraparenchymally compared to application to the exposed MCA,
the former of which may limit diffusion and prolong the action of ET-1. Whilst CBF
was essentially similar to that following permanent MCA occlusion in this model, the
time for half-maximal restoration of pial vessel diameter following ET-1 application
is reported to be in the order of 45-60 minutes (Robinson & McCulloch, 1990),
which would suggest that the MCA would be more than 50% patent after three hours.
Since the MCA is not a resistance vessel such a relaxation would effectively allow
full flow through to downstream territories. That structures within the MCA are still
densely ischaemic, may therefore be explained in a number of ways. First, the t1/2 for
ET-1 on the rat MCA may differ. Indeed, the study by Robinson & McCulloch
(1990) was performed on the pial vessels of chloralose-anaesthetised cats. Second,
post-ischaemic microvascular obstruction may limit reperfusion. This has been
proposed to account for the limited reperfusion seen 2 hours following ET-1
application to the exposed MCA (Gartshore et al. 1996). Furthermore, ET-1 itself
may diffuse to act on cerebral vessels other than the MCA and limit perfusion from
other vessels which has previously been suggested (Gartshore et al. 1996).
Local CBF of <25ml/min/100g has been reported as necessary to produce
histopathological damage in the rat, although this is somewhat variable (Tamura et
al. 1981b; Symon et al. 1975) and may be higher in primates (Blair & Waltz, 1970;
Tamura et al. 1981b). Whilst CBF was still profoundly reduced within the cortex
supplied by the MCA three hours after ET-1, the levels reported here (30-
60ml/100g/min) are somewhat higher than those reported to produce ischaemic brain
damage. However, correlating CBF changes to histopathological outcome is difficult
and variable (Hakim et al. 1992). Furthermore, this discrepancy may be explained by
the effects of time on the required ischaemic intensity. Heiss & Podreka (1983)
determined a relationship between the duration of ischaemia and residual CBF,
whereby the severity of ischaemia required to produce irreversible damage decreases
with the duration of ischaemia. Whilst very low flow levels below 25ml/100g/min
may be required to produce ischaemic damage when measured acutely, this threshold
increases with the duration of ischaemia, such that by three hours post MCA
occlusion higher flow levels of ~30-60ml/100g/min may be sufficient to produce
ischaemic damage. Given difficulties in predicting histological outcome based on
CBF and the effects of time on required ischaemic severity following focal cerebral
ischaemia, the levels of CBF within the cortex three hours after ET-1-induced MCA
occlusion are both compatible with those required to produce histological damage
and are essentially consistent with a model of permanent MCA occlusion.
Three hours following ET-1-induced MCA occlusion, CBF in the dorso- and
mediolateral caudate nucleus was -50% of flow in the contralateral hemisphere,
which is significantly higher than is found after 10 minutes (Sharkey et al. 1993).
The finding of greater CBF recovery in the caudate-putamen in this study is similar
to that reported by Gartshore et al. (1996), in which, whilst CBF was still
<50ml/100g/min in many cortical structures 2 hours following ET-l-induced MCA
occlusion, CBF in the caudate-putamen was ~80-90ml/100g/min, a similar level to
that found in the present studies. The explaination for this is unclear. Indeed, studies
suggest that the greater the ischaemic intensity, the more limited subsequent
reperfusion is (Hakim et al. 1992; Gartshore et al. 1996). Anatomical differences in
the cerebrovasculature may lead to improved CBF to structures within the MCA
territory, and the presence of Hubner's arteries, branches of the anterior cerebral
artery that feed the caudate-putamen, have been attributed to higher CBF within the
striatum following MCA occlusion (Gartshore et al. 1996). However, it is generally
accepted that the caudate-putamen is an end vessel territory that receives almost no
collateral perfusion, which has been proposed to account for the common lack of
efficacy of neuroprotectantion in the striatum (Sharkey & Butcher, 1994). Another
possibility is that MCA constriction begins to relax after 3 hours leading to a return
of CBF. Formation of a thrombus at the site of constriction might mean that whilst
flow returns to the proximal region of the MCA branches, such as the lenticulostriate
branches that feed the striatum, flow to structures distal to the MCA trunk do not
initially receive perfusion. However, this would have to consistently occur, and since
these animals were heparinised and no evidence of thrombi within the MCA were
visible in any brains, this proposal seems unlikely.
Since ischaemia is densest in the striatum in this model (Sharkey et al. 1993),
accumulation of vasodilator metabolites such as C02 and H+ will be greatest and may
drive any residual CBF within the MCA territory. This may account for the higher
flow within the striatum relative to other cortical structures, and has previously been
proposed to account for luxury perfusion (Hoedt-Rasmussen et al. 1967). However,
since cortical CBF is still profoundly reduced, suggesting the MCA is still
constricted, it seems unlikely that physiological function within the
cerebrovasculature would be capable of driving this. The exact explanation remains
obscure and might be a combination of one or more of these factors.
Comparison of local CBF 3 hours post MCA occlusion compared to 10 minutes
also suggests local CBF recovers in a heterogeneous manner across the hemisphere
(Table 5), which has been shown previously (Gartshore et al. 1996). Local CBF in
the pons was included as a control area, and was found to be almost identical
between studies and did not change following MCA occlusion which is as reported
previously (Tamura et al. 1981b). CBF recovery in the present study is correlated to
an extent to the initial intensity of ischaemia. The order of cortical ischaemic
intensity in the present study was:
piriform > area 10 > area 8 > parietal = temporal
whilst CBF intensity in the cortex in the study by Sharkey et al. (1993) was:
frontal area 8 > frontal area 10 > parietal > piriform > temporal
Such a correlation have also been reported previously (Hakim et al. 1992;
Gartshore et al. 1996). CBF in frontal cortex areas 8 and 10 had changed little three
hours following MCA occlusion (<10%), however, local CBF had decreased by a
further 10-46% in piriform, parietal and temporal cortex, relative to the flow decrease
determined 10 minutes following MCA occlusion. By contrast, local CBF had
recovered by 13 and 43% in somatosensory cortex and lateral caudate nucleus
respectively, by 3 hours post ET-1-induced MCA occlusion.
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Analysis of local CBF within flow thresholds from 0->250ml/100g/min,
demonstrated that whilst only -1% of the contralteral hemisphere had local CBF
below 25ml/100g/min, a significant shift to lower flow levels was found in the
ipsilateral hemisphere, cortex and caudate-putamen nucleus. Analysis of the shift
determined that at low flow thresholds (CBF 0-75ml/100g/min), the percentage of
the region was significantly greater in ET-1 treated animals, whilst at the high flow
levels (100->250ml/100g/min) sham operated animals had a significantly greater
percentage of the region within that flow band. This supports and compliments the
previous findings where 1CBF was measured 10 minutes after ET-1 (Sharkey et al.
1993). The insight available from comparison may be limited however by the
original ET-1-induced MCA occlusion procedure being performed in concious
animals using a dose of 120 pmols. Flowever, in those studies, the percentage of the
hemisphere with ischaemic levels of CBF <25ml/100g/min was 17%, whilst in these
studies -11% of the hemisphere still had local CBF levels <25ml/100g/min. This
demonstrates that the significant and profound reduction of local CBF throughout the
MCA territory found 10 minutes post ET-1 are sustained for as long as 3 hours
following ET-1-induced MCA occlusion. The finding that CBF had decreased further
in some regions 3 hours post MCA occlusion suggests that processes that affect
microvascular integrity may be limiting any available CBF. This suggests that the
phenomenon of "no reflow" may be an important factor in the profile of blood flow
return in this model. "No reflow" (Ames, 1968) refers to limitations in the
microvascular patency to flow, which may be caused by a multitude of microvascular
changes such as oedema, alterations of endothelial cells, leukocyte-endothelial cell
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interaction and coagulation system activation (del Zoppo et al. 1991; del Zoppo,
1994; Akopov et al. 1996).
A number of brain regions outwith the vascular territory of the MCA undergo
CBF changes following MCA occlusion (Tamura et al. 1981b), and this includes
some of the structures of the basal ganglia. This has been proposed to occur as a
consequence of functional connectivity between regions. In the case of the substantia
nigra & globus pallidus, this probably occurs due to loss of the inhibitory input from
the striatum (Tamura et al. 1993; Sharkey et al. 1993). In the present study,
ipsilateral CBF within the substantia nigra was somewhat higher than in sham
lesioned animals (150ml/100g/min compared to 130 ml/lOOg/min) but this did not
reach statistical significance. However, other studies employing ET-1 to occlude the
rat MCA have not reported significant increases in local CBF within the substantia
nigra (Robinson et al. 1990), so the discrepancy noted in this study does is not
entirely at odds with the established literature.
CBF within the globus pallidus was found to be significantly decreased in the
present study, and has previously been reported to increase (Tamura et al. 1981b;
Sharkey et al. 1993), decrease (Gartshore et al. 1996) or remain unchanged
(Robinson et al. 1990) following MCA occlusion. These discrepancies may be
explained by the complex nature of the vascular and neuronal innervation of this
structure. The lateral segment of the globus pallidus is perfused from the MCA
(Nedergaard, 1988), which may explain the mild reduction in CBF within this
territory. However, the globus pallidus receives inhibitory input from the caudate-
putamen (Heimer et al. 1995), the loss of which has been proposed to account for
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hyperperfusion within this region following MCA occlusion (Tamura et al. 1981b).
Since the globus pallidus receives excitatory cortical input from the neocortex
(Heimer et al. 1995), loss of this input subsequent to energy failure within the
ischaemic neocortex may lead to reduced metabolic demands on this region with
subsequent reductions in CBF. Inter-study discrepancies are also likely to reside on
experimental & model differences and the time post-MCA occlusion that CBF was
determined. With regards to this latter point, whilst CBF may increase at acute time
points when CBF is measured 10-30 minutes post MCA occlusion (Tamura et al.
1981b; Sharkey et al. 1993), it is conceivable that the hyperperfusion consequent on
loss of inhibitory input may be transient. At later time points, hypoperfusion may
develop since the globus pallidus is anatomically adjacent to the densely ischaemic
caudate-putamen, and mechanisms have been proposed to explain hypoperfusion in
territories outwith the MCA vascular field (Slater et al. 1977; Tamura et al. 1981b).
Release of vasoactive agents, of which ET-1 is a likely candidate (Patel et al. 1995a),
may account for the hypoperfusion in the globus pallidus 3 hours after MCA
occlusion.
Ipsilateral local CBF in the nucleus accumbens in the present study was
significantly reduced by 36% compared to the contralateral side, which is similar to
the reduction of 24% found in the study by Tamura et al. (1981b), although this area
has been reported not to undergo changes in local CBF following MCA occlusion
(Robinson et al. 1990; Gartshore et al. 1996). The nucleus accumbens is generally
considered part of the striatum and is within the structures of the basal ganglia
(Heimer et al. 1995). It receives at least part of its blood supply from a branch of the
anterior cerebral artery (Scremin, 1995) which explains the relatively minor change
in CBF following MCA occlusion, and it is likely that the close proximity of this
structure to the ischaemic caudate-nucleus (Heimer et al. 1995), as well as loss of
cortical input may explain these changes.
Regions within the thalamus, as well as the hippocampal CA1 region have
previously been reported to undergo local CBF changes following MCA occlusion.
The thalamus and hippocampus receive their vascular supply from branches of the
posterior cerebral artery (Scremin, 1995), and the explanation for CBF changes has
been based on neuronal connectivity. In the present study, local CBF within the
hippocampal CA1 was not affected by MCA occlusion, which has been reported
previously (Robinson et al. 1990), although mild decreases (Tamura et al. 1981b)
and increases (Sharkey et al. 1993) have been reported.
In this study, CBF in the anterior-medial thalamic, and ventrothalamic nuclei
was 9-11% lower ipsilaterally although this was not significant, whilst CBF in the
subthalamic nucleus was unaffected which has been reported previously (Tamura et
al. 1981b). The anterior-medial thalamic nucleus, like the other anterior nuclei,
receive the major source of input from the hippocampal formation, and the major
cortical projections are to the retrosplenial and cingulate cortices that are outwith the
MCA territory (Price, 1995; Scremin, 1995), which would explain why MCA
occlusion had only minimal effect on local CBF within these areas.
The ventral thalamic nuclei (lateral and medial) are major relay structures
between the cerebellum and motor cortex (Price, 1995), and since the cerebellum is
outwith the MCA territory, whilst the motor cortex is at least partially fed by the
posterior cerebral artery (Scremin, 1995), the relatively minor changes in local CBF
within this structure would be expected.
The subthalamic nucleus is a strategic relay structure between the globus
pallidus and the major output nuclei of the basal ganglia which includes the
substantia nigra, whilst there is evidence of some small striatal projections to the
subthalamic nucleus (Heimer et al. 1995). This structure is not within the vascular
territory of the MCA (Scremin, 1995) and given this structure's anatomical
connectivity, it is not surprising that this area did not undergo significant changes in
CBF following MCA occlusion.
The cause of inter-study discrepancies between CBF changes within thalamic
areas and the hippocampus, is unclear. These brain regions receive a diverse and
heterogeneous neuronal innervation from both excitatory and inhibitory nerve
supplies (Price, 1995), and changes in CBF to these structures after MCA occlusion
have been explained based on loss of striatal inhibitory input (Sharkey et al. 1993).
However, the thalamus is a major relay structure, receiving substantial input from
neocortical brain regions such as the somatosensory cortex (Price, 1995), loss of
input from which may lead to reductions in metabolic demand, counterbalancing the
loss of inhibitory input from the caudate-nucleus. It is conceivable that discrepancies
in CBF following MCA occlusion may also be accounted for by the criteria on which
the region is selected, model & experimental differences and the time after MCA
occlusion at which CBF is measured, and explanations based on assertions of
neuronal connectivity are probably superfluous.
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3.4.7. Conclusions
The most important conclusions that can be drawn from these studies concern the
duration of the ischaemic insult following ET-1-induced MCA occlusion. Two
measures of the ischaemic insult, striatal oxygen tennsion and local CBF suggest that
there is minimal recovery of blood flow to the vascular territory of the MCA three
hours following MCA occlusion in this model, findings complimented by LDF
recordings within the parietal cortex. The factors responsible for the lack of
reperfusion remain a matter of debate however. Taken with the experimental
evidence from previous studies suggesting 3 hour MCA occlusion produces an
ischaemic lesion not different from permanent MCA occlusion, it may be concluded
that the ET-1 induced MCA occlusion model represents a model of permanent MCA




CHAPTER 4: NEUROPROTECTIVE & BEHAVIOURAL




Alzheimer's disease (AD) is the most common cause of progressive intellectual
failure in aged humans (Games et al. 1995). The accumulation of a truncated form
PAPP has been suggested as one of the causes of the pathology of the disease
(Checler, 1995; Cotman et al. 1995), formation of which may rest on genetic or
posttranscriptional processing abnormalities, whilst abnormal phosphorylation of
neurofilaments & MAP tau protein have also been implicated (Neve et al. 1990;
Goldgaber et al. 1987). The P-amyloid precursor protein (PAPP) is a large
transmembrane protein that is the source of the amyloid P-peptide (PAP), a 40-42
amino acid segment of PAPP, that accumulates in senile plaques in Alzheimer's
disease (Smith-Swintosky et al. 1994).
PAPP is widely distributed within a number of cell types and is encoded within a
single gene on chromosome 21. pAPP's may exist in a number of forms which arise
from differential processing (Selkoe et al. 1989). Cleavage of PAPP within the PAP
region can generate secreted forms of PAPP (APPs) and non-amyloidogenic peptide
fragments (Mattson et al. 1993). These include forms containing (APP751 &
APP770) or lacking (APP695 & APP714) a Kunitz-type protease inhibitor region
(Smith-Swintosky et al. 1994). APP751 has been identified as nexin-11 (Oltersdorf et
al. 1989). The most abundant form in the brain is the APP695 (Pluta et al. 1994;
Smith-Swintosky et al. 1994), and both PAPP and PAP are produced and secreted
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under physiological conditions (Selkoe 1993). Such plaque accumulation has been
investigated in various species of laboratory animals. Whilst (3AP accumulates in
Alzheimer's brain, Vaughan & Peters (1981) showed that aged rodents do not
generally develop PAP plaques, or show them only sporadically (Pluta et al. 1994).
However, Coria et al. (1992) found that rodent brain contains the same forms of
PAPP as well as similar immunoreactivity to these proteins, with the greatest
expression in neurones, which corresponds with that found in humans. It is possible
that sequence differences in the PAPP molecule cause differential processing,
making rodents less prone to PAP protein deposits (Pluta et al. 1994).
The toxicity of the P-amyloid molecule may reside within an ability to form
insoluble sheet-like structures in vitro and in vivo since injection of aggregated P-
amyloid peptides into rat brain has been found to result in some AD-like pathology
(Pike et al. 1991; Kowall et al. 1992). The issue of what causes P-amyloid induced
cell death and by what pathway, is poorly understood and controversial (Cotman &
Anderson 1995). Evidence for an apoptotic rather than necrotic pathway for P-
amyloid-induced cell death has come from the finding that lactate dehydrogenase
(LDH) release, a marker of glutamate-induced necrosis (Koh & Choi, 1987), did not
correlate to P-amyloid-induced pathology, and p-amyloid-exposed neurones
exhibited small, condensed, irregular shaped bodies, a morphology in line with that
seen with apoptosis (Loo et al. 1993; Cotman & Anderson 1995). Furthermore, post
mortem examination of AD brain suggests evidence of apoptosis at the scanning and
transmission electron microscope level revealing ultrastructural indicators of
apoptosis (Loo et al. 1993; Watt et al. 1994). Neurones exhibit DNA laddering after
150
a 24 hour exposure to (3-amyloid peptdies (Cotman & Anderson, 1995), although
reports of (3-amyloid-induced necrotic death are also in the literature (Behl et al.
1994). Cotman & Anderson (1995) suggest that some contradictory findings may be
consequences of different culture environments, and that secondary necrosis,
whereby cells which have proceeded through an apoptotic pathway lyse in a necrosis¬
like manner due to insufficient phagocytic removal of apoptotic bodies, may be
confusing findings in culture. Further evidence for P-amyloid-induced apoptosis, and
apoptosis in AD comes from use of histological 3' -OH end break labelling, and
Cotman & Anderson (1995) demonstrated this marker exists in post-mortem AD
brains.
The mechanism of P-amyloid-induced apoptosis has been addressed in a number
of studies. Oxidative damage has been suggested as a factor in AD as well as other
neurodegenerative disorders such as Parkinson's disease for which there is evidence
(Ames et al. 1993; Olanow, 1993). Furthermore a number of studies have linked
oxidative actions in mediating apoptosis (Hockenberry et al. 1993; Kane et al. 1993).
Furthermore, immunoreactivity for the antioxidants superoxide dismutase and
catalase are co-localised in AD plaques (Pappolla et al. 1992), and Cotman &
Anderson (1995) suggest that P-amyloid and oxidative injury may contribute to AD
cell loss.
Calcium has been implicated in pAP-mediated cell death. Orrenius et al. (1989)
and Mattson et al. (1992; 1993) have reported P-amyloids destabilise calcium
homeostasis in neurones. Calcium increases have been shown to occur in cells
stimulated with apoptosis-inducing agents (McConkey et al. 1989) Arispe et al.
(1993a; 1993b) have reported that P-amyloid forms calcium channels and multilevel
cation channels in bilayers presenting a possible pathway for p-amyloid to induce
apoptosis.
The physiological role of PAP proteins in the brain is unclear, although a
number of functions have been suggested including non-neuronal cell-proliferation
(Palacios et al. 1995), a role in blood coagulation, cell adhesion and the potentiation
of NGF effects (Smith-Swintosky et al. 1994). A role for secreted pAPPs has also
been proposed in consolidation or retrieval of memory (Huber et al. 1993). Evidence
is accumulating for a role for secreted PAPPs in the CNS response to injury
(Robinson et al. 1993; Tomimoto et al. 1994; Pluta et al. 1994; Stephenson et al.
1992). Nakamura et al. (1992) found PAPP deposits after excitotoxic lesions of the
rat hippocampus using ibotenic acid, while Wakita et al. (1992) showed
accumulation of PAPP in rodent models of cerebral ischaemia. Furthermore, Mattson
et al. (1993) showed protection of cultured hippocampal and cortical neurones with
PAPP against excitotoxic lesions.
4.1.2. 17mer in neuroprotection & behavioural studies
Secreted p-amyloid peptides can be both neurotoxic and neuroregenerative (Yankner
et al. 1990; Takadera et al. 1993). These multiple activities are dependent on the
form of P-amyloid that was used, with the neurotoxic portion being residues 1-42
containing the hydrophobic rich amino acid end, while the non-toxic region was
contained within residues 1-28 (Pike et al. 1991; 1993).
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A number of studies have demonstrated that a specific 17mer sequence of
secreted pAPPs has trophic and neuroprotective actions in vitro (Mattson et al. 1993;
Jin et al. 1994; Yamamoto et al. 1994), and neuroprotective actions in vivo (Bowes et
al. 1994; Smith-Swintosky et al. 1994). The 17 amino acid sequence corresponds to
Ala-319 to Met-335 of the APP-695 secreted form of PAPP (Jin et al. 1994). This
peptide contains a central molecule containing the RERMS sequence which
Yamamoto et al. (1994) identified as crucial to the peptide's trophic
properties.essential to these properties (Yamamoto et al. 1994). The primary amino
acid sequence of this 17mer peptide is shown in Figure 19.
Two functional profiles of this PAPP fragment have been demonstrated, that
being a neuroprotective ability and a capacity to facilitate functional recovery as a
consequence of promoting neurite extension. Jin et al. (1994) and Yamamoto et al.
(1994) demonstrated that this 17mer sequence stimulated neurite extension of CNS
neurones in culture, and enhanced neuronal survival in culture. This was mediated
via binding to a specifc cell surface receptor, although it is unclear as to whether
neurotrophic actions are mediated via a different receptor to that mediating the
survival properties (Yamamoto et al. 1994). In vivo studies in rats demonstrated that
intracerebroventricular (i.e.v.) infusion of the 17mer fragment protected hippocampal
neurones from ischaemic injury in a four-vessel occlusion model of global ischaemia
(Smith-Swintosky et al. (1994) and reduced the neurologic consequences of spinal
cord ischaemia (Bowes et al. 1994). This peptide has not yet been investigated in
models of focal cerebral ischaemia. Consequently, two questions have been
addressed using the ET-1 induced MCA occlusion model. First, whether the 17mer
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peptide is neuroprotective, and second, whether the 17mer peptide may improve
recovery as assessed by behavioural outcome, after ET-1-induced MCA occlusion.
These questions will consequently address the two properties identified in previous
studies, that being a neuroprotective capacity and an ability to mediate functional
improvement by promotion of neurite outgrowth.
4.1.3. Experiments (1): Neuroprotection model
The neuroprotection model was a modification of the ET-1-induced MCA occlusion
model described in section 2.2.1. The 17mer P-amyloid sequence or a scrambled
version of the same amino acids was delivered intracerebrally via mini-pumps for
three days prior to ET-1 induced MCA occlusion, with the volume of ischaemic brain
damage determined three days later.
4.1.4. Experiments (2): Behavioural model
The ET-1 model has been characterised in terms of the behavioural consequences
subsequent to MCA occlusion (Marston et al. 1995). In these studies, a skilled paw
reaching task, adapted from that described by Montoya et al. (1991), was employed
to assess behavioural recovery following MCA occlusion. The staircase task is a
model of learned paw use, whereby food pellets are retrieved by separate paws across
the staircase divide. Following ET-l-induced MCA occlusion, there is a bi-lateral
impairment in successful pellet retrieval (Marston et al. 1995). This was interpreted
as consequent not only on impaired tactile, tacto-motor control and/or control of fine
motor movements, but also impairment in some aspects of interhemispheric
communication. Importantly there is a small but significant recovery in pellet
retrieval in the days following MCA occlusion. This staircase task was employed in
the assessment of behavioural recovery in these studies. The experimental approach
was to train the animals on the staircase task until reaching asymtote and then induce
MCA occlusion and begin peptide infusion during a single surgical procedure.
Beginning infusion immediately after MCA occlusion would circumvent any
potentially confusing effects of neuroprotection, and allow only effects of the 17mer
peptide on behaviour to be addressed. Then following an initial recovery period,
behavioural testing was recomenced for 9 days, and then animals were killed and the
volume of ischaemic brain damage quantified.
4.2. Methods
4.2.1. Mini-pumps
Osmotic mini-pumps were employed in both neuroprotection and behavioural studies
in order to deliver the peptide intracerebroventricularly. This circumvents the need to
penetrate the BBB and proteolysis consequent on systemic administration of
peptides. The pumps (Alzet, model 2002) delivered at a rate of 0.5pl/hr and could
run for 14 days. In all studies using the mini pumps, 17mer or scrambled were
delivered at a rate of 0.25nmols/hr (0.51pg/hr). This infusion quantity was
determined based on previous studies (Roch et al. 1994), and a personnel
communication from T. Saito. The pumps consist of an L-shaped steel cannula
infusion "arm" connected by a short polyethylene catheter (~10cm long) to the pump
which contains enough solution to work for 14 days.
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4.2.2. Surgery & protocol for neuroprotection study
This study employed SD rats (280-320g) randomly assigned to either the 17mer or
scrambled treatment groups. The protocol involved the i.c.v. infusion of
17mer/scrambled sequence for three days prior to MCA occlusion. On the day of
mini-pump insertion, animals were anaesthetised as in section 2.2.1., and placed in a
stereotaxic frame. Following a midline incision, bregma was located and a
craniotomy performed (coordinates from bregma: AP=-1.5mm, L=-2mm). A second
craniotomy was drilled a short distance away and a surgical screw affixed to the
skull. A minipump, loaded with 17mer or scrambled sequence, was then
stereotaxically lowered 3mm below skull and cemented in place. A "pocket" was
then opened to accommodate the pump between the scapulae by freeing the skin
from the connective tissue behind the shoulders. The scalp wound was then sutured
and the animal allowed to recover in an incubator.
Three days later, animals were anaesthetised as in section 2.2.1., and placed in a
stereotaxic frame. Following a midline incision, bregma was located and a
craniotomy performed (co-ordinates from bregma AP=0.9mm, L=-5.2mm). A 28
gauge cannula was lowered 8.7mm below skull and ET-1 (150pmols in 3pl) injected
(lpl/90 sec). The cannula was left in situ for five minutes and then slowly
withdrawn. The scalp wound was sutured and the animal placed in an incubator to
maintain normothermia until the animal had recovered from anesthesia. Three days
later, animals were transcardially perfused and the brain removed and stored until
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histological processing and volume of ischaemic damage calculation as in section
2.2.2.
4.2.3. Surgery & protocol for behavioural study
Male Lister hooded rats, maintained in the housing conditions previously outlined in
section 2.2.1. were maintained on a food restricted diet that maintained animals at
85-90% of their free feeding weight such that animals gained 3-5g per week. The
staircase apparatus has been described in detail elsewhere (Marston et al. 1995).
Briefly, a perspex enclosure (300 x 67 x 95mm, long x wide x high) contained a
stainless steel central platform with a staircase either side containing six wells. The
apparatus is constructed such that only the ipsilateral paw could reach the pellet and
the animal is unable to visually identify pellets. Each well was baited with two
pellets (45mg, Noyes formula P). The training regime consisted of two sessions, 4
hours apart during which time the animal was given 5 minutes to recover pellets.
Performance was scored as the number of pellets recovered. Training was continued
until animals had reached asymtote (9-10 pellets on both sides) which took 9-10
days. Animals were then randomly assigned to ACSF, scrambled or 17 mer
sequence, and underwent mini-pump insertion and ET-1-induced MCA occlusion.
ET-l-induced MCA occlusion was performed as in section 2.2.1. and a minipump
was inserted as described above in section 4.2.2. Animals were perfusion fixed and
brains processed for quantitative histopathology as previously described in section
2.2.2.
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Paw-reach training was perfromed with the assisstance of Miss T. Higgins of the
Fujisawa Institute ofNeuroscience, University of Edinburgh.
4.2.4. Analysis of data and statistics
Data are expressed as mean ± s.e.mean. The volume of hemispheric, cortical and
striatal ischaemic brain damage was calculated for each treatment, and analysed by
Student's T test.
For behavioural data and statistics, paw reach data from left (contralateral) and
right (ipsilateral) paws were calated from both a.m. and p.m. testing sessions, after a
three day recovery period following MCA occlusion. Data were analysed separately
for ipsilateral and contralateral paws, and a.m. and p.m. data combined for 1 day pre-
operatively, and in three day blocks (i.e. post operative testing day 1-3, 4-6 and 7-9),
postoperatively. The volume of ischaemic damage from animals in the behavioural
study as well as the behavioural performance, were analysed by one-way ANOVA.
4.2.5. Drugs/ACSF
ET-1 was dissolved in saline. 17mer and the scrambled sequence of the same peptide
were a gift from Tsunao Saitoh, University of California, San Diego. Stock
concentration of 17mer and scrambled were made up at 0.5mM, and stored frozen at





In rats treated with the scrambled sequence of the 17mer peptide (n=9) the volume of
hemispheric ischaemic brain damage following ET-1-induced MCA occlusion was
231±25mm3. By contrast, in rats treated with the 17mer sequence (n=7), the volume
of hemispheric damage was significantly reduced by 48% (P=<0.05). The volume of
cortical ischaemic damage in scrambled treated rats was 191±24mm3, whilst it was
significantly reduced in 17mer treated rats to 100±22mm3 (P=<0.05). The striatal
infarct volume was also significantly smaller in the 17mer group (18±5mm3)
compared to scrambled treatment (40±lmm3) which was a 55% reduction in
ischaemic brain damage (P=0.001) (Figure 20).
4.3.2. Behavioural results
All animals used in these studies reached paw-reach asymtote for at least 1 day
before MCA occlusion. Statistical analysis determined that the volume of cortical
and striatal ischaemic damage in ACSF, 17mer and scrambled groups was not
significantly different between groups when 17mer infusion was initiated after
induction of ET-1-induced MCA occlusion (figure 21).
Statistical analysis of paw-reach data in the behavioural model employed in
these studies determined that pre-MCA occlusion paw reach data were not
significantly different between right and left paws for all three treatment groups
(Figure 22). Following MCA occlusion, retrieval significantly fell bilaterally in all
three groups. This reduction was profound on the contralateral side, but was






























































Figure 20. Neuroprotective efficacy of the 17mer peptide, when infused
intracerebroventricularly for 3 days prior to ET-1 -induced MCA occlusion 17mer
(n=7) reduced the volume ofhemispheric (top), cortical (middle) and striatal (bot¬
tom) ischaemic damage compared to treatment with a scrambled sequence (n=9)
of the same peptide. Data are presented as mean ± s.e.mean. */>=<0.05.
***P=<0.001.
Cortical and striatal ischaemic damage for treatment












































Figure 21. Volume of ischaemic damage following ET-1-induced MCA occlusion
for cortex (top) and striatum (bottom) for animals treated with ACSF (n=7), scram¬
bled (n=9) or 17mer (n=9) in behavioural study. Data are presented as mean ±
s.e.mean. No significant differences were found between treatments in either cor¬
tex or striatum.
Paw-reach paradigm assessment of the effects of 17mer peptide









































Figure 22. Effects ofACSF (n=7), scrambled (n=9) and 17mer (n=9) on behav¬
ioural outcome and recovery for left (top) & right (bottom) paws following ET-1-
induced MCA occlusion as assessed in a paw-reach paradigm. Data are expressed
as mean ± s.e.mean. No significant differences were found for any treatment for
either the ipsilateral or contralateral side.
significant on the ipsilateral side also. Some recovery of function was noted between
all three groups was found, but recovery was not significantly different between
17mer, scrambled and ACSF groups at any day post MCA occlusion.
4.4. Discussion
4.4.1. Neuroprotection results
Sequences of the secreted form of the PAPP have previously shown to confer
neuroprotection to neurones and promote neuronal sprouting and regrowth
(Yamamoto et al. 1994; Mattson et al. 1993; Smith-Swintosky et al. 1994). Other
growth factors have also been shown to possess neuroprotective capacity in models
of focal cerebral ischaemia (Yamada et al. 1991) and in in vitro models of ischaemic
damage (Finkelstein et al. 1993; Mattson & Cheng, 1993; Maiese & Boccone, 1995).
The model used in these studies, whereby a peptide was infused
intracerebroventricularly prior to MCA occlusion, has also been employed to
determine the neuroprotective capacity of IL-1 receptor antagonist (Rothwell et al.
1995).
The ET-1 model of MCA occlusion has previously shown to be a useful tool in
the evaluation of putative neuroprotectants (Sharkey & Butcher, 1994), whilst the
mini-pumps employed have been previously validated in behavioural work
(Bannerman et al. 1995). The data from these studies confirm and extend previous
studies, demonstrating that intracerbroventricular infusion of 17mer for three days
prior to ET-1-induced MCA occlusion, profoundly reduced the volume of
hemispheric, cortical and striatal ischaemic brain damage compared to control rats
that were infused with a scrambled sequence of the same peptide. By contrast, when
17mer peptide infusion was begun post MCA occlusion, the peptide was not
neuroprotective.
The degree and extent of neuroprotection in the pre-treatment study exerted by
the 17mer sequence was unexpected since brain penetration following
intracerebroventricular administration of a peptide is often limited. Furthermore
neuroprotection was observed in the striatum, an end-vascular territory structure,
which is seldom salvaged by neuroprotectants following MCA occlusion (Sharkey &
Butcher, 1994).
The mechanism by which secreted forms of PAPPs may exert neuroprotection is
unclear although indirect evidence might suggest an involvement in cellular repair
(Pluta et al. 1994). In vitro studies suggest that PAPPs may regulate intracellular
Ca2+, which might offer insight into the mechanism by which these proteins confer
neuroprotection given the role of Ca2+ in ischaemic cell death. In the study by
Mattson et al. (1993), they found secreted forms of PAPPs reduced intracellular Ca2+,
stabilised intracellular Ca2+, and increased neuronal survival in glucose-deprived
neuronal cultures. Both APP695 and APP751 peptides caused a rapid and prolonged
reduction in [Ca2+]i that accompanied the response to hypoglycaemia. Furthermore,
PAPPs protected neurons from glutamate neurotoxicity. Mattson et al. (1993),
proposed that the secreted forms of PAPP, APP695 and APP751, may have
neuromodulatory roles, and their loss in Alzheimer's disease may explain neuronal
death. A vascular site of action may explain better the neuroprotection of neocortex
by the 17mer, and may represent another mechanism of the 17mer peptide. Further
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studies would be required to establish whether 17mer mediated any direct effects on
the cerebrovasculature.
It is conceivable that the degree on neuroprotection is artifactually large as a
consequence of a toxic effect of the scrambled sequence. However, such a neurotoxic
effect has not been reported previously in studies with the scrambled sequence.
Furthermore, the volume of ischaemic damage in the scrambled group is not greatly
outwith that reported previously in studies with this model (Sharkey & Butcher,
1995), and the volume of ischaemic damage found between 17mer and scrambled
sequence in the behavioural study was not significantly different, which would
suggest that the scrambled peptide is not exerting a neurotoxic effect. However, it is
possible that the scrambled sequence lowers the capacity of neurones to resist focal
cerebral ischaemic insults, which would not be detected in the protocol used in the
behavioural study. Further studies would be necessary to confirm whether such an
action contributed to the large neuroprotective profile of 17mer in these studies.
4.4.2. Behavioural results
In assessing the 17mer for capacity to facilitate behavioural recovery, we infused the
17mer sequence, a scrambled sequence or ACSF following MCA occlusion and then
tested the behavioural recovery. An ACSF group was included to determine if either
protein alone had a specific effect on behaviour. The intraventricular infusion was
begun at the same time as the MCA occlusion was performed to avoid any potential
complicating factors that might arise from possible neuroprotective capacity of the
17mer peptide. Consequently, the initial behavioural consequences of MCA
occlusion would be independent of the volume of ischaemic brain damage resulting
from ET-1-induced MCA occlusion. Indeed, quantitative analysis of ischaemic brain
damage determined that the volume following ET-1-induced MCA occlusion was not
significantly different between either 17mer, scrambled or ACSF treated animals in
either the cortex or the striatum. That the volume of damage was not different in both
the cortex and the striatum was important given the role of both these brain regions
in behaviour in this model (Marston et al. 1995).
The behavioural model used to assess behavioural impairment of skilled paw
reaching in these studies has previously evaluated to assess performance in this
stroke model (Marston et al. 1995). In these studies, animals from all three groups
showed the same extent of impairment in skilled paw-reaching following MCA
occlusion.
The similar volume of ischemic damage found between treatment groups was
reflected in identical reductions in paw reach performance on postoperative block 1.
The impairment was bilateral, as seen by the reduction in right paw performance as
well as the contralateral (left) paw. This corresponds to previous findings using this
behavioural assessment, whereby the contralateral limb (receiving cortical and
striatal input from lesioned side), has the greatest degree of impairment. However,
the ipsilateral performance was also impaired, although to a lesser extent.
Behavioural impairment showed some recovery with time over the 9 testing days
following MCA occlusion. The rate of functional recovery was not different in either
the 17mer, scrambled or ACSF groups. This suggests that 17mer does not promote
functional recovery, as assessed in this behavioural model, following ET-1-induced
MCA occlusion. Whether a more sensitive test of behavioural function may have
detected an effect of 17mer sequence remains to be determined. Many tests have
been employed in the determination of behavioural impairment following MCA
occlusion in the rat such as memory and learning tasks. The test used in these studies
assess the fine motor control of animals, incorporating both neocortical and striatal
components. It is conceivable that behavioural assessment of another parameter
might have determined an effect of 17mer.
A different strain of rat was employed in the behavioural model (Lister-hooded)
to that used in the neuroprotection study (Sprague-Dawley). The Lister-hooded strain
have been demonstrated to possess greater sensory capabilities than the albino SD
strain, which are almost blind and do not possess acute hearing (personnel
communication - Dr H. M. Marston). The possibility that SD rats might have
responded differently to the LH rats in behavioural outcome following 17mer
therefore exists.
4.4.3. Conclusions
These studies investigated the effects of a 17mer sequence of the secreted form of
pAPP in the ET-1 model. The present data demonstrate for the first time that this
peptide is neuroprotective in a model of focal cerebral ischaemia. However, using a
behavioural model to assess skilled motor control in the rat, the 17mer sequence was





CHAPTER 5. DEVELOPMENT OF A NOVEL REPERFUSION
MODEL
5.1. Introduction
5.1.1. Current reperfusion models
The study of reperfusion in experimental ischaemia has become a central topic in
stroke. Reperfusion of occluded vessels occurs in humans following a stroke
(Overgaard, 1994), and consequently study of the biochemistry, pharmacology and
pathology associated with reperfusion injury is essential in developing our complete
understanding of the possible pathophysiological outcomes following stroke
(Wardlow et al. 1993; Clark et al. 1994). With the advent of tissue plasminogen
activator (t-PA) and the prospect of future therapies designed as "clot-busters", there
exists a need for more accurate experimental modelling of arterial occlusion with
subsequent reperfusion. Current models include the intraluminal filament occlusion
(Koizumi et al. 1986) snare ligature occlusion via the transorbital approach (Shigeno
et al. 1985), and transient global ischaemia (Pulsinelli & Brierley, 1979). Whilst
return of CBF to the previously ischaemic territory effectively provides tissue with
the vital metabolic substrates it requires, paradoxically, re-introduction of blood flow
to an ischaemic area has been recognised as being potentially detrimental (McAuley,
1995). Thus reperfusion following cerebral ischaemia may provide restoration of
substrate, whilst providing a source of tissue damage exacerbation (Hallenbeck &
Dutka, 1990).
5.1.2. Biochemical changes related to reperfusion
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Studies in models of global and focal cerebral ischaemia have addressed the
consequences of reperfusion on the extent of depletion of energy-related metabolites,
and the extent to which they return to preischaemic values during the recirculation
period. PCr, the substrate which is initially reduced at the expense of maintaining
intracellular ATP levels during ischaemia, recovers to preischaemic values, and may
overshoot, while the ATP-adenylate energy change (relationship between ATP, ADP
and AMP) also fully recovers, requiring up to several hours of reperfusion for full
recovery (Lust et al. 1985; Nowak et al. 1985; Onodera et al. 1986a; Crumnne &
LaManna 1991; Pulsineli & Duffy 1983; Sims & Zaidan 1995). This time delay is
thought to be a consequence of complete adenine nucleotide depletion due to
breakdown, and is related to the duration of ischaemia (Lust et al. 1985; Onodera et
al. 1986a; Sims & Zaidan 1995).
Restoration of ATP levels intracellularly is essential to the cell's ability to
survive, restoring ionic gradients intracellularly and across the plasma membrane.
Restoration of cellular ATP is dependent on the duration of the ischaemic insult
(Selam et al. 1990). However, within limits, recovery may be essentially complete
within the first 20 minutes of recirculation, although this may be duration dependent
(Hasen 1985; Silver & Ericinska 1992). In the study by Sun et al. (1995), ATP levels
decreased to 26% of control following MCA occlusion with bilateral common
carotid occlusion, with an increase in AMP levels. Levels recovered to 80% of
control following a 60 minute MCA occlusion with 4 hours of reperfusion, whilst
ADP and AMP levels fully recovered within the 4 hour recirculation period.
Furthermore, restoration of most other metabolites are also generally reversed
quickly (Sims & Zaidan 1995), including extracellular neurotransmitter
concentrations (Globus et al. 1991; Baker et al. 1991). An important point made by
Sims & Zaidan (1995) is that whilst energy metabolites may recover on recirculation
this does not mean metabolism has returned to a preischaemic state. Almeida et al.
(1995) examined the activity of the mitochondrial respiratory chain from gerbil brain
subjected to ischaemia-reperfusion, using the method of surgical occlusion of the
common carotid arteries. Reperfusion was varied between treatment groups while the
ischaemic episode was of 30 minute duration. Measurement of respiratory chain
components showed complex II-III activity was restored following 5 minutes of
reperfusion, activity in complexes I & V required 30 minutes, while complex IV
activity was relatively unaffected by ischaemia-reperfusion. Other studies have also
shown mitochondrial function to be depressed following ischaemia, while
reperfusion reverses those deficits (Rehncrona et al. 1979; Hillered et al. 1984; Sims
& Pulsinelli, 1987).
Further to the issue of delayed full recovery, studies using the deoxyglucose
method for assessing glucose utilisation suggest glucose oxidation is depressed
following reperfusion and may remain depressed for several days, despite recovery of
ATP levels (Pulsinelli et al. 1982; Choki et al. 1983; Kozuka et al. 1989; Jorgensen
et al. 1990). By contrast, during early reperfusion, glucose utilisation may be
exaggerated (Diemer & Siemkowicz 1980; Choki et al. 1983), although since
calculations with this technique are based on measurements in normal brain,
definitive interpretations are precluded (Sims & Zaidan 1995).
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Protein synthesis is particularly sensitive not only to ischaemia but to
reperfusion, with reductions in synthesis developing following initial reperfusion
(Nowak et al. 1985; Widmann et al. 1991). Restoration of function may not be
complete for hours or even days after recirculation (Sims & Zaidan, 1995). The
cerebrovasculature may also be affected directly by the effects of reperfusion. Cipolla
et al. (1997) determined that reperfusion was detrimental to MCA myogenic
reactivity, which seems to be dependent on the duration of the reperfusion.
As was mentioned in the introduction to this section, re-introduction of blood
flow may bring with it factors detrimental to tissue survival. The involvement of free
radicals and oxidative damage in reperfusion has been postulated as a cause of injury
and dysfuntion, although the difficulty in measuring such short lived molecules in
vivo has meant limited understanding of the mechanism of their production
(Traystman et al. 1991). Oxygen radicals can be generated following ischaemia-
reperfusion from sources such as activated leukocytes & endothelial cells (del Zoppo,
1994). However, the most likely source is from the metabolism of free fatty acids and
adenine nucleotides, which accumulate during ischaemia (Traystman et al. 1991).
Targets of free radicals include cell membrane lipid, NADPH, nucleic acids and
proteins (Freeman & Chapo, 1982, del Zoppo, 1994). A number of free radical
scavengers are endogenous to the brain, which may limit the extent of damage, and
include glutathione peroxidase and superoxide dismutase (del Zoppo, 1994). Studies
have demonstrated the presence of these highly reactive species, including hydrogen
peroxide (Simonson et al. 1992) and the products of superoxide and hydroxyl radical
interactions (Cao et al. 1988; Nelson et al. 1992; Zini et al. 1992), as well as lipid
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peroxidation (Watson et al. 1984), in a number of stroke models. These studies
indicate that an oxidative burst occurs as a transient peak of free radical production
during the first minutes of recirculation following transient cerebral ischaemia (Sims
& Zaidan 1995). However, as yet there is insufficient research to determine the
differences between global and focal ischaemia, as well as species to species
variation, which is another possibility. Indeed, while Oliver et al. (1990) determined
a protein oxidative loss of glutamate synthetase in gerbil brain following
recirculation, Pahlmark et al. (1993) did not note a comparable change in the rat, and
it is likely the largest contribution of radicals is seen in global rather than focal
models of cerebral ischaemia.
The efficacy of radical scavenging agents has helped to establish a significant
contribution of oxy-radicals to reperfusion injury. These include the "lazaroids"
(Braughler et al. 1989), superoxide dismutase (Kitagawa et al. 1990; Uyama et al.
1992), oxypurinol, a xanthine oxidase inhibitor (Phillis, 1989b) and a lipid
peroxidation inhibitor (Hara & Kogure 1990) and many other compounds of this
class have been studied and found to be effective in reducing ischaemic brain
damage. These studies used global ischaemia models where ischaemia is of short
(usually 5 minutes) duration. Whether these compounds are equally effective in
longer duration episodes or focal ischaemia is unclear. Indeed, Yue et al. (1992)
demonstrated reduced efficacy of protection when duration of ischaemia was
increased to 10 minutes in their model. While Martz et al. (1989) demonstrated a
neuroprotective effect of dimethylthiourea (hydroxyl radical scavenger) and
allopurinol (xanthine oxidase inhibitor) in a rat model of MCA occlusion, others
have not found protection. Kiyota et al. (1993) found that when changes in body
temperature were compensated for in control groups (not done by Martz et al. 1989)
there was no neuroprotective effect of dimethylthiourea in a rat model of MCA
occlusion.
Another postulated mediator of reperfusion damage is calcium. It has been
suggested that reintroduction of blood flow may kill surviving neurones with a
previously intact calcium homeostasis, due to re-exposure to calcium levels
(Hallenbeck & Dutka, 1990).
The temporal profile of morphological and inflammatory changes following
temporary MCA occlusion with reperfusion (TMCAO) has also been addressed.
Reperfusion is associated with inflammatory cell infiltration (del Zoppo, 1994), and
this inflammatory cell infiltrate differs from models of permanent MCA occlusion
(PMCAO) (Clark et al. 1994). Clark et al. (1994) found that while there is an
inflammatory cell response following PMCA occlusion, it is more rapid and
extensive following TMCAO. Clark et al. (1994), found a much heavier macrophage
and neutrophil infiltrate following TMCAO as well as a pronounced fibroblast and
astrocyte infiltrate, absent in the PMCAO model. Whilst re-introduction of CBF in
TMCAO models provides an infiltration route, the route of inflammatory cell
infiltration in models of PMCAO is currently unclear. Kamijyo & Garcia (1975)
attribute the route of infiltration in models of PMCAO as due to the retrograde flow
between major arteries. The resolution of the infarct (5-30 days) in terms of
macrophages on the matrix, neovascularisation and gliosis, followed by removal of
necrotic tissue and glial scar formation progresses at a similar rate in both models
(Clark et al. 1994). However, they do report that resolution was more complete at the
15 day time point in the TMCAO model. Thus we can see that while progression of
the ischaemic lesion follows some temporal similarities between models, important
differences exist in the inflammatory response in both onset and extent.
5.1.3. Endothelium, oedema and structural consequences
The endothelial lining of cerebral blood vessels has a profound role in brain function
under homeostatic and pathophysiological situations. Cerebral ischaemia may trigger
endothelial reorganisation with cells becoming active in inflammatory processes that
may lead to the recruitment of inflammatory cells into the brain parenchyma
(Akopov et al. 1996). Such blood cell activation may lead to microvascular plugging,
tissue oedema and cytotoxic effects which contributes to the development of an
ischaemic lesion (Akopov et al. 1996). Furthermore, inflammatory activation may
reciprocate, and lead to microvascular reorganisation which has implications for
ischaemically injured tissue (del Zoppo, 1994).
The endothelial lining of cerebral blood vessels is a cell monolayer that
expresses many receptors for interactions with circulating blood elements and the
continuous sensing changes to the mechanical and chemical milieu of the
vasculature, blood and underlying parenchyma (Akopov et al. 1996). There is now
extensive evidence that following an ischaemic insult, the endothelium mediates a
myriad of responses that alter the usually immunologically priveledged brain
parenchyma. Three main factors determine the role of blood-parenchymal signalling
carried out by the endothelium. These are the formation of receptors for circulating
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blood borne elements, the synthesis and release of chemical mediators and the
conversion of circulating signal molecules (Akopov et al. 1996). These functions
shall be discussed in detail in the subsequent section addressing the role of the
immune system in stroke. However, key changes to the endothelium and
microvascular environment occur subsequent to ischaemia, which may be
detrimental to both brain parenchyma and the endothelium itself (del Zoppo, 1994).
Of these perhaps the most important is the development of the no-reflow phenomena
identified by Ames et al. (1968), in which re-introduction of blood may be impeded
by changes within the microvascular environment following ischaemia. This may be
caused by mechanical compression of the lumen by tissue oedema, endothelial cell
damage, swelling of astrocyte foot-processes, and the attachment of circulating blood
elements to the endothelium (del Zoppo, 1994; Garcia et al. 1994a; 1994b).
Microvascular patency is impeded following ischaemia by the accumulation of
leukocytes such as polymorphonuclear leukocytes (PMNLs), which are by far the
most abundent leukocytes (del Zoppo et al. 1991; Garcia et al. 1994b).
The role of inflammatory components is not limited to simple physical
impedence that limits blood flow return, but evidence has accumulated to suggest
that recruitment of inflammatory mediators contribute directly to ischaemic brain
damage. The mechanism by which this occurs will be addressed in the subsequent
section.
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5.1.3. Inflammation and immune responses
The immune system and inflammatory response have been identified as of key
importance as mediators of post-ischaemic pathophysiological changes. The
inflammatory response comprises cellular elements, such as the neutrophils &
lymphocytes, and a chemical components which includes the cytokines. Interactions
between inflammatory cells and chemical signal molecules direct and control
inflammatory responses following cerebral ischaemia. Cytokines are low molecular
weight glycoproteins, that are released from one cell to be active either on
themselves (autocrine) or on other cells (paracrine). They mediate communication
between both the immune system cells and noninflammatory cells. Some 40 or more
cytokines have been discovered (Bennett & Beeson 1953; Atkins & Wood 1955;
Aarden, 1979; Henderson & Poole 1994). The family can be broadly divided into the
interleukins (1-12), cytotoxic factors (tumour necrosis factor), interferons (a, P and
y), colony stimulating factors (CSFs), intercrines/chemokines and the growth factors.
All cytokines are polypeptides which exert diverse actions on a multitude of cells,
and function as important mediators and regulators of inflammation and cell growth
& differentiation (Rothwell & Strijbos, 1995). The cytokines exert their effects via
cell surface receptors, and binding is of very high affinity, responding in the case of
IL-1 to femtomolar concentrations, while expression of receptor numbers may be
very low (Rossof et al. 1988; Henderson & Poole, 1994).
Under homeostatic conditions circuiting leukocytes and inflammatory mediators are
largely prevented from entry to the brain by the BBB. Thus in order to enter the
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ischaemic territory, leukocytes must move out of the blood stream and pass through
this wall in order to contact the brain parenchyma (Sharkey et al. 1996).
Membrane glycoproteins, expressed on the surface of cells play a role in cell-cell
interactions and cell-matrix functions during haematological and inflammatory
responses during tissue injury (McEver, 1991). Cells involved in this process include
leukocytes, platelets and endothelial cells, which mediates the migration of cells into
injured or infected tissue (Springer 1990; Osborn, 1990). Such molecules enable
migration between endothelial cells, through the basement membrane, and in some
instances also activate leukocytes (Montefort & Holgate 1991). Expression is
transient, and co-ordinated to allow adherence at the appropriate place and time
(Kishimoto & Rothlein 1994).
Central to recruitment is the ability of circulating blood cells, which are in a
nonadhesive state, to become adhesive and subsequently attach to endothelial cells at
an appropriate place and time (Kishimoto & Rothlein, 1994). To date, three families
of adhesion molecules have emerged; the integrins, the intracellular adhesion
molecules and the selectins. The integrins represent a supergene family of receptor
complexes which are present on cell surfaces. They are comprised of a heterodimer
of an a and P subunit, and were among the first leukocyte adhesion molecules
discovered (Montefort & Holgate, 1991; Kishimoto & Rothlein, 1994). The
subfamilies are known after the common p, subunit, pi, P2 and P3, while the basic
structure of the a and P units of an integrin comprise an extracellular domain, a
membrane spanning region and a cytoplasmic domain (Montefort & Holgate, 1991).
The pi and P3 integrins are predominantly extracellular matrix receptors (Kishimoto
& Rothlein, 1994). The |31 integrins include the very late antigens, which may be
important in the migration of leukocytes through the endothelial cells and matrix of
the extracellular milieu (Montefort & Holgate, 1991). The [13 integrins include the
vitronectin receptor and the platelet protein gpIIb/IIIa, a deficiency in the latter of
which causes Glanzmann's thrombasthenia, a disease characterised by haemophilia
due to failure of platelet-to-platelet aggregation (Ruoslanti & Pierschbader, 1987;
Montefort & Holgate, 1991).
The integrin family most relevant to immunological disease are the [32 (CD 18)
integrins, also known as the leukocyte adhesion protein subfamily (LEUCAMs)
(Montefort & Holgate 1991; Kishimoto & Rothlein 1994). The P2 integrins comprise
three glycoproteins; lymphocyte-function-associated antigen (LFA-1), Mac-1 and
pi50.95 (Montefort & Holgate, 1991; Chopp et al. 1994). As with the other members
of the integrin family, the p2 integrins, while sharing a common P subunit (CD 18)
have different a subunits (CD11). LFA-1 is composed of CD 18 + CD1 la, Mac-1 of
CD18 + CDllb and pi50.95 of CD 18 + CD1 lc (Montefort & Holgate, 1991; Chopp
et al. 1994; Zhang et al. 1995a; 1995b). Each subunit in the P2 integrins has differing
molecular weights, with the common CD 18 being a 95kDa molecule, while CD1 la is
180 kDa, CDllb 165 kDa, and CDllc being 150 kDa. The P2 subfamily are
involved in leukocyte-to-leukocyte, leukocyte-to-endothelium and leukocyte-to
epithelium interactions (Montefort & Holgate, 1991). Expression levels of the p2
integrins is cell dependent, restricted to leukocytes, and more specifically Mac-1 and
pi50.95 to macrophages and granulocytes while LFA-1 is expressed on all
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leukocytes including T and B lymphocytes, macrophages and granulocytes
(Kurzinger et al. 1981; Arnaout 1990; Kishimoto & Rothlein, 1994).
The CD 18 integrins mediate adhesion through a number of ligands, with LFA-1
binding intercellular adhesion molecules, which are the second family of adhesion
molecules (Rothlein et al. 1986; Staunton et al. 1989; Montefort & Holgate, 1991;
deFougerolles & Springer, 1992; Kishimoto & Rothlein, 1994). There are three
members of the intercellular adhesion molecule (ICAM) family (ICAM-1,2 & 3)
which are members of the immunoglobulin supergene family, and all are related to
other Ig-like adhesion molecules such as VCAM-1 and NCAM (Kishimoto &
Rothlein, 1994). All are ligands for LFA-1, but ICAM-1 will interact with Mac-1 and
CD43 (leukosialin). Regulation and distribution of the three ICAMs are distinct and
expression is differential between ICAMs (Kishimoto & Rothlein, 1994). Whilst
little is known of the functional roles of ICAM-2 & ICAM-3, ICAM-1 has been
implicated in neutrophil recruitment, leukocyte diapedesis, cell mediated cytolysis,
antigen presentation, lymphocyte homotypic aggregation, leukocyte-endothelial cell
interactions and transendothelial migration (Smith et al. 1988; 1989; Buston et al.
1989; Montefort & Holgate, 1991; Kishimoto & Rothlein, 1994).
The third family of adhesion molecules are the selectins. This family functions
to mediate interactions of leukocytes with the blood vessel wall (McEver, 1991). To
date, three selectins have been identified, named LAM-1 (leukocyte adhesion
molecule-1 or L-selectin), ELAM-1 (endothelial-leukocyte adhesion molecule-1 or
E-selectin) and GMP-140 ( granule-membrane protein 140 or P-selectin) (McEver
1991; Montefort & Holgate 1991; Kishimoto & Rothlein, 1994). The selectins all
share a common structure and are all heavily glycosylated (Bevilacqua et al. 1987;
Johnston et al. 1989), and have distinct cellular distributions (Kishimoto & Rothlein,
1994).
Whilst L-selectin is expressed on most leukocytes, E-selectin is confined in
expression to stimulated endothelium, and is not present on normal endothelium
(McEver, 1991; Kishimoto & Rothlein, 1994). Like E-selectin, P-selectin is
expressed on endothelial cells only following stimulation, as well as platelets
(McEver et al. 1989; 1991), and it is not a receptor for lymphocytes but for
neutrophils and monocytes (McEver et al. 1991). As yet the precise ligands for
selectins (the counter-receptors) are unidentified (McEver, 1991; Kishimoto &
Rothlein, 1994), although some of the ambiguity is being cleared up, and some
putative ligands (e.g. Lewis X as a P-selectin receptor) have been identified
(Kishimoto & Rothlein, 1994).
The process of leukocyte movement (and extravasation) is regulated by the
mechanisms of selective leukocyte-endothelial cell recognition (Butcher, 1991),
mediated by adhesion receptors. Butcher (1991) in his model of leukocyte-
endothelial cell adherence identifies three steps: reversible adhesion, leukocyte
activation and activation-dependent binding. Neutrophils begin to loosely interact
with the vessel walls, seen as a rolling action at the site affected. It seems that all
three selectins are involved in this process (Lawrence & Springer, 1991).
Furthermore, certain endothelial stimulators cause translocation to the surface of P-
selectin, which is contained in endothelial cell secretory organelles (Weibel-Palade
bodies), and once brought to the surface, P-selectin may act to bind surface adhesion
molecules on the neutrophil (Pober & Cotran, 1990a). What determines the
specificity of neutrophil or monocyte recruitment is unclear at present although the
activating signals which differ between these cell types may be the factor (Butcher,
1991).
Other factors which are involved in the evolution of the inflammatory response
in the rapid/acute stages include endothelial secretion of prostacyclin and EDRF as
well as endothelial synthesis of PAF (Pober & Cotran 1990b). These events are
mediated by factors such as histamine and thrombin. Such factors consequently
induce vasodilation and endothelial cell contraction, facilitating the necessary
reduction in shear forces. PAF may have a role in activation of bound neutrophils,
causing upregulation and activation (Tonnesen 1989; Pober & Cotran 1990b).
The transition from rolling to a resting state requires chemotactic factors
(Kishimoto & Rothlein, 1994). The most important change is the shedding of L-
selectin from the cell surface and expression of the integrin molecules (Kishimoto et
al. 1989; Butcher, 1991). The transition marks a change to activation-dependent
adhesion receptors and it is Mac-1 (CD18-CD1 lb), in the case of the neutrophil, that
mediates the next stage of leukocyte-endothelial cell interaction (Kishimoto &
Rothlein, 1994). While L-selectin was required to localise the neutrophil to the
endothelium, it is the CD 18 integrins that move the neutrophil across the
endothelium (Kishimoto & Rothlein, 1994). As yet the specific factor(s) responsible
for activation of rolling neutrophils in situ is not known, and Butcher (1991) suggests
that this may vary with the inflammatory state, but include IL-1, IL-8, C5a, fmet-leu-
phe and PAF (Pober & Cotran, 1990a; Kishimoto & Rothlein, 1994).
Following activation of neutrophils by the endothelial cell wall and the transition
to integrin-dependent adhesion, the third step in the interaction process is initiated,
that being stable binding and leukocyte aggregation within the microvascular lumen.
The process of aggregation of neutrophils may amplify recruitment and this occurs to
such an extent that vessels can become occluded following inflammation (del Zoppo
et al. 1991; Kishimoto & Rothlein, 1994). Like adhesion, aggregation is a Mac-1-
dependent event, although L-selectin may act as a counter receptor in aggregation
(Dana et al. 1985; Schwartz et al. 1985; Anderson et al. 1986; Simon et al. 1992).
Following firm adherence, neutrophils begin the process of transmigration, mediated
again by adhesion molecules and promoted and effected by the presence of
chemotactants such as cytokines. The neutrophils penetrate the vessel wall by
moving by diapedesis between the endothelial cells at the interendothelial cell
junction and then proceeding through the underlying basement membrane to the
tissue space behind, which does not require disruption of tight cell junctions (Huber
et al. 1991). Following penetration of the endothelial cell wall, they flatten out before
proceeding through the basement membrane (Kishimoto & Rothlein, 1994).
However, understanding of this phase, is incomplete (Akopov, 1996). Smith (1992)
reports that a chemotactic gradient is crucial for effective transmigration of
neutrophils through brain parenchyma, and studies have shown that cytokines such as
IL-1 may be involved in production of this chemotactic gradient (Kishimoto &
Rothlein, 1994). Many studies have shown transmigration to be a (12 integrin
dependent event (Smith et al. 1988; 1989b; 1991; Luscinskas et al. 1989; 1991;
Hakkert et al. 1991; Furie et al. 1992), whilst the selectins by contrast are found not
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to be functional in transendothelial migration of neutrophils (Smith et al. 1991;
Kishimoto et al. 1991).
The expression of the molecules and the temporal profile of leukocyte
recruitment during the inflammatory response to ischaemia has been addressed in a
number of studies (Garcia et al. 1994a; 1994b; Clark et al. 1994; Schroeter et al.
1994; Jander et al. 1995; Wang et al. 1994a; 1995b; 1995c; 1995d; Matsuo et al.
1994; Okada et al. 1994; Zhang et al. 1994a; 1995b; 1995c; Kim et al. 1995) and is
summarised in Figure 23.
Activated, invading leukocytes kill cells by a number of methods including
lysozyme, peroxidases, lactoferrin and a range of neurotoxins. The cytokine IL-ip is
of key importance as a mediator of brain damage and recent studies have found that
endogenous IL-1 can mediate ischaemic cell death (Yamasaki et al. (1995), brain
oedema (Gordan et al. 1990), and breakdown of the blood brain barrier (Quagliarello
et al. 1991). Studies have demonstrated that Abs and antagonists to IL-1 p are
neuroprotective in experimental stroke (Yamasaki et al. 1995; Yang et al. 1995).
The effectiveness of Ab directed against inflammatory cells has also been
addressed in a number of neuroprotection studies and is summarised in Table 6. As
can be seen, therapies tend to be effective in models of TMCAO, whilst inhibition of
the inflammatory process did not alter outcome in models of PMCAO. This
compliments the findings of the relative inflammatory components between the two
forms of ischaemia. Whilst such therapies have proven successful at limiting
ischaemic damage, the most commonly used model for studying stroke with
reperfusion is the filament occlusion technique. This has been critised for the pro-
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in the spinal cord
model
Clark et al. (1991)
Anti CD18 90 min TMCAO (clip) in
the cat
No effect of Mab Takeshima et al.
(1992)
Anti CD18 2 hrs TMCAO (filament)
in the Wistar rat
4 infarct -50% Zhang et al. (1995)
Anti LFA-1 1 hr TMCAO (filament)
in the Wistar rat
4 oedema & infarction Matsuo et al.
(1994)
Anti Mac-1 2 hrs TMCAO (filament)
in the Wistar rat
4 infarct by 28% Chopp et al. (1994)
Anti Mac-1 2 hrs TMCAO (filament)
in the Wistar rat
4 infarct by 37-44% Zhang et al. (1995)
Anti Mac-1 2 hrs TMCAO (filament)
+ PMCAO in the Wistar
rat
4 in damage in
TMCAO but not
PMCAO
Chopp et al. (1995)
Anti
ICAM-1
2 hr TMCAO (filament)
in the rat
4 infarct by 41% Zhang et al. (1994)
Anti
ICAM-1
2 hrs TMCAO (filament)
and PMCAO in the
Wistar rat
4 in TMCAO (44%)
but not PMCAO
model
Zhang et al. (1995)
Anti
ICAM-1








2 hrs TMCAO (filament)
in the Wistar rat
4 infarct (48%) Jiang et al. (1995)
Table 6. The effectiveness of antibody procedures targeted at components of the
immune system in models of cerebral ischaemia. Approaches were predominantly
effective in models of transient MCA occlusion that incorporate a reperfusion phase.
inflammatory nature of the procedure, whereby the endothelial lining of cerebral
blood vessels is extensively damaged, compromising the BBB integrity, and most
likely leading to an artifactually greater inflammatory component which may not be
present in the clinical setting. A second critism may be levelled at the time course of
the inflammatory process itself. As can be seen from the diagram illustrating the
temporal profile of the inflammatory response to cerebral ischaemia (Figure 23),
tissue penetration of leukocytes may not peak for up to 12 hours following
ischaemia. Since many studies suggest that 3-4 hours of arterial occlusion produces
maximal damage, it is questionable as to whether leukocyte recruitment at time
points delayed as long as 6-12 hours can significantly affect pathophysiological
outcome. Indeed, the release of cytotoxic substances by activated inflammatory cells
does not occur until a peak recruitment of inflammatioy cells up to 48 hours
following the inital insult (Giulian et al. 1993). This consequently brings into
question the mechanism by which Ab directed at leukocyte recruitment are effective.
It is likely that the mechanism may be due to blocking leukocyte accumulation alone,
alleviates microvascular plugging ensuring patency on reperfusion.
5.1.5. Experimental strategy
In these studies the specific ETA receptor antagonist FR139317, was employed to
interupt ET-1-induced MCA occlusion by competing for receptors, to introduce
reperfusion. A dual cannula system, whereby a 24 gauge outer cannula contained a
31 gauge needle within its lumen, was employed to deliver ET-1 and FR139317 or
vehicle intracerebrally to parenchyma underlying the MCA. The top of the cannulae
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were connected to polyethylene catheters to injection syringes. This dual cannula
system is illustrated in Figure 24. FR139317 (or vehicle) was injected 10 minutes
after ET-1 and histological assessment of ischaemic brain damage performed after
three day recovery. In other studies, LDF was employed to monitor the tissue
perfusion profile of the effects of FR139317 and SNP on ET-1 induced MCA
occlusion.
5.2. Methods
5.2.1. Surgery for FR139317 post treatment
Surgery was performed as previously described in section 2.2.1. Following a
craniotomy, a 24 gauge dual cannula was stereotaxically lowered into piriform cortex
approximately 0.5mm dorsal to the MCA (co-ordinates from bregma; AP=0.9mm;
L=-5.2mm, and -8.7mm below skull; tooth bar at -3.7mm). FR139317 (3 or 30nmols
in 3pl) or vehicle (3pl) was injected 10 minutes after ET-1 (100 pmols in 2pl). The
cannula was left in situ for 5 minutes, and then slowly withdrawn. The wound was
sutured with Ethicon 4/0 silk, and animals were returned to an incubator where
normothermia was maintained until the rat had fully recovered from anaesthesia.
Three days later animals were reanaesthetised, transcardially perfused with
paraformaldehyde in PBS as previously described in section 2.2.2. and the brains
processed for quantitative histopathology.
LDF was employed to record cortical CBF changes following ET-1 induced
MCA occlusion, with FR139317 injection 10 minutes afterwards. Sodium
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described for previous LDF experiments performed in section 3.2.3., with minor
modifications. Animals were implanted with an indwelling cannula for intracerebral
injection of ET-1 and other drugs. Following 5-10 day recovery, animals were
reanaesthetised and a polyethylene catheter inserted into the right femoral artery for
blood pressure monitoring and blood gas analysis. Animals were then ventilated
artificially (Flarvard Rodent ventilator) and placed in a stereotaxic frame. A
craniotomy was performed over the parietal cortex, and a LDF probe advanced to
touch the intact surface of the dura. The site was irrigated with ACSF and recordings
made for 15-30 minutes prior to ET-1 injection (100 pmols in 2pl). 10 minutes
following ET-1 injection, FR139317 (3 nmols in 3pi), SNP (3 nmols in 3pi) or
vehicle (3pi) was injected and recordings were made for a further 90 minutes. Blood
analysis was performed at regular intervals for determination of pH, pC02, p02 and
plasma glucose concentration.
At the end of the experiment, a zero flow reading was taken and the value
subtracted from LDF recordings. At the termination of the experiment, brains were
excised and inspected under an operating microscope for evidence of reperfusion
and/or ischaemia (tissue pallor).
5.2.2. Drugs
ET-1 and the lower dose of FR139317 were dissolved in saline to the appropriate
concentration that would deliver 50 pmols/pl and 1 nmol/pl respectively. Stock
FR139317 for 30 nmol injection, was made up in Tween (<1%) in saline vehicle.
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5.2.3. Statistical analysis
All data are presented as mean ± s.e.mean. Histological data were analysed by
Student's T test. Physiological variables for LDF studies were compared by ANOVA
on ranks. LDF data were expressed as % change from baseline and data from LDF
recordings following FR139317/SNP injection were compared by Two-way ANOVA
with post-hoc Tukey test to vehicle post-injected controls.
5.3. Results
5.3.1. Post treatment with FR139317/saline
In control, vehicle post-injected controls (n=9), the volume of damage following ET-
1-induced MCA occlusion was 115 ± 24 mm3. The volume of ischaemic damage
when FR139317 (3nmols; n=9) was delivered 10 minutes following ET-1 injection
was 80 ± 35mm3, which was not significantly different. Furthermore, the 10-fold
higher dose of FR139317 (30 nmols; n=6) did not significantly reduce ischaemic
damage compared to vehicle treatment (n=4) (108 ± 62mm3 vs 170 ± 67mm3
respectively) (Figure 25).
5.3.2. LDF assessment of reperfusion
Physiological variables were kept within normal limits for both the FR139317 and
SNP post-injection experiments compared to controls, and no significant differences
were found between groups at any time point (Tables 7 & 8 respectively). ET-1
injection reduced the LDF signal to 84 ± 5% in FR139317 (n=4) post-treated
animals, and 75 ± 6% in vehicle post-treated controls (n=5), which was not





















































Figure 25. Effects of intracerebral injection ofFR139317 10 minutes after ET-1 -
induced MCA occlusion. 3nmols of FR139317 (n=9) or vehicle (n=9) (top), or
30 nmols ofFR139317 (n=6) or vehicle (n=4) (bottom) were injected 10 minutes
following ET-1 (100 pmols). Data are presented as mean ± s.e.mean. No signifi¬
cant differences were found between vehicle and FR139317 post-treatment on
ET-1-induced MCA occlusion at either dose.
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significantly different between treatments. Injection of FR139317 (3 nmols) 10
minutes following ET-1 did not effectively reverse the reduction in perfusion
compared to vehicle injection, and LDF was not significantly different between
treatments at any time point. (Figure 26). Microscopic inspection of the vascular
territory of the MCA after termination of recording revealed profound tissue pallor
throughout the MCA territory.
LDF was reduced to 73 ± 4% in SNP post-treated rats, and 79 ± 7% in vehicle
controls, 5 minutes after ET-1-injection, a reduction not significnatly different
between treatments. By contrast to FR139317, the same dose of SNP effectively
reversed the ET-1-induced reduction in the LDF signal within 15 minutes, compared
to the vehicle injection group, in which the LDF signal did not recover. The LDF
signal then remained stable for the duration of recordings thereafter (Figure 27).
5.4, Discussion
5.4.1. General
The studies described in this section addressed whether ET-1-induced MCA
occlusion could be interupted by the intracerebral co-injection of an ET receptor
antagonist. Previously, studies described in chapter 3 suggested ET-1-induced MCA
occlusion has the pathophysiological profile of a model of permanent MCA
occlusion. The extent of reperfusion was limited, and not controlled. Models of focal
cerebral ischaemia that incorporate a phase of reperfusion are however essential in
improving our understanding of the pathophysiology of stroke. Consequently, the
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Figure 26. LDF recording ofthe effects ofFR139317 (3nmols; n=4) or vehicle (n=5)
injection 10 minutes after ET-1 -induced MCA oclusion. Data are presented as mean ±
s.e.mean. LDF signal fell to -30% ofbaseline following ET-1 (100 pmols). Two-way
ANOVA determined LDF in FR139317 injected animals was not show significantly
different from vehicle controls at any time.
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Figure 27. LDF recording ofthe effects ofSNP (3nmols; n=4) and vehicle (n=4) on
ET-1 -induced MCA oclusion. Data are presented as mean ± s.e.mean. LDF signal fell
to -25% ofbaseline following ET-1 (100 pmols) in both treatment groups, 5 minutes
after injection. LDF had recovered to -50% 5 minutes after SNP injection, and had
recovered to -95% ofbaseline after 20 minutes, remaining stable for the duration of
remining recordings. By contrast, LDF in vehicle controls showed no significant signal
recovery during the recordings. *P=<0.05 compared to vehicle controls.
manipulation of the current model was investigated with a view to producing a model
of MCA occlusion in which reperfusion could be introduced in a controlled manner.
A number of models of focal cerebral ischaemia have been developed that
encompass a reperfusion phase, including compression occlusion of the surgically
exposed MCA by reversible snare ligature (Shigeno et al. 1985), intraluminal
occlusion by filament (Koizumi et al. 1986), and abluminal endothelin-1 (Macrae et
al. 1993). However, the intraluminal filament model has been the most extensively
adopted for MCA occlusion with reperfusion. Models which employ physical
approaches to arterial occlusion inherently cause damage to the artery, and the
intraluminal filament approach causes extensive damage to the endothelial lining of
the cerebral arteries. The consequences of these may be two-fold. Mechanical
damage to the cerebral artery and endothelial denudation will impair vessel
responsivity and cerebrovascular tone (McAuley, 1995). Second, denudation of the
endothelium will compromise BBB integrity, promoting oedema, whilst potentially
exacerbating the inflammatory signal (McAuley, 1995). Both these events are likely
to affect the pathophysiological response to ischaemia, due to the role of the
microvasculature in stroke (del Zoppo, 1994). Consequently there exists a need to
investigate focal cerebral ischaemia with reperfusion using a model that does not
incur such extensive physical damage to the cerebrovasculature. The use of ET-1 to
produce MCA occlusion circumvents the physical damage associated with the other
models of stroke (Macrae, 1992; Sharkey et al. 1993). Whilst studies in which ET-1
was applied to the exposed MCA document reperfusion to the MCA territory in a
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dose-dependent manner, the control of reperfusion is limited when compared to the
rapid reflow possible with ligature and filament approaches.
The approach employed in the present studies, was to intracerebrally inject
microlitre volumes of an ET receptor antagonist after ET-1 to reverse MCA
occlusion. The rationale for this was based on a number of decisions. First, use of a
specific ET receptor antagonist may interupt ET-induced MCA occlusion by
blocking the site at which the agonist acted. Consequently this would inhibit
contraction and lead to reperfusion. Second, the intracerebral injection minimises
potentially confounding effects of a systemic injection of antagonist, and systemic
administration of an ET receptor antagonist has been shown to decrease ischaemic
brain damage after MCA occlusion (Patel et al. 1996b). The alternative approach to
pharmacological interuption of ET-induced MCA occlusion is physiological
antagonism by agents that indirectly block or reverse the effects of the ETs. Early
research on ET demonstrated that agents such as isoprenaline, a non selective (3
adrenoceptor agonist, and sodium nitroprusside (SNP) or SIN-1, which releases nitric
oxide, was capable of reversing the effects of ET-1 (Yanagisawa et al. 1988;
Gologorsky et al. 1994). Consequently the duration of ET-1-induced MCA occlusion
could be interupted by injection of one of these agents. However, the disadvantage
with such approaches are the complications in data interpretation. Specifically, in the
case of SNP, the problem is the role of nitric oxide in the brain (Dawson, 1994). It
could be argued that a small intracerebral infusion of SNP would be unlikely to have
profound effects on CBF outside of a localised site, given the short half-life of NO.
However, a factor of perhaps greater importance is the role of NO in the
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pathophysiological process itself. NO has been suggested as a mediator of ischaemic
brain damage (Boje & Arora, 1992; Dawson et al. 1993; 1994) which would
complicate interpretation. However, since the site of NO action is within the core
region of ischaemia, the tissue would enevitably become infarcted at the injection
site. NO is also implicated in the inflammatory response, inhibiting a number of
platelet activation-related processes, potentiating the actions of prostaglandin I2
(PGI2), blocking PAF production, and preventing blood cell activation & adhesion
(Akopov et al. 1996). Consequently, additional introduction of NO into the
microvascular environment central to the site of potential inflammatory response
would complicate interpretation of the pathophysiological response to ischaemia,
introducing artifactual components and limiting the application of the model.
In these studies FR139317, a specific ETA receptor antagonist was used. The
rationale was based on autoradiographic data (De Oliveira et al. 1995), suggestting
that the ETA receptor predominates on the cerebrovasculature of the rat. Furthermore,
the specific ETA receptor antagonists BQ123 and FR139317 prevent ET-1 induced
contraction of cerebral arteries in vitro (Salom et al. 1993; Feger et al. 1994;
Kitazono et al. 1995a; Goadsby et al. 1996). This is supported by the order of ET
isopeptide potency (Feger et al. 1994), whilst ETB selective agonists such as IRL
1620 do not produce vasoconstriction when applied to cerebral arteries in vivo
(Kitazono et al. 1995a).
FR139317 is a potent and selective ETA receptor antagonist both in vitro and in
vivo (Sogabe et al. 1993; Gross et al. 1994; Goadsby et al. 1996), displaying 20-
200,000 fold selectivity for the ETA receptor, and subnanomolar affinity for the ETA
receptor with a KD= 0.4nM (Bacon & Davenport, 1996; Peter & Davenport, 1996).
Another possible advantage of using FR139317 is that it is a peptide-based
antagonist (Sogabe et al. 1993) which is unable to cross the BBB. This would have
the effect of minimising tissue distribution of FR139317.
A number of potential cannula systems were considered for experiments in
which an ET antagonist was delivered intracerebrally to the same site as an ET
isopeptide. Two main approaches could be considered. Antagonist and agonist could
be delivered via the same cannula, with each drug loaded separately, with an air
bubble or mineral oil separation. Second, the two drugs could be physically separated
by employing a dual cannula system, whereby a large gauge cannula contained a
narrower gauge needle within the lumen. Such a system prevents the possibility of
drug mixing which might interfere with drug action. The advantage of the former
would be less needle tract damage and the simplicity of the system. However, the
latter, dual cannula system, approach was employed.
5.4.2. Histological and LDF assessment
The data from these studies have shown that ET-1 does not represent a suitable
candidate for MCA occlusion with pharmacological reversal of ischaemia. Whilst
intracerebral injections prevent determination of drug concentration, the 30 and 300-
fold higher dose of antagonist used in these studies compares well to the dose ratio of
FR139317 capable of blocking the effects of endothelin in vitro and in vivo (Sogabe
et al. 1993; Gross et al. 1994). The antagonist was injected 10 minutes after ET-1
rather than at a later time point since MCA occlusion of sort (30 minutes) duration
does not produce an ischaemic brain lesion when assessed after 3 days (Du et al.
1996). If FR139317 effectively blocked the action of ET-1, then very little brain
damage would result. In these studies, injection of 3 or 30 nmols FR139317 failed to
block ischaemic damage consequent on ET-1-induced MCA occlusion, as assessed
by a histological endpoint 3 days after drug injection. These findings were
complimented by LDF, which determined that injection of FR139317, 10 minutes
following ET-1 injection, did not effectively reverse the ET-1-induced reduction in
the LDF signal, and the vascular territory remained ischaemic afterwards. By contrast
to FR139317, LDF determined that the physiological antagonist SNP, effectively
reversed the effects of ET-1, which confirms previous studies that have shown NO
donors reverse the effects of ET-1 (Goligorsky et al. 1994).
The ineffectiveness of FR13 9317 against ET-1 may be explained by the nature
of ET-1 to ETa receptor interactions. ET-1 receptor binding is pseudoirreversible,
and with increasing incubation time, the effectiveness of antagonists decreases
further (Sagher et al. 1994; Flay & Luttmann, 1997; Marsault et al. 1991; 1993;
Waggoner et al. 1992; Ohlstein et al. 1995; Wu-Wong et al. 1995), although some
studies have suggested that ET receptor antagonists may be effective after ET-1 has
been exposed to tissue (Patel et al. 1995a; 1996b). This suggests that ET-1 binding to
the ETa receptor displays non-equilibrium (irreversible) binding characteristics that
will not obey typical dose-shift pharmacological responses to competitive
antagonists. In vitro studies report that ETA receptor antagonism is only effective
when the antagonist is introduced to the test system in conjunction with ET-1 or prior
to ET-1, and antagonism was ineffective when the antagonist was delivered after ET-
1 had been exposed to the tissue (Sagher et al. 1994; Yoneyama et al. 1995; Hay &
Luttmann, 1997; Awane-Igata et al. 1997; Warner et al. 1993). It is conceivable that
even if FR139317 was effective at an early time point, since incubation time
increases the binding affinity of ET-1 (Wu-Wong et al. 1995), reversal at later
(practical time point of 90 / 120 min occlusion) would still be ineffective. In
conclusion, ET-1 is unlikely to be a suitable candidate substrate with which to




CHAPTER 6. ENDOTHELIN-3-INDUCED MCA OCCLUSION
6.1. Introduction
6.1.1. Background
This chapter addresses the pharmacological characteristics of the receptor mediating
ET-induced MCA occlusion, and whether ET-3 represents a more suitable substrate
for MCA occlusion with controlled reperfusion. The previous chapter demonstrated
that ET-1 is not a suitable substrate for controlled reperfusion using a specific ETA
receptor antagonist (FR139317). Consequently, a novel approach was taken to
develop a model of controlled reperfusion that utilised ET-3, an isopeptide of ET-1,
to produce MCA occlusion.
6.1.2. ET-3 pharmacology
Identification of the gene for the ET isopeptide, ET-3 was described by Inoue et al.
(1989) and its location found to be on chromosome 20. ET-3, and ET-2, were shown
to possess a high degree of amino acid sequence homology to ET-1 (see Figure 1).
These peptides were also 21 amino acid peptides containing two disulphide bonds
and an identical hydrophobic C-terminal hexapeptide sequence (Goto et al. 1996).
The structure of ET-3 has been analysed by proton NMR (Bortman et al. 1991; Mills
etal. 1992).
ET-3 has a lower affinity to ET-1 at the ETA receptor (Miller et al. 1993), and ET-3
has a lower potency than ET-1 at the ETA receptor (Feger et al. 1994). By contrast
ET-3 is equipotent with ET-1 at the ETB receptor. A third, ET-3-selective (ETC)
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receptor has been proposed at which ET-3 is more potent than ET-1 (Emori et al.
1990).
A number of studies have addressed the effects of ET-3 on the
cerebrovasculature. ET-3 has been demonstrated to mediate both vasoconstriction
and vasodilatation of cerebral arteries in vitro (Schilling et al. 1995), with a lower
affinity and efficacy than ET-1 & ET-2. In vitro studies on cerebrovascular cells have
demonstrated that ET-3 has lower potency at stimulating an intracellular increase in
[Ca2+] (Salom et al. 1995).
6.1.3. Rationale for studies
Both ETa and ETB receptor subtypes have been identified in the cerebrovasculature
(Salom et al. 1995), although radioligand binding studies suggest that the ETA
subtype predominates (Davenport et al. 1995; De Oliveira et al. 1995; Pierre &
Davenport, 1995). This proposal is supported by in vitro functional studies that
employed specific ET receptor antagonists (Kitazono et al. 1995a).
Central to the rationale behind using ET-3 to produce MCA occlusion is based
on the pharmacological evidence that ET-1 has a higher affinity than ET-3 at the ETA
receptor. By contrast, the ETB receptor is an isopeptide non-selective receptor
(Masaki et al. 1994; Rubanyi & Polokoff, 1994; Salom et al. 1995; Goto et al. 1996).
According to receptor binding theory, a lower affinity ligand exhibit a faster
dissociation rate. This would suggest that whilst ET-1 binding is too permanent to
facilitate reversal by an antagonist within a suitable operating regime, the lower
affinity of ET-3 for the ETA receptor suggests that it may be more amenable to
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reversal by an ET receptor antagonist. In these initial studies, the ability of ET-3 to
produce MCA occlusion and ischaemic brain damage has been addressed.
Furthermore, the characteristics of the receptor mediating ET-induced MCA
occlusion were addressed.
6.2. Methods
6.2.1. Surgery & histology
Surgery was performed as described in section 2.2.1. Following a craniotomy, a 28
gauge steel cannula was stereotaxically lowered into piriform cortex approximately
0.5mm dorsal to the MCA (co-ordinates from bregma; AP=0.9mm; L=-5.2mm, and -
8.7mm below skull; tooth bar at -3.7mm), and 2pl of ET-3, ET-1, BQ3020, IRL1620
or vehicle was injected (lpl/90 seconds). The cannula was left in situ for a further 5
minutes and then slowly withdrawn. The wound was sutured, and animals were
returned to an incubator where normothermia was maintained until the rat had fully
recovered from anaesthesia. Three days later animals were reanaesthetised, perfusion
fixed and the volume of infarction was calculated as previously described in section
2.2.2..
For studies using co-intracerebral application of FR13 9317 with ET isopeptide, a
24 gauge dual cannula was employed as previously described in section 5.2.1. ET-1
or ET-3 (100 pmols in 2pl) was administered via the internal cannula 10 minutes




Laser Doppler flowmetry (LDF) was utilised to assess tissue perfusion velocity in the
cerebral cortex following ET-l/ET-3 injection. Animals were implanted with an
indwelling cannula prior 5-10 days prior to study as described previously in section
3.2.1.
On the day of study, animals were anaesthetised, and a catheter inserted into the
right femoral artery for blood pressure monitoring (Transonic Systems Inc.), blood
gas analysis (Ciba Corning model 238) and plasma glucose determination (Beckman
Glucose Analyzer 2). A craniotomy was performed in the parietal bone at a site more
ventral than was employed in section 3.2.3. to ensure the doppler probe was located
in a region closer to the core of the ischaemic area (co-ordinates from bregma:
AP=0mm; L=-5-6mm, and 5-6mm below skull level). LDF probes (24 gauge) were
advanced by a micromanipulator to rest on the surface of the parietal cortex.
Recordings were made for 15-30 minutes prior to the insertion of a 33 gauge needle
into the lumen of the indwelling cannula to deliver ET-1 or ET-3 (100 pmols in 2pl).
Recordings were then continued for 3hrs. At the end of the recording period animals
were killed by anaesthetic overdose (5% Halothane) and a zero flow recording taken
which was later subtracted from LDF signal values.
Arterial blood gases (pC02 and p02), blood pH and plasma glucose
concentration were determined for animals in the LDF study. Variables were
measured before and 15-30 minutes after ET-l/ET-3 injection, and then subsequently
1,2 and 3 hours post ET-l/ET-3.
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6.2.3. Experiments performed
The dose response relationship of ET-3 (10-300 pmols in 2pi) was examined, as were
the effects of two ETB receptor agonists, BQ3020 (100 pmols in 2pl) and IRL1620
(100 and 1000 mols in 2pl). The temporal profile of ischaemia following ET-1 (100
pmols in 2pl) and ET-3 (100 pmols in 2pl) induced MCA occlusion was addressed
by LDF.
Finally, FR139317 (3nmols in 3pl) was injected 10 minutes before ET-1 or ET-3 to
determine the pharmacological profile of the receptor mediating MCA occlusion.
6.2.4. Drugs
BQ3020 was purchased from Research Biochemicals Inc. IRL1620 was from
NovaBiochem. Both drugs were dissolved in an alkaline saline vehicle, pH adjusted
with sodium hydoxide to pH ~9. ET-1 and FR139317 were made up as previously
described. ET-3 was dissolved in saline, and aliquots frozen at -70°C until use, as
previously described for ET-1.
6.2.5. Statistical analysis
All data are presented as mean ± s.e.mean. Data from the dose response study and the
effects of ETb receptor agonists were analysed by ANOVA on Ranks with post hoc
Dunn's method. LDF data were analysed by two-way ANOVA. Data from the
comparison of 100 pmols of ET-1 with ET-3-induced MCA occlusion, and the effect
of FR139317 pretreatment on ET-1 & ET-3-induced MCA occlusion, were analysed
by Student's T test or Mann-Whitney Rank Sum test.
6.3. Results
6.3.1. Dose-response relationship for ET-3
Intracerebral injection of ET-3 into the piriform cortex adjacent to the MCA
produced a large ischaemic brain lesion of 78 ± 22mm3 (33 pmols; n=l 1), 127 ±
21mm3 (100 pmols; n=ll) and 96 ± 20mm3 (300 pmols; n=ll), which was confined
to the vascular territory of the MCA. Damage extended from the frontal cortex
through to occipital cortex with concomitant damage to medial and lateral striatum.
There were no significant differences in the volume of hemispheric ischaemic
damage produced by these doses . At the lowest dose studied (10 pmols), volume of
hemispheric ischaemic damage was 5 ± 2mm3 (n=l 0), which was significantly
reduced compared to the other doses (P<0.05), and was not significantly different
from vehicle (sham lesioned) treatment (Figure 28).
Comparison of the effects of 100 pmols ET-3 to the same dose of ET-1 on the
volume of hemispheric ischaemic damage revealed no significant differences
between the isopeptides. Comparison of the area of ischaemic damage at 8 stereotxic
levels also determined no significant differences between isopeptides at the 100 pmol
dose (Figure 29).
6.3.2. Temporal profile of ET-3-induced MCA occlusion (comparison to ET-1)
During LDF studies, physiological parameters were kept within normal limits, and
no significant differences were found between groups (Table 9). LDF determined that
ET-1 and ET-3-induced MCA occlusion produced maximal reductions in parietal
cortex perfusion velocity within 5 minutes, of 78±6% and 68±6% respectively. The
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Figure 28. Dose-response relationship for ET-3-induced MCA occlusion. Vehi¬
cle (n=10), or 10 (n=10), 33 (n=ll), 100 (n=ll) or 300 (n=ll) pmols ET-3 was
injected, and hemispheric ischaemic damage determined. Data are presented as
mean ± s.e.mean. *P=<0.05 compared to other doses.
ET-1 vs ET-3-induced MCA occlusion
Figure 29. Comparison of the area at eight stereotaxic levels (Top) and hemi¬
spheric volume (Bottom) of ischaemic damage following injection of 100 pmols
of ET-1 (n=12) and ET-3 (n=13). Data are presented as mean ± s.e.mean. No
significant differences were found between ET-1 and ET-3 in either the area or
hemispheric volume ofdamage.
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LDF signal remained depressed by >50% following both ET-3 and ET-1 for three
hours. Statistical analysis determined that the maximal reduction, and temporal
profile of the reduced tissue perfusion following ET-1 and ET-3, was not
significantly different at any time points (figure 30).
6.3.3. Effects of ETB agonists
Intracerebral injection of the putatively selective ETB receptor agonists BQ3020 (100
pmols; n=5) and IRL 1620 (100 pmols; n=8) (lnmol; n=8) did not produce an
ischaemic brain lesion, and damage consisted only of a small needle tract injury
within the cerebral cortex, which was not significantly different from that found in
sham operated animals (hemispheric ischaemic damage was <8mm3 for all
treatments) although it was significantly different (P<0.05) to that produced by 100
pmols ET-3 (120 ± 15mm3; n=13) (Figure 31).
6.3.4. Effects of FR139317 on ET- induced MCA occlusion
Intracerebral injection of FR139317 (3nmols) 10 min before ET-1 (100 pmols; n=12)
produced an hemispheric ischaemic brain lesion of 147±25mm3, which was not
significantly different to the volume of ischaemic brain damage in ET-1 + vehicle
(n=12) treated animals (140±27mm3). By contrast, intracerebral injection of
FR139317 10 minutes prior to ET-3 significantly reduced the volume of ischaemic
brain damage to 7±lmm3 (n=10), compared to 116±23mm3 in the vehicle (n=10)
pretreatment group (P<0.001) (Figure 32).
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Figure 30. LDF profile of ET-1 (n=4) and ET-3 (n=4) induced MCA occusion.
Data are presented as mean ± s.e.mean. No significant differences were found
between the isopeptides for either the maximal reduction or the temporal profile
of ischaemia.
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Figure 31. Effects of intracerebral ETB receptor agonists. 100 pmols ET-3 (n=l 3),
100 pmols BQ3020 (100 pmols), 100 pmols IRL 1620 (n=8), lnmol IRL 1620
(n=8) or vehicle (n=5) were injected. ETB receptor agonists did not produce sig¬
nificantly more damage than vehicle injected controls. Data are presented as mean
± s.e.mean. *P=<0.05 compared to ET-3 control group.
Effects of pretreatment with FR139317 on ET-1 and
ET-3-induced MCA occlusion
Figure 32. Effects of intracerebral FR139317 10 minutes before ET-1 (top) and
ET-3 (bottom) -induced MCA occlusion. 3nmols of FR13 9317 (n=12) or vehicle
(n=12) were injected 10 minutes before ET-1 (100 pmols), and 3nmols ofFR139317
(n=10) or vehicle (n=10) before ET-3 (100 pmols). Data are presented as mean ±
s.e.mean. FR139317 pretreatment had no effect on ET-1-induced MCA occlu¬
sion, whilst FR139317 blocked ET-3-induced MCA occlusion. *P=<0.001.
6.4. Discussion
6.4.1. ET-3 vs ET-1 induced MCA occlusion
Quantitative analysis of ischaemic brain damage determined that 33-300 pmols of
ET-3 produced a consistently large ischaemic brain lesion which was restricted to the
vascular territory of the MCA. This MCA occlusion-like pattern of damage was lost
when using 10 pmols ET-3, with animals displaying only needle tract damage in the
cortex. ET-3 was effective over the same dose range as previously reported for ET-1
(33-300 pmols) (see section 2.3.2.) and isopeptides shared the same minimal
effective dose of 33 pmols. Neither 10 pmols ET-1 or ET-3 was capable of producing
more ischaemic damage than that found in sham operated animals. Comparison of
the lesion volume produced by 100 pmols of ET-1 or ET-3 confirmed that the
isopeptides are equipotent in this model.
LDF recordings in the present studies determined that ET-1 and ET-3 produce
similar reductions in cortical flow velocity which were sustained for 3 hours. The
magnitude of the reduction in perfusion following both ET-1 and ET-3-induced
MCA occlusion, and the subsequent temporal profile of perfusion deficit, is
consistent with findings in other models of MCA occlusion (Dirnagl et al. 1989).
Comparing these LDF results of ET-1-induced MCA occlusion with the LDF
study in Chapter 3 demonstrates a difference in the temporal profile of ischaemia. In
the former studies, the LDF signal showed a degree of recovery over the three hour
recording period, whilst in these studies there was no such recovery. This difference
may be due to a number of factors. Possibly the most important is the positioning of
the LDF probes between these studies. Whilst both studies sampled from parietal
cortex, the former study sampled a dorsal region compared to the more ventral site
chosen for these studies. The absence of LDF signal recovery in the present studies
may reflect a recording site lying within the core zone of the ischaemic territory,
whilst the earlier studies sampled from the area of the penumbra. This difference is
reflected in the pseudocolour transform of local CBF following [14C]-iodoantipyrine
autoradiography taken 3 hours after ET-1-induced MCA occlusion, shown in figure
33. This illustrates the relative positions of LDF probes between the previous and
present studies. An area of higher perfusion is evident at the level of prior probe
placement, whilst local CBF at the probe site chosen in the current study remains
ischaemic even at three hours. Such differences may explain the proportionally
greater recovery seen in the earlier study. Thus both histopathology and LDF
recordings suggest that ET-1 and ET-3 are equipotent in the ischaemic insult
produced by MCA occlusion.
6.4.2. ETb agonist effects
The equipotency of ET-3 with ET-1 in our model was unexpected because ET-3 is
less potent than ET-1 at the ETA receptor (Goto et al. 1996). Consequently, the
possibility that ET-3 might be acting via a non-ETA receptor was examined. BQ3020
and IRL1620 are potent and selective ETB receptor agonists both in vitro and in vivo
(James et al. 1993; Battistini et al. 1994; Ishikawa et al. 1994; Nambi & Pullen,
1995; Widdowson & Kirk, 1996). Since the in vitro and in vivo potency of these
drugs and the endothelin isopeptides is equivalent (James et al. 1993; Bacon &
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Figure 33.
Pseudocolour transform of local CBF determined by [14C]iodoantipyrine
autoradiography three hours after intracerebral injection of 100 pmols ET-1 adjacent
to the MCA. Arrows delineate (a) approximate site of LDF probe placement for
dorsal parietal cortex recordings in chapter 3 & (b) approximate site of LDF probe
placement for "core" recordings in chapter 6. Note the "penumbral" hyperperfusion
lies within the area of tissue commonly sampled in chapter 3 studies, whilst local
CBF is still markedly reduced within the region sampled in the later studies.
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Davenport, 1996), the dose range employed in this study would be expected to
elucidate any ETB receptor-mediated response.
In the present studies, injection of either drug did not produce ischaemic brain
damage, with only needle tract damage within the cortex, that was not significantly
different from vehicle-injected animals. This suggests that an ETB receptor does not
mediate the vasoconstrictor effects of ET-3. This finding confirms previous studies
using ETb receptor agonists in vitro, in which ETB receptor agonists did not cause
vasoconstriction (Willette et al. 1994; Kitazono et al. 1995a; Schilling et al. 1995).
6.4.3. FR139317 effects
In the final studies addressed in this chapter, a specific ETA receptor antagonist was
employed to determine if ET-3-induced MCA occlusion could be blocked by
FR139317. Intracerebral injection of FR139317 (3 nmols) 10 minutes before ET-3,
abolished ET-3-induced MCA occlusion. By contrast, ET-l-induced MCA occlusion
was not blocked by intracerebral injection of the same dose of FR139317, 10 minutes
before ET-1. Whilst some previous studies have shown ETA receptor antagonists can
block the effects of ET-1 on the cerebrovasculature (Salom et al. 1993; Feger et al.
1994; Patel et al. 1996b), other studies have reported relative ineffectiveness of ETA
antagonists at putative ETA receptors (Sudjarwo et al. 1993; Yoneyama et al. 1995;
Patel et al. 1995b).
6.4.4. Evidence for a non ETA/atypical ET receptor on the rat MCA
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The present data are consistent with the presence of an atypical ET receptor on the rat
MCA. A selective antagonist for the ETA receptor would be expected to have similar
potency against ET isopeptides if they are equipotent. However, whilst ET-1 and ET-
3 were equipotent in this model, only ET-3-induced MCA occlusion was blocked by
FR139317. Since ETB receptor agonists were ineffective in this model, an atypical
ET receptor may be involved. Whilst no functional studies have directly addressed
the effects of ETs on the rat MCA, the effects of ETs on the rat basilar artery have
been studied (Feger et al. 1994), as well as the MCA of a number of other species
including the cat (Jansen et al. 1989; Saito et al. 1989), goat (Salom et al. 1993), and
dog (Asano et al. 1990). The findings from these studies have suggested that ETA
receptors mediate constriction (Salom et al. 1993; Feger et al. 1994), whilst a
population of ETB receptors are also present and mediate vasodilatation (Feger et al.
1994; Schilling et al. 1995), although ETB-mediated dilatation was not noted in the
study by Saito et al. (1989). Whilst only the basilar artery of the rat has been studied
in any detail in vitro, the ET receptor pharmacology on the dog basilar artery was the
same as on the dog MCA (Asano et al. 1990), although extrapolation of this trend to
the rat MCA may not be legitimate.
An alternative explanation may be derived from the irreversibilty of ET-1
binding. If ET-1 to ETA receptor association is irreversible, then receptor activation
could still occur in the presence of a competitive antagonist that displayed rapid
dissociation from the receptor. However, FR139317 binds to the ETA receptor with
very high affinity. In the study by Bacon & Davenport, (1996) the KD for FR139317
displacement of [125I]ET-1 binding to the ETA receptor was subnanomolar, which
suggests the dissociation rate is not only very slow for ET-1 but also for FR139317.
Furthermore, Wu-wong et al. (1994) reported pseudo-irreversible binding for
FR139317 as well as ET-1. These findings suggest that the lack of effect of
FR139317 against ET-1 is unlikely to be a consequence of such pharmacokinetics.
There are some discrepancies in the ET receptor pharmacology of the
cerebrovasculature, and the existence of an atypical ETA receptor, and ETA receptor
subtypes, have been proposed following receptor binding and functional responses of
the cerebrovasculature to ETs (Salom et al. 1993; Feger et al. 1994; Patel et al.
1995b). Studies in other tissues support the existence of further subtypes of
endothelin receptors that do not comply to the ETA/ETB nomenclature (Emori et al.
1990; Summner et al. 1992; Sudjarwo et al. 1994; Yoneyama et al. 1995), although
the existence of an ETC receptor is still a matter of debate (Masaki, 1995). Further
studies might elucidate as to whether the endothelin receptor mediating
vasoconstriction of the rat MCA is an atypical ETA or non ETA/ETB receptor.
6.4.5. Conclusions
The studies described in this chapter document a number of novel findings in regard
to this model of stroke. First that ET-3 is shown to produce ischaemic brain damage
by occlusion of the rat MCA, following intracerebral injection. ET-3 has not been
studied as extensively as ET-1 in its effects on the cerebrovasculature, and this is the
first demonstration that ET-3 is capable of producing ischaemic brain damage by
occlusion of a major cerebral artery.
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Second, is the finding that ET-3 is equipotent with ET-1 in the ischaemic insult
it produces. This finding was determined by both histopathological end-point, and by
examining the temporal profile of ischaemia using LDF. Further studies determined
that this equipotency was not a consequence of an action at the ETB receptor. Finally
the disparate effects of FR139317 against ET-1 and ET-3-induced MCA occlusion in
combination with these findings, suggest the presence of an atypical ETA or non








The two previous chapters have demonstrated two important points with respect to
modifying the ET-1 model to produce a controlled reperfusion model. First, ET-1-
induced MCA occlusion is not effectively interupted by an ETA receptor antagonist.
Second, the ET isopeptide ET-3 is capable of producing a large ischaemic brain
lesion by occlusion of the rat MCA. ET-3 was equipotent with ET-1 in this respect,
being effective over the same dose range, producing a similar volume of ischaemic
brain damage and possessing the same LDF temporal profile of ischaemia, and
furthermore, it was demonstrated that ET-3-induced MCA occlusion could be
effectively blocked by pre-treatment by the ETA receptor antagonist FR139317. In
these studies, we address whether ET-3-induced MCA occlusion can be manipulated
by the specific ETA receptor antagonist FR139317 to produce a model of MCA
occlusion with controlled reperfsuion.
7.1.2. Apoptosis component in focal cerebral ischaemia
As has been addressed in preceeding sections, focal cerebral ischaemia that
encompases a phase of reperfusion has a different pathophysiology to models of
stroke in which arterial occlusion is permanent. A further characteristic of stroke
models is the mechanism of cell death. As was mentioned in section 1.3.2., cells may
die by two distinct processes, necrosis and apoptosis, and both these forms of cell
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death have been identified following focal cerebral ischaemia. Identification of the
contribution of apoptosis to stroke in which reperfusion may affect
pathophysiological events may have important consequences for the treatment of
stroke pateints. For example, cells within the region of salvage, the penumbra, have
been shown to be effectively salvaged by agents such as MK801, but if cells were to
die by apoptosis-like mechanisms it is possible that intervention could be modelled
on our growing understanding of what controls this cell death.
Linnik et al. (1993) first identified evidence of programmed cell death
(apoptosis) in a model of focal cerebral ischaemia using the intraluminal filament
technique. Furthermore a number of recent studies support these findings. Li et al.
(1995d) produced MCA occlusion using an intraluminal filament in Wistar rats. A
two hour occlusion was followed by 22 hours of reperfusion prior to histological
examination, and identification of apoptotic cells by 3 -OH DNA end labelling. They
reported apoptotic cells throughout the MCA territory although the majority were
localised to the inner boundary zone of infarcted tissue (216±43 per section), which
suggests apoptosis contributes to infarct development after focal cerebral ischaemia
with reperfusion. Whilst a number of studies have provided evidence for apoptosis in
models of focal cerebral ischaemia with reperfusion (Charriaut-Marlangue et al.
1995; 1996; Li et al. 1995a; 1995b; 1995c), the number of studies comparing to
permanent MCA occlusion are limited. Linnik et al. (1995) addressed whether
apoptotic cells contribute to the infarct after permanent focal cerebral ischaemia,
whereby gel electrophoresis of cortical DNA 24 hours post permanent MCA
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occlusion revealed characteristic DNA laddering in the "penumbral" region. Analysis
further showed that DNA fragmentation occurred as soon as 1 hour post-occlusion.
Du et al. (1996) identified a model of stroke in which apoptosis is the dominant
mechanism by which cells may die. Using an intraluminal filament model of MCA
occlusion, they demonstrated that a 30 minute MCA occlusion did not produce a
large ischaemic lesion when assessed three days following occlusion. However, they
demonstrated that if the survival period was extended to 14 days, then a large volume
of ischaemic cell death was found which was not significantly different to that
produced by a 90 minute MCA occlusion. They concluded that this "very delayed
cell death" is due to apoptosis of cells injured by the brief ischaemic challenge that
consequently triggered the process of programmed cell death. One aspect of the ET
model of MCA occlusion addressed using a model of controlled reperfusion was
whether there was a significant component of very delayed ischaemic cell death.
7.1.3. Experimental approach
In order to determine if ET-3-induced MCA occlusion could be interupted by an ET
receptor antagonist the following experimental approaches were taken:
1. FR139317 was delivered 10 & 90 minutes following ET-3 and the histological
outcome was assessed.
2. LDF assessment of the temporal profile of FR13 9317 effects on ET-3-induced
MCA occlusion, and comparison to the physiological antagonist sodium
nitroprusside, as performed for ET-1 in chapter 5.
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3. [l4C]iodoantipyrine assessment of FR139317-induced reversal of ET-3-induced
MCA occlusion
4. Histopathological and immunocytochemical assessment of histopathological
outcome following 30 minute occlusion addressing the component of very
delayed (apoptotic) cell death.
7.2. Methods
7.2.1. Histological studies
Surgery and histological techniques employed in the assessment of ischaemic brain
damage for 10, 30 and 90 minute time points have been described previously in
sections 2.2.1. & 2.2.2. with the modifications outlined in section 5.2.1. Following
craniotomy, a 24 gauge dual cannula was lowered 8.7mm below skull. ET-3 (100
pmols in 2pl) was injected (1 pl/90 sec) via the inner (31 gauge) cannula. A period of
10, 30 or 90 minutes elapsed before delivery of FR139317 (3 nmols in 3pl) at the
same rate. The cannula was left in situ for 5 minutes following the final injection
before being slowly withdrawn. Following suturing of the scalp wound, animals were
placed in an incubator prior to being returned to cages. Following 3 or 14 day
recovery, animals were transcardially perfused, the brain removed and stored, and the
volume of ischaemic brain damage quantified as previously described.
7.2.2. Immunocytohistochemistry
Representative sections from standard ET-1 lesioned brains, as well as brains from
30 minute ET-3-induced MCA occlusion animals fixed after 3 or 14 day recovery,
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were processed for immunocytochemistry to determine the number of apoptotic cells
within the respective ischaemic lesions. The procedure used the ApopTag© (Oncor)
in situ apoptosis detection kit. The method uses the enzyme deoxynucleotidyl
transferase (TdT) to catalytically add digoxigenin-nucleotide residues to the 3'-OH
ends of double or single stranded DNA that are generated during endonucleotide
(apoptotic) DNA fragmentation. An anti-digoxigenin Ab is then added that carries a
conjugated peroxidase enzyme, which binds the digoxigenin-nucleotide and
generates a signal (brown colour) from a chromogenic substrate (diaminobenzidene),
which is clearly distinguishable from background (methyl green).
Since DNA nick-end labelling has been detected in necrotic cells (Collins et al.
(1992; Columbano), identification of apoptotic cells was supported by morphological
identification of apoptosis based on the light-microscopy criteria described by Wyllie
et al. (1980). These criteria include chromatin aggregation, cytoplasmic condensation
and rounding of the cell.
Sections were processed according to the manufacturers instructions. Briefly,
perfused brains were stored for 12-24 hours in 4% paraformaldehyde in PBS, and
then frozen and sectioned (20pm) on a cryostat. Sections were then collected on glass
microscope slides, and processed according to the protocol in Appendix A. The
apoptotic component in these three models of ET-induced MCA occlusion was
determined by counting the numbers of apoptotic cells within the both ischaemic and
contralteral hemispheres at the sterotaxic level of bregma.
Staining of histologically prepared sections was performed by Mr. G. Carlsson
of the Fujisawa Institue ofNeuroscience, University of Edinburgh.
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7.2.3. LDF studies
LDF studies were performed as previously described in section 6.2.2., and animals
were implanted with an indwelling cannula as described in section 3.2.1. Following a
5-10 day recovery period, animals were re-anaesthetised and a catheter inserted into
the right femoral artery for blood pressure monitoring (Transonic systems Inc.) and
frequent blood gas and plasma glucose analysis (Ciba Corning model 238 and
Beckman Glucose analyser 2). A tracheotomy was then performed and the animal
artificially ventilated (Harvard Instruments Rodent ventilator model 2).
The animal was placed in a stereotaxic frame. A craniotomy was performed over
the parietal cortex and LDF probes (24 gauge) advanced by a micromanipulator to
rest on the surface of the intact dura overlying the parietal cortex. Recordings were
made for 15-30 minutes prior to the insertion of a 33 gauge needle into the lumen of
the indwelling cannula to deliver ET-3 (100 pmols in 2pl). Ten minutes following
ET-3 injection, FR139317, SNP (3nmols in 3pl) or vehicle was injected. Recordings
were then made for 90 minutes. At the end of the recording period animals were
killed by anaesthetic overdose (5% halothane), a zero flow recording taken which
was later subtracted form LDF signal values, and the brain inspected under a
microscope. Arterial blood gases (pC02 and p02), blood pH and plasma glucose
concentration were determined for animals in the LDF study. Physiological variables
were measured before and 15-30 minutes after ET-3 injection, and then subsequently
one hour post FR139317/SNP.
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7.2.4. [14C]iodoantipyrine studies
[l4C]iodoantipyrine autoradiography was employed to assess local CBF one hour
after FR139317 injection, 10 minutes following ET-3-induced MCA occlusion.
Animals were prepared with an indwelling cannula 5-10 days before blood flow
studies as previously described in section 3.2.1. The protocol for [l4C]iodoantipyrine
autoradiography followed that described in section 3.2.4. with some modifications.
On the day of study, rats were anaeathetised with halothane (5%) in a nitrous
oxide:oxygen mixture (80/20% v/v). Both femoral arteries and veins were
catheterised, the incision sites infiltrated with anaethetic gel (xylocaine 2%), and the
wound sutured closed. A plaster of Paris cast was then applied, body temperature
maintained by means of a rectal probe and heating lamp, and a blood pressure
monitor was connected. Anaethesia was discontinued and the animal allowed to
recover for at least 2 hours prior to further experimentation. Injection of drugs was
performed following brief re-anaesthetisation of the animal. ET-3 (100 pmols in 2pi)
was injected via a 31 gauge injection cannula inserted into the lumen of the
indwelling cannula. Ten minutes following ET-3 injection, FR139317 (3nmols in
3pi) or vehicle (3pi of saline) was injected. The cannula was then withdrawn and
anaesthesia discontinued. Samples of arterial blood were taken for blood gas, blood
pFl, and plasma glucose determination immediately before the animal was re-
anaesthetised for injections, following discontinuation of anaesthesia, and then once
again immediately prior to infusion of [14C]iodoantipyrine. One hour following
FR139317/vehicle injection, [14C]iodoantipyrine autoradiography was performed
according to the protocol described previously in section 3.2.4.
[14C]iodoantipyrine studies were performed with the assistance of Dr. J Sharkey
of the Fujisawa Institue of Neuroscience, Univeristy of Edinburgh.
7.2.5. Statistical analysis
All data are presented as mean ± s.e.mean. Analysis of data from 10 minute and 90
minute MCA occlusion were compared to vehicle injected control by ANOVA on
ranks with post hoc Dunn's method. Data from the comparison of 30 minute group
were compared by Mann-Whitney Rank sum test. LDF data were analysed by Two-
way ANOVA with post hoc Tukey test. Data from local CBF studies were compared
by Student's T test.
7.3. Results
7.3.1. Histological studies
Intracerebral injection of FR139317 (3 nmols) 10 minutes following ET-3 (n=10),
significantly reduced the volume of hemispheric ischaemic brain damage to
12±3mm3, compared to 132±27mm3 in the vehicle post treatment group (n=10)
(P<0.05) (Figure 34). By contrast, the volume of hemispheric ischaemic damage in
the group receiving FR139317 (3 nmols), 90 minutes following ET-3 (n=8), was
103±23mm3 which was not signifcantly different to that seen in the control ET-3
group, but was significantly larger than in the 10 minute group (P=<0.05).
The total volume of hemispheric ischaemic damage in rats undergoing 30 minute
ET-3-induced MCA occlusion was not significantly different between animals fixed
after 3 day (n=10) or 14 day (n=9) recovery (P=0.903) (figure 35).
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Figure 34. Effects of intracerebral FR139317 (3 nmols), injected 10 (n=9) or 90
(n=8) minutes after ET-3 (100 pmols) compared to standard ET-3-induced MCA
occlusion. Data are presented as mean ± s.e.mean. Whilst FR139317 blocked ET-
3-induced MCA occlusion when injected 10 minutes after ET-3, injection 90 min¬
utes after ET-3 resulted in a volume of ischaemic damage not significantly differ¬
ent to a standard ET-3 infarct. *P=<0.05 compared to other groups.
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Figure 35. Histopathological outcome following 30 minute ET-3-induced MCA
occlusion. FR139317 (3nmols) was injected 30 minutes after ET-3 (100 pmols),
and animals were fixed after 3 (n= 10) or 14 (n=9) day recovery. Data are pre¬
sented as mean ± s.e.mean. No significant differences were found between treat¬
ments.
7.3.2. Immunocytohistochemical identification of apoptosis
The infarct volume between brains processed for immunocytohistochemistry was
kept within a narrow range (30-80mm3). The number of apoptotic cells found in the
contralateral hemisphere was <3 per brain between treatment groups. The number of
apoptotic cells within the ischaemic hemisphere of ET-1-induced MCA occlusion
rats was 50 ± 4. This was not significantly different from the number found in
sections from rats that underwent 30 minute ET-3-induced MCA occlusion fixed
after 3 days (49 ± 9) or 14 days (47 ± 8). Examples of apoptotic cells are shown in
Figure 36.
7.3.3. LDF studies
During LDF studies, physiological parameters for FR139317 and SNP effects on ET-
3-induced MCA occlusion were kept within normal limits, and no significant
differences were found between groups for any parameter at any time point (Tables
10 and 11 respectively).
ET-3 injection resulted in a profound reduction in LDF signal relative to baseline in
all studies. This reduction in FR139317 post-treated rats was 60 ± 5%, and 65 ± 5%
in control animals, and was not significantly different between treatments. FR139317
completely reversed the effects of ET-3 within five minutes. The signal did not
significantly change compared to baseline for the duration of the remaining
recordings (Figure 37). By contrast, LDF in vehicle treated animals showed no
recovery throughout recordings.
Figure 36.
High-power light microscope pictures of apoptotic cells from rats perfusion fixed
three days following 30 minute ET-3-induced MCA occlusion. Both pictures
illustrate profound immunohistochemical staining of individual cells that have
undergone endonuclease-induced cleavage to form 3'-OH DNA end breaks, stained
by ApopTag®. Morphological signs of apoptosis are also identifiable as chromatin
marginalisation & clumping, and cell rounding. Magnification = x 400
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Figure 37. LDF recordings ofthe effects ofFR139317 (3nmols;n=4) and vehicle
(n=5) on ET-3-induced MCA occlusion. Data are presented as mean ± s.e.mean.
LDF signal fell to -40% ofbaseline following ET-3 (100 pmols). LDF recovered to
-85% within 5 minutes ofFR139317 injection and fully recovered after 20 minutes,
remaining stable for the duration ofthe remaining recordings. By contrast, LDF in vehi¬
cle controls showed no significant signal recovery during the recordings. *P=<0.05
compared to vehicle controls.
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Figure 38. LDF recordings ofthe effects of SNP (3nmols; n=4) or vehicle (n=5) on
ET-3-induced MCA oclusion. Data are presented as mean ± s.e.mean. LDF signal fell
to -30% ofbaseline following ET-3 (100 pmols). LDF recovered to -100% (base¬
line) within 5 minutes of SNP injection, although a secondary, non-significant LDF
drop 20-3 5min after SNP occcured before remaining stable for the duration of the
remaining recording period. By contrast, LDF in vehicle controls showed no significant





In SNP post-treated rats, ET-3 injection resulted in a reduction of 68 ± 7% in the
LDF signal, compared to 69 ± 5% in vehicle post-treated animals, which was not
significantly different between treatments. SNP rapidly reversed the ET-3-induced
LDF signal reduction within 5 minutes. By contrast to FR13 9317, the signal
following SNP injection showed a secondary reduction which later recovered to
baseline (Figure 38). Microscopic inspection of the vascular territory of brains
showed no evidence of tissue palor within the MCA territory for either group.
7.3.4. [l4C]iodoantipyrine autoradiography studies
Physiological parameters taken immediately prior to [14C]iodoantipyrine
administration were within normal limits and showed no significant differences
between groups for any parameter (Table 12). Analysis of local CBF as measured by
[I4C]-iodoantipyrine autoradiography determined that local CBF was significantly
reduced in 10 of 29 brain regions compared to contralateral hemisphere in animals
treated with ET-3 plus vehicle 10 minutes post ET-3. By contrast, in animals treated
with FR139317 10 minutes following ET-3, ipsilateral local CBF was not
significantly different to the contralateral hemisphere, or the contralteral hemisphere
of control (ET-3) treated animals in any brain region studied (Table 13). The
reductions in local CBF in ET-3 + vehicle and ET-3 + FR139317 are illustrated in
the pseudocolour transform autoradiograms in Figure 39 which contrast control ET-
3-induced MCA occlusion sections at two stereotaxic levels to FR139317 post-
treated animals in which local CBF is essentially normal within the ipsilateral
hemisphere.
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Local cerebral blood flow FR139317 reversal of
ET-3-induced MCA occlusion
ET-3 MCA occlusion ET-3 +FR139317
reverse after 10
minutes
Brain region Blood flow Blood flow Blood flow Blood flow
ipsilateral contralateral ipsilateral contralateral
Superficial cerebral structures
Medial prefrontal cortex 173±11 196±13 193±15 191±17
Frontal cortex area 8 37±10* 217±17 212±25 210±24
Frontal cortex area 10 25±7* 228±14 175±26 191±24
Piriform cortex 45±12* 235±18 219±21 226±18
Somatosensory cortex 45±11* 249±4 213±22 215±19
Cingulate cortex 234±13 236±10 235±26 233±27
Parietal cortex 42±12* 243±12 235±19 225±20
Temporal cortex 36±12* 208±17 240±28 225±19
Retrosplenial cortex 225±14 232±16 216±23 219±23
Entorhinal cortex 43±12* 130±17 153±22 148±21
Primary visual cortex 52±12* 193±16 224±31 230±26
Deep cerebral structures
Genu of corpus callosum 46±5 48±4 48±7 47±7
Nucleus accumbens 89±20 107±20 108±14 112±13
Caudate-putamen (dorso-lateral) 58±10* 131±7 121±9 120±10
Caudate-putamen (medio-lateral) 68±10* 151±15 148±11 149±15
Septal nucleus 108±10 110±11 101±15 98±13
Anterior-medial thalamic nucleus 222±14 230±15 231±21 227±22
Ventrothalamic nucleus 151±18 175±24 155±20 159±21
Subthalamic nucleus 137±10 137±11 139±14 136±17
Globus pallidus 97±12 105±16 104±16 103±14
Hippocampal CA1 88±8 88±9 87±13 87±12
Dentate gyrus 124±10 129±10 122±11 121±9
Internal capsule 75±4 79±3 88±8 84±8
Lateral geniculate nucleus 162±12 162±10 155±10 159±11
Substantia nigra 133±13 118±7 132±21 122±16
Cerebellum & pons
Pontine nucleus 98±6 101±7 120±11 119±12
Cerebellar white matter 40±4 42±4 42±2 41±2
Cerebellar grey (minimum) 108±3 107±3 116±9 115±10
Cerebellar grey (maximunm) 237±17 234±17 262±25 263±22
Table 13. Local cerebral blood flow (ml/lOOg/min) in 29 anatomically defined
regions of the brain, measured 1 hour after ET-3-induced MCA occlusion or
FR139317-reversal of ET-3-induced MCA occlusion. Data are presented as mean ±
s.e.mean for control ET-3 (n=5) or FR139317 treated (n=5) injection. One-way
ANOVA *P=<0.05.
Figure 39.
Local CBF determined by [l4C]iodoantipyrine autoradiography one hour after co-
intracerebral injection of FR139317 (3 nmols), or vehicle 10 minutes following ET-
3-induced MCA occlusion. Pseudocolour transforms represent local CBF at the level
of bregma in (a) ET-3 + vehilce & (b) ET-3 + FR139317 at the same level, and local
CBF at the level of the hippocampus (Bregma -4.0mm) in (c) ET-3 + vehicle & (d)
ET-3 + FR139317 injected animals (d). Note the profound reductions in local CBF
throughout the MCA vascular territory in animals subjected to ET-3-induced MCA,
whilst ipsilateral local CBF is essentially the same as the contralateral hemisphere in
FR139317 post-injected animals.
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7.4. Discussion
7.4.1. 90minute vs 10 minute MCA occlusion
These data demonstrate that ET-3-induced MCA occlusion is a suitable substrate as a
model of focal cerebral ischaemia with controlled reperfusion. Histopathological
analysis of ischaemic brain damage, determined that injection of FR139317 (3nmols)
10 minutes after ET-3 injection interupts MCA occlusion sufficiently rapidly to
effectively block any ischaemic damage. By contrast, the volume of ischaemic brain
damage was not significantly different between the control ET-3 lesion and animals
receiving the antagonist 90 minutes following ET-3 injection. This confirms that the
cannula system only delivers the drugs at the appropriate time, rather than the
antagonist diffusing out of the cannula at an earlier time point. These findings
suggest that FR139317 is an effective agent with which to interupt ET-3-induced
MCA occlusion. Furthermore, the duration of MCA occlusion required to produce a
lesion of maximal size with ET-3 is at least 90 minutes. Indeed, the volume of
ischaemic damage following 90 minute ET-3 MCA occlusion is similar to that seen
following permanent MCA occlusion by electrocoagulation in the same strain in
previous studies (Park et al. 1988; Morikawa et al. 1991), although studies have
suggested a 3 hour MCA occlusion is required to produce maximal damage (Kaplan
et al. 1994).
Since the volume of damage was not significantly greater in the 90 minute
group, it would seem that FR139317 controlled interuption of ET-3-induced MCA
occlusion does not lead to a reperfusion-induced exacerbation of damage as has been
previously suggested (McAuley, 1995).
7.4.2. 30 minute MCA occlusion: Apoptosis implications
The contribution of apoptosis to cell death is currently a central topic in cerebral
ischaemia research. Recently, Du et al. (1996) described a model of MCA occlusion
in which the predominant mechanism of cell death bears many signs of apoptosis.
They demonstrated that whilst a 30 minute MCA occlusion did not produce an
ischaemic lesion when histopathology was determined three days following
occlusion, when analysed 14 days post 30 minute occlusion, the volume of damage
was the same as that seen in animals subjected to a 90 minute MCA occlusion.
Whilst evidence for the involvement of apoptosis in cell death following
cerebral ischaemia cells is increasing, a number of issues remain to be resolved.
Specifically, the cause of the extended time-frame for the appearance of apoptotic
cells post insult, and the relative apoptotic contributions in different MCA occlusion
models. It has been suggested that apoptosis may still occur rapidly, but the
commitment phase may be greatly extended in the brain, whereby the final initiation
of the cell to undergo apoptosis is variable (Li et al. 1995d).
The present study determined that numbers of apoptotic cells were not
significantly different between brains from rats subjected to a standard ET-1-induced
MCA occlusion, and 30 minute ET-3-induced MCA occlusion, fixed at either 3 or 14
days. Furthermore, the numbers of cells reported in the present study for all MCA
occlusion groups were less than have been reported previously in models of transient
MCA occlusion that employed the intraluminal filament approach (Li et al. 1995a;
1995d) in which -200 or more cells were identified at a single coronal section after 2
hour MCA occlusion. The technique for labelling apoptotic cells in the present study,
has previously been verified as highly specific for identifying apoptosis in ischaemic
brain (Li et al. 1995a; 1995d). The procedure is based on immuno-labelling 3'-OH
DNA strand breaks that are formed by endonucleolytic cleavage of DNA into
multiple nucleosomal units of ~180 base pairs, which is a feature of apoptosis, and
can be visualised by gel electrophoresis (Linnik et al. 1995). Since such DNA strand
breaks have been reported previously following necrotic cell death (Collins et al.
1992; Li et al. 1995c), labelled cells were also examined for morphological features
of apoptosis such as chromatin marginalisation and clumping.
The present data suggest that both the ET-1 model and the ET-3 reperfusion
model may be associated with a differential apoptotic component to the intrluminal
filament models, and conflict with the findings of Du et al. (1996) in which a large
lesion developed between 3 and 14 days, in which cell death had features of
apoptosis. This suggests that the contribution of very delayed (apoptotic) cell death is
not significant following 30 minute ET-3-induced MCA occlusion. If we assume
experimental conditions to be essentially the same between studies the main
difference between these models is the method by which MCA occlusion is
produced. The model of Du et al. (1996) employs the intraluminal filament
technique. Consequently the large component of apoptosis in that study may be a
consequence of this approach. Evidence suggests that inflammation may directly lead
to apoptosis. Chopp et al. (1996) demonstrated that antibodies against ICAM-1 and
the P2 integrin Mac-1, not only reduced leukocyte infiltration, but reduced the
number of cells undergoing apoptosis in the ischaemic hemisphere. Leukocytes have
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also been shown to induce apoptosis directly in cells (Squier et al. 1995), whilst the
neutrophil is a source of oxygen free radicals which have been implicated in
apoptosis (Hockenbery et al. 1993). These data therefore suggest that inflammatory
cell infilatration may be minimal in the ET MCA occlusion models, and the
potentially artifactual contribution to inflammation from cerebral vessel damage in
intraluminal filament models should be addressed in detail. Further studies to
identify the extent of inflammation following ET-induced MCA occlusion may
clarify these discrepancies.
7.4.3. Temporal profile of reperfusion
LDF recordings determined that FR139317 rapidly reverses ET-3 induced MCA
occlusion within 5 minutes. This profile is similar to that seen following clip release
of the MCA (Soriano et al. 1997). Furthermore, perfusion returned to pre-occlusion
levels without a significant hyperperfusion after FR139317, which contrasts some
reperfusion models in which hyperperfusion occurs (Shigeno et al. 1985; Dirnagl et
al. 1989). However, the findings after 10 minute occlusion do not necessarily extend
to what would occur at later (e.g. the 90 minute reperfusion group) time points,
where pathophysiological changes within the brain tissue might alter this profile.
Reperfusion using SNP was employed to compare to reversal of ET-3-induced MCA
occlusion by FR139317. In these studies, SNP rapidly reversed the effects of ET-3,
although there was a period of hypoperfusion 15-45 minutes after addition. This may
be a consequence of the continued presence of ET-3 within the tissue, whilst SNP
rapidly decomposes to the short lived (~4 sec) NO molecule. Thus it is conceivable
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that the effects of SNP rapidly wear off, and consequently some vasoconstriction
returns as ET-3 is less rapidly metabolised. Reversal of ET-1 -induced MCA
occlusion by SNP did not demonstrate such a hypoperfusion phase, although the
reasons for this are unclear. It is possible that ET-1 causes more rapid receptor
tachyphylaxis or internalisation preventing the rebound hypoperfusion seen with ET-
3.
7.4.4. Local CBF determination of reperfusion
[14C]iodoantipyrine autoradiography was employed to determine local CBF in 29
brain regions 1 hour following ET-3-induced MCA occlusion, with or without
FR139317 co-intracerebral injection. Local CBF within the septum, pons and white
matter tracts was similar to that reported previously following permanent occlusion
of the rat MCA (Tamura et al. 1993) and was not effected in these studies. All
cortical structures, with the exception of the midline retrosplenial and cingulate
cortices, ipslateral to the ET-3 + vehicle injections exhibited profound reductions in
CBF. This was greatest within areas 8 & 10 of the frontal cortex, as well in the
piriform and temporal cortex, where local CBF was <40 ml/lOOg/min. The relative
reduction of cortical CBF varied between 89% in frontal cortex area 10, to 67% in
the entorhinal cortex, which is only partially fed by the MCA (Tamura et al. 1981b).
The reduction in local CBF within the lateral caudate nucleus (55%) was less
profound, with local CBF levels of 58-68ml/100g/min 1 hour post ET-3. This
contrasts local CBF levels 10 minutes (Sharkey et al. 1993) and 30 minutes (Tamura
et al. 1981b) following MCA occlusion, in which CBF was <30ml/100g/min, but is
lower than following 2 hours of ET-1-induced MCA occlusion by topical application
(Gartshore et al. 1996). The explanation for higher CBF in this region at later time
points in the ET-1 model has been addressed previously in chapter 3, and may be due
to factors such as cerebrovascular anatomy, metabolic changes and deteriorating
vasoconstrictor effects of ET-3 with time.
Ipsilateral local CBF within the thalamus, the substantia nigra and the globus
pallidus were not significantly affected by ET-3-induced MCA occlusion. As has
been addressed previously, there is considerable inter-study differences in the local
CBF changes in these structures. Whilst local CBF in the substantia nigra and globus
pallidus has been shown to increase following MCA occlusion (Tamura et al. 1981b;
Sharkey et al. 1993), other groups have reported little change in these structures
(Robinson et al. 1990) or decreases in local CBF (Gartshore et al. 1996). Such
discrepancies may arise due to model & experimental differences, local CBF
measurement time and the complexities of inter-structural neuronal and vascular
innervation.
By contrast with vehicle treated rats, injection of FR139317 10 minutes
following ET-3 produced a pattern of ipsilateral local CBF when assesed 60 minutes
later, that was not significantly different to the contralateral hemispheres. All
ipsilateral cortical structures and the caudate-putamen exhibited local CBF
significantly greater than in animals injected with ET-3 followed by vehicle, and
CBF was not significantly different to the contralateral hemisphere. This finding
confirms previous histopathological and LDF findings that FR139317 effectively
reverses ET-3-induced MCA. The protracted study time (1 hour after FR139317)
may in fact obscure any acute effects of FR13 9317 reversal such as hyperperfusion
within the MCA territory. However, the LDF profile of reversal did not reveal any
hyperperfusion within the parietal cortex, and so this may not be a feature that occurs
with a short period of ischaemia. It would be interesting to examine whether reversal
of ET-3-induced MCA occlusion at later time points such as 30 and 90 minutes
included in the histopathological studies, led to hyperperfusion within or without the
MCA vascular field.
7.4.5. Conclusions
A range of methodological approaches were utilised in these studies to characterise
and evaluate the effectiveness of ET-3-induced MCA occlusion as a substrate for
controlled reperfusion by the intracerebral co-injection of a specific ETA receptor
antagonist. The data demonstrate that unlike ET-1, ET-3-induced MCA occlusion is
amenable to reversal by FR139317. It appears that the system can be used to produce
MCA occlusion of varying duration. LDF suggests that the reversal of ET-3-induced
MCA occlusion is rapid following FR139317 (within 5 minutes). Indeed the reversal
followed the same time course as the physiological antagonist SNP which causes
vasodilation by production of NO. These findings were supported by
[l4C]iodoantipyrine autoradiographic mapping of local CBF, which determined that 1
hour following 10 minute FR139317-reversal of ET-3-induced MCA occlusion, local
CBF is normal throughout both hemispheres, supporting the efficacy of FR 13 9317 at
interupting ET-3-induced MCA occlusion.
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These data suggest that ET-3-induced MCA occlusion can be manipulated to
produce a viable model of reversible focal cerebral ischaemia that does not involve
physical damage to the major cerebral arteries. Furthermore, the finding of no
rebound-hyperperfusion following reversal of occlusion, and the low-apoptotic
component of this model suggests that this model may lack potentially artifactual





CHAPTER 8. SUMMARY AND DISCUSSION
A range of models of focal cerebral ischaemia are currently in use in stroke research,
although models employing the subtemporal approach or intraluminal filament
procedure, currently predominate in the literature. Whilst these models allow control
over the duration of ischaemia, surgery is quite intricate, and inherently leads to
damage to the vascular endothelium of cerebral arteries. Such damage has been
implicated in exaggerating the inflammatory response which follows focal cerebral
ischaemia, which may complicate interpretation of pathophysiological outcome. The
present thesis, describes the characterisation and manipulation of an established
model of MCA occlusion by intracerebral injection of ET-1, to produce a novel
model of ET-induced MCA occlusion with controlled reperfusion.
ET-1, a 21-amino acid peptide with potent vasoconstrictor effects on cerebral
arteries, was employed in the study by Robinson et al. (1990) to produce focal
cerebral ischaemia by application to the surgically exposed MCA of the rat.
Modification of this approach to inject ET-1 into the brain parenchyma adjacent to
the MCA by Sharkey et al. (1993) led to a model that required only relatively simple,
less invasive, surgery, and avoided the damage to cerebral arteries associated with the
physical approach of most other stroke models. Whilst this model has subsequently
been applied to neuroprotection and behavioural studies (Sharkey & Butcher 1994;
Sharkey et al. 1995; Marston et al. 1995), features of this model were still unknown.
Specifically, whether the ischaemic insult reflects transient or permanent MCA
occlusion, and whether ET-1-induced MCA occlusion could be interupted to control
reperfusion.
The optimal dose and injection volume range appear to be quite broad. Indeed,
within a 10 fold dose range from 33 pmols to 300 pmols, and within a 1-3pi injection
volume, a large ischaemic lesion, restricted to the vascular territory of the MCA was
produced. As previously reported, the volume and extent of the infarct is comparable
to that following permanent occlusion of the MCA. The ischaemic insult was
characterised by measuring striatal oxygen levels, cortical tissue perfusion and local
CBF. Oxygen tension recordings and [14C]iodoantipyrine autoradiographical
determination of local CBF suggest that the ischaemic insult is of at least three hours
duration, with little evidence to suggest reperfusion occurs within a time-frame that
might be of pathophysiological significance. Whilst LDF recordings during the
characterisation of the ET-1 model suggested perfusion did gradually return, LDF
recordings in subsequent studies from a different cortical position did not suggest any
reperfusion occurs within three hours of ET-1 injection. These findings, combined
with the size and distribution of the ischaemic lesion suggest that the
pathophysiology of this model is representative of permanent MCA occlusion.
This model was applied to the neuroprotective and behavioural evaluation of a
novel trophic peptide derived from the p-amyloid precursor protein.
Intracerebroventricular infusion of the 17mer sequence was shown to confer potent
neuroprotection to both the cortex and striatum following ET-1-induced MCA
occlusion. By contrast to previous studies with this peptide, the 17mer peptide did
not facilitate behavioural recovery in a skilled paw reach paradigm that has been
shown to measure motor control disturbances following MCA occlusion.
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The approach to manipulating the ET-1 model to allow reperfusion, was to inject
the specific ETA receptor antagonist FR139317 intracerebrally following ET-1.
However, both histopathological and LDF assessment suggested that the effects of
ET-1 are not reversed by FR139317. The isopeptide ET-3 was subsequently
investigated since this peptide has been shown to have lower affinity and more
reversible binding to the ETA receptor. ET-3 was found to be equipotent in the
ischaemic insult it produced, being effective over the same dose range and producing
the same LDF profile as ET-1. This is the first demonstration that ET-3 is capable of
producing ischaemic damage by constricting a major cerebral artery. These findings
stimulated investigation of the characteristics of the receptor mediating ET-induced
MCA occlusion. The isopeptide equipotency was predictive of an ETB receptor rather
than an ETA subtype which is the ET receptor previously reported to predominate on
the cerebrovasculature of the rat. However, intracerebral injection of the ETB receptor
agonists BQ3020, and IRL1620 did not produce the MCA occlusion-like pattern of
ischaemic brain damage. Further to the receptor pharmacology, FR139317
pretreatment had no effect on ET-1-induced MCA occlusion but completely blocked
ET-3-induced MCA occlusion. This suggests an atypical ET receptor may mediate
MCA constriction in the rat.
By contrast to ET-1, ischaemic brain damage following ET-3-induced MCA
occlusion was shown to be effectively blocked by injection of FR139317 10 minutes
after ET-3. This was confirmed by LDF, which suggested that complete reperfusion
occurs within 5 minutes with no hyperperfusion evident. [14C]iodoantipyrine
autoradiography confirmed that FR139317 was effective in reversing local CBF
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changes throughout the ipsilateral hemisphere when injected after 10 minutes of ET-
3-induced MCA occlusion. This model was subsequently employed to study the
component very delayed (apoptotic) cell death. Whilst immunocytohistochemistry
detected the presence of apoptotic cells, numbers were very limited and did not
increase with the chronic maturation of the lesion, suggesting only a limited
contribution of this form of cell death to the volume of ischaemic brain damage seen
after a 30 minute ET-3-induced MCA occlusion.
The lack of an effective drug to limit the damage caused by stroke is a huge
problem for medical research. This field is exhaustively researched, and our
knowledge base is now considerable. That no effective treatment is established, may
be a consequence of the complex pathophysiology of stroke, but is undoubtedly in
part due to the experimental approaches employed. A lack of consistency in model
design may prevent "overlooking" that may occur with a narrow range of models, but
prevents cross-study comparison. Whether the first issue is more important than the
second is unclear. However, it is likely that the continuing lack of efficacy of
neuroprotectants at the clinical level is at least in part due to model design and
execution. Guidelines or approved protocol for neuroprotectant study may help
alleviate this, but undoubtedly pursuit of stroke models more accurately representing
the clinical setting are required. The original model of stroke described within has
limitations. The control over ischaemia and reperfusion is limited and penetration of
brain parenchyma by a cannula is required. However, the model does have the
advantage over some of the more popular models in avoiding microvascular injury,
damage to structures outwith the MCA field and body & brain temperature
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fluctuations. Furthermore, surgical intervention is limited by comparison to the
transorbital approach. Adoption of the modifications described herein may provide a
model which addresses the need for control over reperfusion, although control over
the ischaemic insult itself remains limited. The present data with the reperfusion
model suggest that filament and physical MCA occlusion techniques may introduce
artifactual components into the maturation of an ischaemic lesion, that may not be
present within the clinical setting. Clearly further studies are required to more
completely address the aspects of reperfusion injury, inflammation and the
contribution of apoptosis to lesion formation in both the ET models. Indeed whether
this model represents a more accurate reflection of human stroke, or indeed a less
accurate one, should be investigated.
Whilst characterisation of the ET-1 model is now quite extensive, the
reperfusion model requires further study. Other ET receptor antagonists could be
investigated to determine if FR139317 is the most suitable. A higher affinity, perhaps
less selective, receptor antagonist may be capable of reversing ET-1-induced MCA,
or reversing ET-3-induced MCA occlusion more rapidly. The rate of reperfusion at
later time points such as 60 or 90 minutes could be addressed with LDF.
Furthermore, the influx of leukocytes, and their cytotoxic effects should be
addressed, as well as the neuroprotective efficacy of drugs that block inflammatory
cell recruitment. In conclusion, the present thesis has described the characterisation
of the established model of MCA occlusion by intracerebral ET-1 injection, and
documented the development of a novel model of ET-3-induced MCA occlusion
with controlled reperfusion.
APPENDIX A
Protocol for In situ detection of apoptosis
The procedure for labelling apoptotic cells following ET-induced MCA occlusion as
described in Chapter 7, was performed according to the manufacturer's instructions
for ApopTag® (Oncor).
All procedures were performed on sections from brains perfused in 4% formaldehyde
in PBS, at room temperature unless otherwise specified. All washes were performed
in coplin jars.
1. Sections added to coplin jar containing 2-3% hydrogen peroxide for 5 minutes,
followed by two 5 min washes in PBS.
2. Excess removed and 75pl equilibration buffer added to each section, followed by
54pl of terminal deoxynucleotidyl transferase (TdT) in reaction buffer. Apply
plastic cover slip and incubate in a humidified chamber at 37°C for 1 hour.
3. Remove coverslip, and add slide to coplin jar of stop/wash buffer for 10 minutes,
followed by three 5 minute washes in PBS.
4. Apply 55pi of anti-digoxigenin-peroxidase to sections, and add cover slip and
add to a humidified chamber at room temperature.
5. Wash in 4 changes of PBS for 5 minutes
6. Add 125 pi of DAB substrate (chromogenic) and leave for 3 to 6 min.
7. Wash in 3 changes of distilled water for 1 minute each
8. Counterstain with methyl green in a coplin jar, then repeat step 7.
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9. Wash slide in 100% butanol (~1 min), xylene (2 min) and mount under
permanent coverslip with DPX.
Sections were subsequently examined under light microscopy for evidence of
apoptosis, based on the immuno-labeling and morphological identification of features
of apoptosis, as has been described in detail above.
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APPENDIX B
Solution for transcardiac perfusion
Heparinised saline comprised 0.1M phosphate buffered saline (pH adjusted to 7.4)
comprising di-sodium hydrogen orthophosphate and hydrogen di-sodium
orthophosphate with heparin (lOIU/ml).
Paraformaldehyde solution comprised 4% paraformaldehyde in 0.1M phosphate
buffered saline (pH adjusted to 7.4) containing di-sodium hydrogen orthophosphate and
hydrogen di-sodium orthophosphate.
Paraformaldehyde/sucrose storage solution comprised 4% paraformaldehyde in
0.1M phosphate buffered saline (pH adjusted to 7.4) containing di-sodium hydrogen
orthophosphate and hydrogen di-sodium orthophosphate plus 20% sucrose.
Composition of artificial cerebrospinal fluid
Composition of ACSF:
NaCl = 148.2mM, MgCl2 - 0.8mM, KC1 = 3.0mM
CaCl2 = 1.4mM, Na2HP04 = 0.8mM NaH2P04 = 0.2mM
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